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A.    Introduction 
 
 
A. 0. Preface 
 
Small molecules played the crucial role in the beginning of life.  
Hence, of course also amino acids are basic building blocks of all vital existence. This appears 
to be the appropriate expression since only 20 different amino acids display the smallest unit 
of peptides and proteins which are responsible for innumerable various activities. They are the 
monomers of entities that build up and maintain life’s structure and are involved in 
coordination of almost all physiological processes. Consequently, they give the cell structure 
and stability through proteins like collagen or elastin. Furthermore, amino acids build up 
macro biopolymers like enzymes as well as many other peptides which play important roles in 
coordination and maintenance of living organisms. Peptides, but also amino acids themselves, 
as well as biogenic amines (generally derived from amino acids) are the major substrates for 
targets like enzymes and receptors.  
Amino acids are naturally synthesised from intermediates of the major metabolic pathways 
like glycolysis or the citric acid cycle. Here α-keto acids like α-ketoglutarate are converted to 
the corresponding α-amino acids by transfer of ammonia catalysed by enzymes, e.g. 
glutaminase to produce glutamate. Other amino acids can be synthesised by transaminases in 
the presence of glutamate or aspartate as amine source.  
The first laboratory preparation of an amino acid was accomplished by Adolph Strecker 
(Figure 1) in 1850. In his pioneering work he was able to synthesise α-amino acids from 
simple readily available building blocks which will be described in the next chapter. 
 
Figure 1. Oil painting of Adolph Strecker.1 
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Currently, amino acids are industrially produced via fermentation or chemical synthesis in 
thousand ton scale per year. They are mainly used as food additives and in cosmetics but also 
as precursors for various other chemical syntheses.  
Moreover, the synthesis of unnatural amino acids is also of high interest. They can serve as 
building blocks for the preparation of foldamers with new interesting secondary structures and 
as subunits in peptidomimetics as well as in α-peptide analogues. Moreover, they are utilised 
as appropriately labelled compounds, e.g. 18F-labelled amino acids in diagnostics of cerebral 
gliomas.2  
The development of methods for the synthesis of amino acids (including complex unnatural 
β- and γ-amino acids), starting from the first syntheses of racemic natural α-amino acids and 
their fields of application will be briefed in the following chapter. 
  
 
A. 1. Synthetic strategies towards α-amino acids 
 
A. 1.1 Racemic syntheses of α-amino acids 
 
The first methodology for the synthesis of α-amino acids was developed in 1850 by              
A. Strecker3 (Scheme 1). Here, aldehyde 1 is condensed with ammonia in the presence of 
hydrocyanic acid, giving rise to an α-amino nitrile 2 which can be hydrolysed to the 
corresponding α-amino acid 3.  
 
Scheme 1. Outline of the Strecker synthesis. 
 
 
 
Another, quite old strategy is the amino acid synthesis via hydantoin intermediates (Bucherer-
Bergs reaction) which is still used by companies like SEKISUI Medical Co., Ltd.4 The 
hydantoin 5 is formed from an aldehyde or ketone 4, sodium cyanide and ammonium 
carbonate. Upon hydrolysis of heterocycle 5, amino acids like 6 can be obtained         
(Scheme 2). 
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Scheme 2. Hydantoin approach towards α-amino acids. 
 
 
 
Furthermore, α-amino acids are accessible via a Gabriel-malonic ester synthesis as shown for 
methionine in Scheme 3.5 Compound 7 can be obtained from diethyl malonic ester which is 
converted to the corresponding α-bromo malonate using a Hell-Volhard-Zelinsky 
transformation followed by the bromide substitution with phthalimide. Subsequently, the side 
chain of methionine was introduced using 2-chloroethyl methyl sulfide in the presence of a 
base to obtain 8. Decarboxylation and ester cleavage gives free methionine 9. 
 
Scheme 3. Gabriel-malonic ester synthesis of methionine. 
 
 
Another interesting methodology utilises N-acylaminomalonates which can be transformed, as 
shown by Matsumoto et al. from Tanabe Seiyaku Co., Ltd. to 3-substituted aspartic acids 
(Scheme 4).6  
 
Scheme 4. Synthesis of 3-amino aspartic acid. 
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Malonate 10 is reacted with ethyl 2-acetoxyglycinate (11; prepared by anodic oxidation of 
another equivalent of ethyl N-acetylaminomalonate) to afford the corresponding N-acetyl-3-
substituted aspartic acid derivative 12. Hydrolysis with hydrochloric acid gives rise to 2,3-
diaminosuccinic acid (13). Another, more sophisticated modification of this method uses 
microwave irradiation.7  
These reactions give just a glimpse of the broad spectrum of possibilities of syntheses known 
for α-amino acids. 
The disadvantage of all the aforementioned reactions is their stereochemical outcome as 
racemic products. Therefore, various methods for the resolution of racemic mixtures have 
been developed.  
The classical ways for these resolutions are:  
(1) Derivatisation of the racemate by another chiral reagent and separation of the resulting 
diastereomers followed by reversal of the derivatisation.  
(2) The use of suitable enzymes which convert only one enantiomer of the racemate, e.g. by 
acetylation. Separation from the unreacted enantiomer followed by its hydrolysis yields amino 
acids in high optical purity. In the case of α-amino acids, this proves to be an especially 
useful approach since they are the natural substrates of enzymes. 
Nevertheless, strategies are needed to produce amino acids in optical pure form without any 
resolution process and without production of the undesired second enantiomer. A brief 
overview of some of the most interesting methods will be given in the next chapter. 
 
 
A. 1.2 Asymmetric syntheses of α-amino acids  
 
Using the aforementioned methodologies enantiopure amino acids can only be accessed after 
a resolution process of the racemic material. Therefore, many asymmetric syntheses were 
developed for the preparation of amino acids as single enantiomers.8 
The first synthesis of α-amino acids using a chiral reagent which can be recovered was 
developed by Corey et al.9 in 1970 based on former investigations by Kagan et al.10 Corey’s 
synthesis starts from a α-keto acid which is converted to the hydrazonolactone 15 using the 
chiral hydrazine reagent 14. The C=N double bond of the hydrazonolactone can than be 
reduced to yield intermediate 16 with the desired stereochemistry at the later α-C of the 
amino acid. Hydrogenolytic cleavage of the N-N bond, followed by an ester saponification 
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gave the corresponding amino alcohol 17 of the chiral hydrazine and the α-amino acid 18 
with selectivities up to 97% ee (Scheme 5). 
 
Scheme 5. Outline of Corey’s methodology. 
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Another approach referred to as intraannular chirality transfer, was introduced by Schöllkopf 
et al. in 1984 for the synthesis of α-vinyl amino acids (Scheme 6).11  
 
Scheme 6. Synthesis of α-vinyl amino acid 23 according to Schöllkopf et al. 
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Here, glycine is condensed with (L)-valine as chiral auxiliary followed by methylation giving 
the bislactim ether 19. Deprotonation of 19 with butyl lithium gives rise to monoanion 20 
which is then reacted with acetophenone to yield 21. The subsequent reaction with thionyl 
chloride in the presence of 2,6-lutidine gave 22 as the major product, which on hydrolysis 
with hydrochloric acid affords the desired α-vinyl amino acid ester 23. It was demonstrated 
that this method can be applied for a broad variety of aldehydes and ketones in the synthesis 
of different natural and unnatural substituted α-amino acids. 
Moreover, catalytic reduction using transition metal catalysts in the presence of chiral ligands 
is another very popular approach. One possibility is the enantioselective introduction of the  
α-hydrogen using α,β-dehydro-α-amino acids to create the chiral centre selectively.12 Since 
the pioneering work of Knowles et al.13 in the synthesis of L-Dopa, one of the most common 
systems is rhodium (I) in the presence of phosphine ligands, to hydrogenate C=C double 
bonds. An additional strategy is the stereoselective reduction of C=N double bonds of           
α-imino esters like 24 from α-keto esters (this somehow mimicks the natural process of 
amino acid synthesis with the help of enzymes as chiral catalyst). A recent example is the 
hydrosilylation by a Re(V)-oxo complex 26 coordinated by a cyano bis(oxazoline) ligand, 
introduced by Toste et al., which furnished N-phosphinyl arylglycines (25) in excellent 
enantioselectivities (Scheme 7).14 
 
Scheme 7. Re(V)-catalysed C=N reduction. 
 
 
All the introduced methods allow the stereoselective synthesis of naturally occurring as well 
as novel, differently substituted α-amino acids. For the preparation of β-, γ- or higher 
homologated amino acids different methods need to be utilised. 
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A. 2. Synthetic strategies towards β- and γ-amino acids 
 
The synthesis of new β- and γ-amino acids is always a remunerative challenge since they 
display important subunits in bioactive compounds, like the highly active anticancer agent 
taxol15 27 (containing a phenylisoserine) or Jasplakinolide 28 (containing a β-tyrosine) which 
has insecticidal, antifungal, and antihelminthic properties16 (Figure 2).  
The most prominent example for a naturally occurring γ-amino acid is GABA (29; γ-amino 
butyric acid), being an important inhibitory neurotransmitter in the central nervous system.  
 
Figure 2. Naturally occurring β- and γ-amino acids in: Taxol 27; Jasplakinolide 28; GABA 
29. 
 
 
 
These types of amino acids often have many beneficial properties such as a higher proteolytic 
stability compared to α-amino acids as well as the ability to induce discrete and predictable 
folding properties in polymers. Hence, they are utilised in the preparation of foldamers, as 
surrogates for natural amino acids in biologically active peptides to study structure-activity 
relationships and as potential therapeutics. The pioneering work of Gellman and Seebach 
starting in the middle of the 1990s in the field of foldamers showed the conformational 
preferences imposed by these unnatural amino acids in oligomers.17 However, the monomeric 
building blocks of these highly interesting oligomers need to be synthesised before.  
One of the simplest methods for the preparation of β-amino acids is the synthesis from the 
natural (L)-α-amino acid by an Arndt-Eistert homologation (Scheme 8).18 
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Scheme 8. Arndt-Eistert homologation of α-amino acids. 
 
 
 
Reagents and conditions: (a) i. Et3N/ClCO2Et, -15° C; ii. CH2N2, -5° C - rt. (b) Cat. PhCO2Ag in Et3N/MeOH. 
 
In the first step carboxylic acid 30 is activated and directly converted to the corresponding 
diazoketone 31 using diazomethane. 31 can then undergo a Wolff rearrangement which is 
conducted in the presence of catalytic amounts of Ag(I)-salts and methanol to give the 
homologated β-amino ester 32. By this homologation β3-amino acids19 can be obtained. 
Furthermore, Seebach et al. reported the synthesis of β2-amino acids, like for instance Fmoc 
protected homo-isoleucine20 (Scheme 9). 33 can be prepared by the standard Evans protocol 
which involves acylation of the lithiated (R)-4-isopropyl-5,5-diphenyloxazolidin-2-one     
((R)-DIOZ) with an acid chloride like (S)-3-methylpentanoic acid. The acyl-DIOZ can then be 
enolised and amidomethylated to give 34. After removal of the auxiliary with LiOH and 
hydrogenolysis of the Cbz group the final Fmoc protection gave β2-isoleucine (35). 
 
Scheme 9. Seebach’s synthesis of Fmoc-protected β2-amino acids. 
 
 
 
Reagents and conditions: (a) i. TiCl4/NEt3, CH2Cl2; ii. CbzNHCH2OMe, TiCl4, 66% (96 % dr). (b) LiOH, 
THF/H2O, 66%. (c) H2/Pd-C, MeOH. (d) FmocOSu, aq. Na2CO3, acetone, 90% (over two steps).  
 
However, not only linear amino acids but also cyclic β-amino acids, being more 
conformationally restricted are of substantial interest. 
The first examples by Gellman et al. for cyclic β-amino acids that can be successfully utilised 
in foldamers were trans-ACPC (trans-2-aminocyclopentanecarboxylic acid) and trans-ACHC 
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(trans-2-aminocyclohexanecarboxylic acid) and some of their derivatives. The general 
synthetic approach of Gellman for different trans-ACPCs is given in Scheme 10.21 In the first 
step the homoallylic benzylalcohol 36 is epoxidised to 37. This epoxide is then converted, in a 
three step procedure, to the corresponding aziridine 38 having the inverse stereochemistry. At 
this point the synthetic route was diverging. On the one hand, the tricycle of the aziridine was 
opened with alcohols and the free amine was Boc protected giving 39. After removal of the 
benzyl group, the primary alcohol can be oxidised to the corresponding carboxylic acid by 
Jones oxidation yielding β-amino acid 40. A two step substitution of the Boc- to the 
corresponding Fmoc-protecting group gives rise to 41. In the second route, aziridine 38 was 
opened using potassium cyanide and the resulting free amine was protected with CbzCl to 42. 
After reduction of the nitrile the resulting primary amine is Boc protected to 43. Finally, the 
Cbz- as well as the Bn-group were removed, the corresponding amino function Fmoc-
protected and the primary alcohol oxidised yielding 44. 
 
Scheme 10. Synthesis of trans-ACPC derivatives by Gellman et al. 
 
 
Reagents and conditions: (a) TiCl4/TBHP, CH2Cl2, 30 min, -78 °C. (b) KOtBu, benzene, rt, 3 h, 85% (over two 
steps). (c) NaN3/NH4Cl, MeOH/H2O, reflux, 12 h, 85%. (d) MsCl, pyridine, 0 °C, 2 h. (e) LAH, THF, 0 °C to rt, 
2 h, 84% (over two steps). (f) Boc2O/NEt3, MeOH, rt, 2 h, 84%. (g) BF3.OEt2/ROH, CH2Cl2, -78 °C, 15 min, 71-
87%. (h) 10% Pd/C, NH4HCO2, MeOH, reflux, 10 h, 93%. (i) Jones reagent, acetone, 0 °C, 2 h, 73-89%. (j) 4 N 
HCl, dioxane, rt, 1 h. (k) Fmoc-OSu/NaHCO3, acetone/H2O, rt, 12 h, 61-74% (over two steps). (l) Cbz-Cl/NEt3, 
CH2Cl2, 0 °C, 2 h, 93%. (m) KCN/18-crown-6, DMSO, 80 °C, 2 h, 90%. (n) BH3.THF, THF, rt, 4 h. (o) 
Boc2O/NEt3, MeOH, rt, 2 h, 75% (over two steps). (p) Na/NH3, -78 °C, 30 min. (q) Fmoc-OSu/NaHCO3, 
acetone/H2O, rt, 12 h, 47% (over two steps). (r) TEMPO/NaClO, CH2Cl2/H2O, 0 °C, 30 min, 57%. 
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Another highly interesting approach towards the enantioselective synthesis of cyclic β- as 
well as γ-amino acids is the use of carbohydrates for the preparation of sugar derived amino 
acids introduced by the groups of Fleet,22 Kessler,23 Chakraborty24 and many others. In the 
synthesis of Kessler et al. diacetone glucose (45) gives rise to β- and γ-amino acids      
(Scheme 11). Triflyl activated diacetone glucose 46 is converted to azide 47 in DMF 
accompanied by inversion of configuration. After azidolysis, the exocyclic hydroxyl group is 
deprotected by acetic acid yielding 48. In the first route towards the β-sugar amino acid the 
diol 48 can be cleaved oxidatively to 49 followed by a one-pot reaction, where the azide is 
reduced and simultaneously Fmoc protected to β-amino acid 50. For the preparation of 52, a 
different route was used in which a similar one-pot reaction like in the first route can be 
applied to yield the Fmoc protected intermediate 51. The selective oxidation of the primary 
alcohol with TEMPO, sodium hypochlorite and KBr provides γ-sugar amino acid 52. 
 
Scheme 11. Synthesis of β- and γ-amino acids derived from D-glucose. 
 
 
 
Reagents and conditions: (a) Tf2O, pyridine, -10 °C, CH2Cl2. (b) NaN3, Bu4NCl (cat), 50 °C, DMF. (c) 77% 
HOAc, 3 h, 65 °C. (d) NaIO4, 5 h, 10 °C, MeOH. (e) KMnO4 , 50% HOAc, rt. (f) H2, Pd/C, MeOH, FmocCl, 
NaHCO3, pH 8 - 9, THF, MeOH, rt, 90%. (g) NaOCl, TEMPO (cat), KBr, CH2Cl2, sat. aq. NaHCO3, Bu4NCl, 
62%.  
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Naturally, like in the case of β-amino acids, also linear γ-amino acids can be prepared. Very 
simple acyclic γ-amino acids were prepared by Hanessian et al. who reported γ-peptides 
derived by homologation of (L)-alanine and (L)-valine to form stable right-handed helical 
secondary structures.25 Besides the facile homologation many other syntheses for γ-amino 
acids with different substitution patterns are in the literature, e.g. the methodology developed 
by Seebach et al. for 2, 3, 4-substituted γ-amino acids (Scheme 12).26 Here the amino acid is 
prepared stereoselectively by a Michael addition of the modified Evans acyloxazolidinone 53 
to nitrobutene, yielding 54. After reductive cleavage the cyclised pyrrolidone 55 can be 
obtained, which upon hydrolysis and N-Boc protection gives γ-amino acid 56. 
 
Scheme 12. Synthesis of 2, 3, 4-substituted γ-amino acids by Seebach et al. 26 
 
 
Reagents and conditions: (a) i. TiCl4/DIPEA; ii. Nitrobutene, TiCl4. (b) Raney-Ni/H2. (c) i. 6M HCl; ii. Boc2O, 
Na2CO3. 
 
 
A. 2.1 Applications of β- and γ-amino acids 
 
As described before there are some examples in nature for β- and γ-amino acids, but there is 
also a large number of new synthetic cyclic as well as acyclic amino acids for a broad range 
of applications. A very interesting β-amino acid is cispentacin 57 and its derivatives since it 
has highly antifungal properties which make it a useful tool as a fungicide in crop 
protection.27 Two other prominent examples for the application of γ-amino acids employed as 
therapeutics are vigabatrin 58 which is used as anticonvulsant and baclofen 59 which is a 
GABAB receptor agonist and is applied in the treatment of spasticity (Figure 3). 
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Figure 3. Biologically active β- and γ-amino acids.  
 
 
 
Furthermore, β- as well as γ-amino acids can be applied in homo- and heterooligomers 
(foldamers), mimicking natural secondary structures like helices or sheets. Since biological 
systems rely almost exclusively on polymers, the intention of foldamer design is to have 
analogue capabilities, like peptides or proteins from unnatural polymers, which are able to 
fold into compact and specific conformations.28 One of the first foldamers that strongly favour 
a helical structure (14-helix) were tetramer and hexamer structures of trans-ACHC 60 by 
Gellman et al.29 However, not only homooligomers but also heterooligomers are able to show 
discrete secondary structures. Reiser et al. showed that α/β-alternating peptides using 3-
amino-cyclopropane-1,2-dicarboxylic acid monomethyl ester (61;β-ACC) and alanine give 
surprisingly stable helical conformations.30  
 
Figure 4. Examples for foldamers giving stable secondary structures. 
 
 
In addition, many foldamers from unnatural amino acids were found to possess highly 
interesting physiological properties. For instance, some arginine rich β-peptides were used to 
investigate the entry process of peptides into HeLa cells in order to gain insight into the 
correlation between structure and endocytic uptake.31 Furthermore, different α,β-peptides 
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were found to have antimicrobial activity32 or to have the ability to disrupt protein-protein 
interactions.33 
Moreover, unnatural amino acids are effective as building blocks in the design of functional 
peptides by substitution of α-amino acids in natural α-peptides. This alteration can have many 
beneficial effects for incorporated peptides, like higher stability to proteolytic hydrolysis or 
the possibility to control the conformation and thereby modify its function. Herein, especially 
discrete structure inducing conformationally restricted amino acids are a useful tool to 
investigate how secondary structures can affect activity. This can help to get a deeper insight 
into structure-activity-relationships (SARs) and give the possibility to alter its function. Very 
often unnatural amino acids are used as turn inducers in peptide analogues, e.g. for the 
gonadotropin releasing hormone. Here, Mulzer et al. could show the turn inducing effect for 
cispentacin derivative34 62 whereas Nagai et al. reported similar effects for the bicyclic amino 
acid 63.35  
 
Figure 5. Examples for various turn inducing amino acids. 
 
 
 
Moreover, the incorporation of β-ACC (64) as constrained β-alanine analogue was 
successfully carried out in the group of Reiser. These modified peptides were very useful in 
receptor-ligand interaction studies on neuropeptide Y (NPY),36 Calcitonin gene related 
peptide37 and orexin peptides.38 In the case of the NPY receptor, truncated NPY analogues 
(residues 25-36) containing β-ACCs in different combinations in close proximity to the two 
C-terminal arginines were synthesised. Some of these NPY fragments showed nanomolar 
affinity towards the Y1 and the Y5 receptor with a good selectivity for the Y1 receptor. 
Thus, the incorporation of conformationally restricted β-amino acids into biologically active 
peptides as well as their application in foldamers is a promising objective. Hence, different 
derivatives of β-ACCs with α-amino acid side chain functionality were prepared.39 
Unfortunately, many of these compounds were not stable or require very special conditions in 
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peptide coupling reactions. This drawback makes it necessary to synthesise cis-β-amino acids 
with a similar stereochemical structure that are able to induce comparable conformational 
properties in peptides, but having a higher stability. Cispentacin derivatives like 65 with its 
annulated γ-butyrolactone moiety as “side chain”, thus allowing a wide range of modifications 
were envisaged to be a worthwhile approach. The lactone can be easily diversified in many 
different ways like opening by hydrolysis and reduction respectively or enolisation. 
 
Figure 6. Outline for a new modifiable β-amino acid lactone ‘side chain’ with comparable 
stereochemical configuration like (+)-β-ACC 64. 
 
 
 
The aim of this work was to develop new unnatural conformationally restricted β- and γ-
amino acids and to investigate their potential applications. These various amino acids were 
derived from the intramolecular 1,3-dipolar cycloaddition products which were obtained as 
diastereomers 66a and 66b ascribed to γ-butyrolactone 67. The synthesis of 67 starting from 
2-furoic methyl ester (68) and its value in the synthesis of different natural products had been 
described before.40   
 
Scheme 13. Retrosynthetic scheme to the two diastereomeric nitrone cycloaddition products 
66a/b. 
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The two diastereomers 66a and 66b can be transformed to a broad variety of β-amino acids as 
well as γ-amino acids. Cispentacin derivatives with an annelated lactone as well as open chain 
products modified with protected alcohol groups and/or protected guanidinium group can be 
obtained. Furthermore, isomer 66a gives rise to a trans-γ-amino acid with a cyclopentane 
backbone and a free alcohol group which allows for further modifications. The second 
diastereomer 66b can be converted to a bicyclic β-amino acid. 
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B. 1. Development of conformationally constrained β-amino acids – New cispentacin 
derivatives  
 
Cispentacin (57) was first isolated independently in 1989 by two distinct Japanese groups 
from Bacillus cereus and Streptomyces setonii respectively and revealed very potent 
antifungal activity.1 Since then, it has gained relevance in agrochemical research,2 but was 
also described to exhibit activity against human pathogens.3 However, not only cispentacin 
but also different analogues are currently under investigation by pharmaceutical companies 
for the treatment of various yeast infections.4  
Their mode of action is based on the inhibition of prolyl-t-RNA synthetase and isoleucyl-t-
RNA synthetase after being transported and accumulated in fungal cells by proline permease 
and other amino acid permeases.5 The interaction with synthetases results then in inhibition of 
protein synthesis and therefore cell growth.  
 
Figure 7. Cispentacin (57) and several highly active antifungal derivatives; PLD-118 (69) and 
Amipurimycin 70. 
 
 
 
 
B. 1. 1. Cispentacin and other cyclic β-amino acids - Highly versatile scaffolds 
 
Besides their pharmacological properties, cispentacin derivatives were also introduced into 
peptides modifying their biological activity.6 In this context, e.g. the turn inducing properties 
of a bicyclic cispentacin derivative in gonadotropin-releasing hormone (GnRH) analogues 
was studied by Mulzer et al.7  
Furthermore, cispentacin was also applied as organocatalyst in the Hajos-Perrish-Eder-
Wichert-Sauer reaction by Davies et al.76  
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Figure 8. Different areas of application of 2-aminocycloalkanecarboxylic acids.8 
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All these examples show the enormous potential of cispentacin and its derivatives in different 
fields, thus making the development of new analogues for various applications, as depicted in 
Figure 8, a promising objective. 
 
 
B. 1. 1. 2. Structure inducing amino acids in Neuropeptide Y (NPY) analogues  
 
Neuropeptide Y is a C-terminally amidated 36 amino acid peptide and was first isolated from 
porcine brain in 1982 by Tatemoto et al.9 It belongs to a peptide family consisting of peptide 
YY (PYY), pancreatic polypeptide (PP) and NPY itself. These peptides exert most of their 
biological effects through five G-protein coupled receptors (GPCRs) Y1, Y2, Y4, Y5 and y6. 
However, there are reports that there might be many more subtypes10 whereas the Y3 receptor 
continues to be an enigma since it was cloned and shortly afterwards concluded not be a NPY 
receptor.11   
NPY and PYY have a high affinity to Y1, Y2 and Y5 whereas PP prefers the Y4 receptor.12  
The PP and the PYY are mainly synthesised and released by intestinal and pancreatic cells 
whereas NPY is distributed in the central nervous system. In the periphery it is ubiquitous in 
the symphatic nervous system and it is also expressed in liver, heart spleen and in endothelial 
cells of blood vessels.13 
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This peptide family was assumed to have a similar secondary structure due to its high 
sequence homology. The first three-dimensional structure of avian PP was determined by    
X-ray crystallography.14 In this structure, which is called PP-fold, a type II β-turn connects a 
type II polyproline helix to an amphiphilic α-helix (Figure 9; right) forming a hairpin fold 
(PP-fold). In contrast, NMR studies have shown that the N-terminal segment of NPY bound to 
the membrane mimetic dodecylphosphocholine micelles extends like a flexible tail (Figure 9; 
left).15 
 
Figure 9. Structures of NPY in the presence of micelles (left) and the PP-fold of bovine 
pancreatic polypeptide.16 
 
 
 
 
 
 
 
 
 
The cloned Y1, Y2, Y4 and Y5 are all coupled to Gi and therefore mediate external stimuli by 
inhibition of cAMP synthesis. Their general structure is depicted in Figure 10. Furthermore, 
NPY receptors are reported to couple to phospholipase C and thus increase the intracellular 
calcium concentration by release of Ca2+ from intracellular stores.17  
 
Figure 10. Structure of a GPCR.18 
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These different subtypes of NPY receptors play an important role in many different 
physiological processes like food intake, regulation of blood pressure, depression and many 
more (Table 1). However, the role of each receptor and its mediated physiological function is 
still not completely understood. Therefore, subtype selective agonists as well as antagonists 
are rewarding targets. There is already a quite large number of more or less selective, 
nonpeptidic as well as peptidic, ligands known.19 They are very useful pharmaceutical tools in 
diagnostics as well as in therapy of many diseases since NPY is such a highly abundant 
peptide and is connected to a broad range of ailments.20 Moreover, these selective ligands can 
contribute to the better understanding of the effects mediated by certain subtypes of receptors. 
 
Table 1. Potential physiological roles of NPY and the receptors proposed to mediate those 
effects.21 
 
Main physiological implications Receptor(s) liable 
Regulation of blood pressure Y1, Y2 
Food intake Y1, Y2, Y4, Y5 
Seizure regulation Y1, Y2, Y5 
Anxiety Y1, Y2, Y5 
Hypothalamic regulation of 
bone formation 
Y2 
LH secretion Y1 
Pain sensitivity Y1, Y2 
Depression Y1, Y2 
Regulation of GI motility Y2, Y4 
Angiogenesis Y1, Y2 
Ethanol consumption Y1 
 
As incipiently mentioned, β-ACC units were already applied successfully as building blocks 
in biological active analogues of NPY and RGD peptides, inducing a particular spatial 
orientation of important side chain moieties for their interaction with the respective receptor.22 
Biological testing of these peptides showed receptor subtype selectivity with a still high 
affinity for some of the derivatives. Conformational investigations could help to get a deeper 
insight into structure-activity-relationships of these peptides and their targets.  
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Especially, the introduction of (+)-β-ACC in the C-terminal part of truncated NPY analogues 
(NPY25-36) led to peptides with good NPY Y1 receptor selectivity. 
The consideration to synthesise NPY analogues with unnatural amino acids was based on Ala 
scans showing the high importance of Arg33 and/or Arg35. The replacement of these two 
arginine residues as well as of the C-terminal tyrosineamide using an (L)-alanine scan leads to 
significant decrease or complete loss of affinity.23 Furthermore, other previous reports by 
Beck-Sickinger and Cabrele, who described different NPY analogues by changing different 
amino acids, also emphasise the importance of this prominent region.24 
All these reports gave motivation to investigate different new unnatural amino acids in NPY 
analogues and furthermore to combine the principle of conformational influence of a 
restricted β-amino acid with a variety of side chains in one amino acid. 
 
 
 
 
B. 1. 2. Synthesis of new cispentacin derivatives 
 
B. 1. 2. 1. Synthesis of the γ-butyrolactone framework 
 
In the synthetic efforts towards new amino acid structures the γ-butyrolactone scaffold was 
envisaged to be an appropriate moiety for the syntheses of new β- and γ-amino acids, since 
lactones have a high potential for various modifications by different ways of ring opening 
giving rise to many alterations. 
γ-Butyrolactones are a widely spread structural motif in numerous natural products. Therefore 
many synthetic approaches towards diverse mono- and polycyclic γ-butyrolactone scaffolds 
are known.25  
A very elaborate strategy en route to monocyclic anti-4,5-disubstituted γ-butyrolactone 
aldehydes (Scheme 14) was first reported in 2001 by Reiser et al. in the synthesis of              
(-)-roccellaric acid using an asymmetric cyclopropanation of furans as one of the keysteps.26 
The possibility of introducing various allylic side chains as well as the high modification 
potential of the aldehyde functionality makes it an interesting and versatile building block. 
Therefore, this scaffold was chosen for the preparation of various new amino acids. 
The initial step of this synthesis is the copper(I)-catalysed cyclopropanation of 2-furoic 
methyl ester (68) using ethyl diazoacetate (EDA) in the presence of the C2 symmetric 
bis(oxazoline) ligand 71 affords bicyclic 72 in 36 % yield with an enantiomeric excess of       
> 99 % after crystallisation. Ozonolytic cleavage of the remaining double bond in the bicyclic 
compound 72, followed by a reductive workup, results in cyclopropane carbaldehyde 73 in 
B.   Main part  24 
92% yield after recrystallisation from diethyl ether. The aldehyde functionality of 73 is then 
subjected to a Sakurai allylation using trimethylallylsilane, giving rise to 74 which is the 
stereoelectronic favoured diastereomer following the rules of Felkin and Ahn.27 Subsequent 
treatment with a base gives the free cyclopropane alcohol intermediate 75, being a donor-
acceptor substituted cyclopropane hence highly unstable and collapses by forming an 
aldehyde via opening of the three-membered ring. A retro-aldol-lactonisation-cascade 
reaction yields the trans-substituted lactone 67 in 41 %. The rearrangement to 67 is reported 
to be initiated by Okawara’s tetrabutyldistannoxane catalyst28 or Ba(OH)2.8H2O.29  
 
Scheme 14. Synthesis of anti-4,5-disubstituted γ-butyrolactone aldehyde according to Reiser 
et al. 
 
 
Reagents and conditions: (a) 0.75 mol% Cu(OTf)2, 1 mol% 71,  PhNHNH2, ethyl diazoacetate (10% – 15% 
solution in CH2Cl2, 1.3 equiv), 0 °C, 45%, after recrystallization 36 % (99% ee). (b) O3, DMS (5.5 equiv), 
CH2Cl2, -78 °C → rt, 24 h, 92 %. (c) Allyl trimethylsilane (1.3 equiv), BF3·OEt2 (1.1 equiv), CH2Cl2, -78 °C. (d) 
Ba(OH)2·8H2O (0.51 equiv), MeOH, 0 °C, 24 h (41 %). 
 
However, the commonly used barium hydroxide procedure is often problematic because of 
the formation of an emulsion during workup and the associated laborious extraction 
procedure. Facing this problem, some investigations on different reagents, in order to improve 
this step, were carried out. In here, the focus was on various basic ion exchange resins as well 
as organic bases. The results are summarised in Table 2. 
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Table 2. Overview of different reagents for the lactonisation of 74. 
 
entry solvent 
 
reagent (properties) yield 
[%] 
1 methanol Ba(OH)2 * 8H2O 41 - 63 
2 methanol Dowex® 1x2, (strong basic IER) 65 
3 methanol Amberlite® IRA-400, (strong basic IER) a) 
4 methanol Amberlyst A21, (weak basic IER) - b) 
5 methanol Amberlite® IRA-68, (weak basic IER) a) 
6 methanol Dowex® 1x8 (strong basic IER) a) 
7 methanol Ionenaustauscher III (strong basic IER) a) 
8 methanol Amberlyst 15 (strong acidic IER) - b) 
9 methanol Amberlite IR 120 plus (strong acidic IER) - b) 
10 methanol DMAP a) 
11 methanol triethylamine 69 
12 methanol DBU a) 
13 methanol DABCO a) 
14 methanol TMEDA a) 
15 methanol p-TosOH - b) 
16 ethyl acetate triethylamine - b) 
17 dichloromethane triethylamine - b) 
18 diethylether triethylamine
 
-
 b)
 
19 ethanol triethylamine a) 
20 methanol (anhydr.) triethylamine (anhydr.) 68 
 
The solvents were, if not otherwise indicated, used without any purification. All reactions were conducted at     0 
°C. (a) no complete conversion after 24 h (TLC control); yield was not determined. (b) no conversion. 
 
It could be shown, that triethylamine in methanol (entry 11 and 20) is as effective as barium 
hydroxide concerning the yield, but allows a simplified workup. In this reaction a solid by-
product was isolated and indentified as a mixture of oxalic esters which were not, like in the 
reaction with barium hydroxide hydrolysed to the corresponding oxalic acid. The use of basic 
Dowex resin (entry 2) gave good yields on a small scale. During scale up of the reactions the 
yields dropped tremendously. 
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Moreover, the lactonisation with triethylamine as well as with basic Dowex resin were shown 
to give a by-product 77 which is claimed to be in an equilibrium with the desired product 6730 
and can therefore be transformed to the very. The proposed mechanism of the formation of 
this secondary product starts with a shift of the oxalic ester moiety to 76 which is followed by 
the formation of acetal 77 as a diastereomeric mixture (80:20). 
 
Scheme 15. Proposed mechanism of the formation of the by-product in the lactonisation 
reaction using triethylamine or basic Dowex ion exchange resin. 
 
 
Due to all these problematic side products and side reactions the ‘classic’ barium hydroxide 
procedure was applied on large scale lactonisation reactions. 
The aldehyde in this final anti-4,5-disubstitued γ-butyrolactone 67 is now assumed to give rise 
to the desired cispentacin precursors via an intramolecular [3+2] nitrone cycloaddition. 
 
 
B. 1. 2. 2. Synthesis of lactone fused cyclopentanes 
 
There is only a rather limited number of possibilities in the literature for the direct 
construction of lactone fused cyclopentanes. Apparently, the intramolecular esterification is 
the simplest approach. Thus, a very straightforward strategy is the selective reduction of 
racemic γ-ketoester 78 either by metal catalysts31 or enzymes32 followed by lactonisation to 
79 or the resolution of the corresponding trans-γ-hydroxyester (80) followed by epimerisation 
and lactonisation (Scheme 16).33  
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Scheme 16. Conversion of γ-ketoester to a fused cyclopentane. 
 
 
 
Furthermore, the desired bicyclic lactones can be obtained by a Baeyer-Villiger oxidation of 
bicyclic butenones as described in the synthesis of the Grieco lactone34 81 which is a 
commercially available starting material for many natural product syntheses especially for 
eicosanoides like prostaglandin and thromboxane derivatives.35 A related methodology 
utilises the Baeyer-Villiger monooxygenase (BVMO), an enzyme mediating a regiodivergent 
biooxidation of fused bicyclic ketones. Here, racemic starting material is converted to two 
regioisomers, in which either the more substituted or the less substituted carbon centre can 
undergo migration thus leading to the ‘normal’ or the ‘abnormal’ lactone (Scheme 17).36  
 
Scheme 17. Regioselective enzymatic Baeyer-Villiger oxidation of fused bicyclic ketones; 
Grieco lactone 81.  
 
 
 
Another interesting approach is a carbon-hydrogen insertion of cyclopentyl diazoacetate 
catalysed by dirhodium(II) carboxamidates as reported by Doyle et al. in 2005.37 Here, the 
cis-fused lactone cyclopentanes were synthesized in good yield with an enantiomeric excess 
of 93% (Scheme 18). Moreover, there are some other methods in the literature including 
radical cyclisation using tributyltin hydride38 or catalytic asymmetric cyclocarbonylation.39  
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Scheme 18. Dirhodium mediated C-H insertion in the synthesis of lactone fused 
cyclopentanes. 
 
 
 
Another quite common methodology to build up bicyclic frameworks utilises cycloaddition 
reactions. 
Cycloaddition reactions are among the most useful and elegant types of reactions to increase 
intricacy40 in molecules by a quite simple transformation. 1,3-dipolar cycloadditions41 are 
reactions that follow a [pi4s+pi2s] paradigm and proceed through a 6pi-electron ‘aromatic’ 
transition state, means concerted. These reactions between the 4pi component (1,3-dipole) and 
the 2pi component (dipolarophile) lead to five-membered heterocycles.42 They are mainly 
controlled by HOMO (dipole) - LUMO (dipolarophile) or HOMO (dipolarophile) – LUMO 
(dipole) interactions as depicted in Figure 11. Moreover, these interactions can be classified 
as so-called Sustmann types depending on the electron demand of the dipole as well as of the 
dipolarophile.43  
 
Figure 11. Frontier molecular orbital (FMO) interactions in 1,3-dipolar cycloadditions. 
 
 
 
In the case of nitrones this cycloaddition leads to the formation of an isoxazolidine which can 
be easily converted to amino alcohols, amino acids and other derivatives. This methodology 
was already used by Aggarwal et al. in the synthesis of (-)-cispentacin (Scheme 19).44 In here, 
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the ketene dithioacetal 82 undergoes a cycloaddition to afford isoxazolidine 83. This 
intermediate could than be easily transformed to cispentacin (57). However, the derivatisation 
of this cispentacin core is not trivial. 
 
Scheme 19. Keystep in Aggarwal’s synthesis of (-)-cispentacin (57). 
 
 
In the approach towards β- and γ-amino acids the highly functionalising intramolecular 1,3-
dipolar cycloaddition reaction was applied as well. In this course, γ-butyrolactone 67 was 
treated with N-benzylhydroxylamine hydrochloride in the presence of NaOAc . 3H2O in an 
aqueous ethanolic solution to afford 84. This nitrone intermediate could not be purified 
because of its instability on silica gel and its poor crystallisation properties. Attempts to 
cyclise the intermediate by heating in ethanolic solution, directly after nitrone formation, were 
not successful. Hence, the crude 84 after strict removal of water dissolved in anhydrous 
benzene and refluxed for 20 hours under nitrogen atmosphere to afford a diastereomeric 
mixture of fused cycloadducts 66a and 66b in a 3:1 ratio (Scheme 20). It is not surprising that 
bridged cycloadduct was not detected.  
 
Scheme 20. Cycloaddition of nitrone 84. 
 
 
 
Reagents and conditions: (a) N-benzylhydroxylamine hydrochloride, NaOAc.3H2O, ethanol/water (4:1), r.t., 2h. 
(b) Benzene, reflux, 20 h, 55%. 
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In both diastereomers all three five-membered rings are annulated in a cis fashion, but the 
quite high flexibility of the nitrone as well as of the terminal double bond allows the 
formation of two diastereomers in favour of the thermodynamically preferred 66a. The ratio 
of 78:22 is in the range of comparable intramolecular nitrone cycloaddition (INC) reactions 
whereas it is suggested that the solvent and the reaction temperature play a crucial role45 
though this effect was not investigated in detail so far. 
It should be mentioned that an epimerisation occurred during the cycloaddition at the 4a-H 
which is the most labile and therefore prone to isomerisation. First investigations of the two 
diastereomers using two-dimensional NMR spectroscopy already suggested that there is an 
inversion at one of the stereocenters since only a cis relationship of 4a-H to 5a-H adjacent to 
the lactone was detected. Hence, only a relative correlation determination of the stereocenters 
was possible. This observation was further confirmed by X-ray crystallography (Figure 12).  
 
Figure 12. Determination of the relative stereochemistry by X-ray structure analysis of the 
major cycloadduct 66a. 
 
  
 
Nevertheless, not only relative but also absolute stereochemistry needed to be determined. For 
that reason, a modified derivative of 66a was prepared and coupled to (R)-1-(4-
chlorophenyl)ethanamine which fortunately could be crystallised to give the desired 
information about the absolute stereochemistry of both 66a (Figure 13) and 66b taking in 
addition the two-dimensional NMR spectra into consideration. The X-ray structure proofed 
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the assumption that the α proton to the aldehyde and nitrone respectively is the most labile 
and is epimerised to give the less strained cis cycloaddition products. 
 
Figure 13. X-ray structure of 85. 
 
 
 
 
 
 
 
 
 
 
 
 
Having this valuable framework in hands a broad range of various cispentacin derivatives are 
accessible. Besides the formation of the desired scaffold, this valuable method provides also 
an amine as well as a carboxylic acid functionality precursor masked as isoxazolidine unit. 
Therefore, the conversion to the bicyclic cispentacin analogue can be achieved in a quite 
straightforward manner. 
As mentioned before the isoxazolidine moiety can be easily transformed into the 
corresponding amino acid. Consequently, the lactone annelated cispentacin is accessible by a 
hydrogenation, protection and oxidation sequence.  
Isoxazolidines are generally stable to hydrogenation conditions and furthermore benzyl 
protecting groups on amines are often difficult to remove too. Thus, it was not surprising, that 
hydrogenation with 10% Pd/C (atmospheric as well as higher pressures) did not affect the 
isoxazolidine moiety. Moreover, these building blocks are stable to a broad variety of other 
hydrogenation catalysts as well as to sodium amalgam or diimide.46 Nevertheless, three 
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methods were applied that showed to be successful in N-O bond cleavage and debenzylation 
of the amine. The first nicely performing method was the use of ammonium formate in the 
presence of Pd/C which needed to be heated in refluxing methanol for 20 hours. In another 
successful methodology zinc and copper(II)acetate in acetic acid were utilised to selectively 
cleave the N-O bond without removal of the benzyl group on the amine. However, these two 
approaches need very harsh conditions like high temperature or the use of neat acetic acid. 
Due to these drastic reaction parameters the formation of by-products and some 
decomposition was observed. Furthermore, they are not really suitable for more sensitive 
functional groups. This fact made it necessary to find easier and milder methods. The mildest 
and also the most yielding conditions were found to be the use of Pd(OH)2/C (Pearlman’s 
catalyst)47 under atmospheric hydrogen pressure which also provides the possibility of an in 
situ Boc protection of the free amine, whereas the protection with different activated Fmoc 
species in one pot failed. The Pd(II) species in Pearlman’s catalyst is reduced with hydrogen 
in situ and gives an extremely active catalyst. The high activity of Pearlman’s catalyst is due 
to his quite high loading (20% Pd(OH)2/C), which is very often advantageous for problematic 
debenzylations.48 It is also reported to be highly selective for N-debenzylation, which can also 
be performed in presence of benzyl ethers.49  
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Scheme 21. Three pathways to the desired amino alcohols. 
 
 
 
Reagents and conditions: (a) Pd(OH)2-C, H2, MeOH, overnight, quant. yield. (b) Zn/Cu(OAc)2, AcOH, reflux, 5 
h, 70 %. (c) Pd/C, NH4CHOO, Boc2O, MeOH, reflux, overnight, 76%.  
 
For the synthesis of the various β-amino acids containing a cispentacin core it was necessary 
to think about further applications, and hence to choose the suitable protecting groups 
accordingly for the amine or the carboxylic acid respectively. Here, the synthesis of Boc 
protected β-amino cyclopentane carboxylic acid (β-APC), as well as the preparation of the 
Fmoc protected analogue will be described. Like it was shown before the Boc amino alcohol 
can be easily prepared in situ during hydrogenation in good yields.  
For the preparation of Fmoc β-APC two routes are conceivable. On the one hand, simply by 
protecting the free amino alcohol and on the other hand the transposition of the Boc group by 
an Fmoc group. During first synthetic approaches the second, more extensive strategy was 
preferred since Fmoc chloride did not give satisfactory yields in the protection of amino 
alcohol 86 but of the corresponding amino acid (Scheme 22, Route A). However, Fmoc 
succinimide was applied successfully in the protection of the amino alcohols and therefore 
made the change of protecting groups redundant (Scheme 22, Route B). Unfortunately, an in 
situ Fmoc protection of the amino alcohol during the hydrogenation like reported by Kessler 
et al.50 for a similar system was not successful. 
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The protected amino alcohols 88 and 90 now needed to be converted to the final target 
molecules.  
 
Scheme 22. Two routes towards Fmoc β-APC. 
 
 
 
Reagents and conditions: (a) RuCl3, NaIO4, CCl4-CH3CN-H2O, 0°C to r.t., 90% (for 88); 75% (for 90). (b) (i) 
HCl/EtOAc, 0°C to r.t., quant. yield. (ii) FmocOSu, NaHCO3, acetone/water, 24 h, 93 %. (c) FmocOSu, 
NaHCO3, acetone/water, 73 % over two steps.  
 
The oxidation to the carboxylic acid can be achieved by a two step process via the aldehyde 
using methods like Dess-Martin periodinane or Swern oxidation followed by treatment with 
NaClO2. These methods provided the product in reasonable yields. However, a conversion in 
one step would be favourable. Unfortunately, there are only a quite limited number of 
methods known which often involve toxic Cr(VI) compounds under harsh conditions like in 
the Jones oxidation, which are incompatible to the sensitive functionalities in the molecule. A 
classical and mild method is the use of molecular oxygen in the presence of a platinum 
catalyst that should also be selective for primary alcohols.51 Regrettably, this approach did not 
show satisfactory results. The method of choice upon this was the employment of RuO452 
which was generated from catalytic amounts of RuCl3 in the presence of the stoichiometric 
oxidant sodium metaperiodate. Here, the methodology of Sharpless et al., avoiding the 
formation of lower valent ruthenium carboxylate complexes, was employed.53 
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This sequence gave rise to Fmoc-β-ACP (91) from 67 in 55%, and to Boc-β-ACP (89) in 68% 
overall yield. 
 
 
B. 1. 3 Modification of the lactone moiety – Synthetic access to different α-amino acid side 
chains 
 
Having this lactone annelated cispentacin in hand there are now a variety of conceivable 
modifications. For this purpose, the lactone moiety is a very versatile building block since it 
can be enolised, hydrolysed or reduced to the corresponding aldehyde or diol respectively. 
These transformations allow a broad range of alterations. However, basic hydrolysis of the 
lactone was not possible because of relactonisation upon acidic workup. Furthermore, 
attempts using boron triiodide-N,N-diethylaniline complex54 or hydrobromic acid under 
various conditions55 failed. For different modifications, reduction of the lactone to the 
corresponding diol was envisaged to be the method of choice. 
The synthesis of the hydroxyl β-APC started from the cycloaddition product 66a. For the 
reduction lithium aluminiumhydride was used obtaining 92 in quantitative yield. For the 
aqueous extraction a Rochelle’s salt solution was helpful to remove all formed aluminates. 
The reduction was followed by a selective protection of the primary alcohol. This was 
achieved using TBDMS chloride in the presence of triethylamine and a catalytic amount of 
DMAP. This selective protection yielded 93 in 92 % yield. The TBDMS group was chosen 
because of its good stability towards basic and slightly acidic conditions but nevertheless easy 
removability under strong acidic conditions or in presence of fluoride ions which have a high 
affinity for silicon.  
The protection of the secondary alcohol was accomplished using iodomethane in the presence 
of sodium hydride as a base to 94 (Scheme 23).  
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Scheme 23. Synthesis of the doubly protected diol 94. 
 
 
 
Reagents and conditions: (a) LAH, THF, 0°C, 1h, 98%. (b) TBDMSCl, NEt3, DMAP, CH2Cl2, 18 h, 92%.        
(c) MeI, NaH, THF, 86%. 
 
During this reaction elimination product 95 was observed occasionally. Therefore, the 
reaction conditions, namely the amount of sodium hydride and especially the temperature 
needed to be monitored carefully. An elimination product was observed when a large excess 
of sodium hydride was used or at temperatures above 30 °C. The formation of this elimination 
product is depicted in Scheme 24.   
 
Scheme 24. By-product formation during the protection of the secondary alcohol in 94. 
 
 
 
However, using 1.5 equivalents of sodium hydride and 5 equivalents of iodomethane the 
protected product can be isolated in 86 %. 
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The additional steps of the synthesis including hydrogenolytic N-O and N-benzyl cleavage 
followed by Fmoc protection and oxidation were performed accordingly to the 
abovementioned protocol (Scheme 25). 
 
Scheme 25. Final steps of the synthesis of the doubly protected hydroxyl β-ACP. 
 
 
 
Reagents and conditions: (a) Pd(OH)2-C, H2, MeOH, overnight, quant. yield. (b) FmocOSu, NaHCO3, 
acetone/water, 24 h, 86%. (c) RuCl3, NaIO4, CCl4-CH3CN-H2O, 0°C to r.t., 74%. 
 
Naturally, the methodology of modifying the side chain of the cispentacin scaffold can be 
further exploited. Demonstrating this high versatility, a conformationally restricted 
homoarginine derivative with a β-APC backbone was prepared. For this purpose, a similar 
route as in the synthesis of hydroxyl β-APC was chosen diverging at the stage of protected 
isoxazolidine 94.  
The acid lability of the silyl protecting group was utilised to selectively deprotect the primary 
alcohol of 94 using acetic acid.56 The hydroxyl group now needs to be converted to a 
guanidine. There are several methods and reagents for the preparation of guanidines57 but 
almost all of them involve the conversion of an amine to a guanidine. For this purpose a broad 
range of reagents is available but their utility is limited by the availability of the starting 
amines. However, there is a very efficient and mild method for the preparation of guanidines 
without using amines as a starting material. Employing a Mitsunobu protocol and N,N-
bis(tert-butyloxycarbonyl)guanidine or N,N-bis(benzyloxycarbonyl)guanidine as nucleophiles 
protected guanidines can be generated starting from an alcohol.58 In this synthesis the 
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deprotected primary alcohol (98) was reacted with a doubly Boc protected guanidine which 
was prepared from guanidinium hydrochloride and Boc2O giving 99 in 76% yield.59  
 
Scheme 26. Acidic deprotection of the TBDMS alcohol followed by guanidinylation using a 
Mitsunobu protocol. 
 
 
Reagents and conditions: (a) AcOH, THF/water, 0°C to r.t., 88%. (b) N,N-bis(tert-butyloxycarbonyl)guanidine, 
PPh3, DEAD, THF, 0°C to r.t., 76%. 
 
The synthesis of the cispentacin arginine analogue was subjected to similar conditions like in 
the aforementioned protocols. The opening of the isoxazolidine and the debenzylation with 
Pd(OH)2 under hydrogen at atmospheric pressure was followed by Fmoc protection.  
However, during the hydrogenolytic formation of the free amine 100 an undesired carbamate 
shift of the Boc group of ε-N in guanidine to the free amine occurred. The following addition 
of FmocOSu then gave rise to a mixed Boc, Fmoc protected guanidine 101 in 69% yield. 
 
Scheme 27. Boc-shift during hydrogenation.  
 
 
This lability of δ-N-Boc groups in arginine and its tendency to migrate was already reported 
by Goodman et al.59 This observation suggests that this shift is an intermolecular process due 
to quite high spatial distance between the β- and the ε-Boc-N.   
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Scheme 28. Synthesis of mixed Fmoc, Boc protected guanidinium β-APC. 
 
 
Reagents and conditions: (a) Pd(OH)2-C, H2, MeOH, overnight, quant. yield. (b) FmocOSu, NaHCO3, 
acetone/water, 5 h, 69%. (c) RuCl3, NaIO4, CCl4-CH3CN-H2O, 0°C to r.t., 65%. 
  
The final oxidation of compound 101 using RuCl3 afforded 102 in 65% yield. 
 
 
B. 1. 4. Application of new cispentacin analogues in peptides 
 
B. 1. 4. 1. Solid phase peptide synthesis (SPPS) 
 
“To equal Nature […] I therefore foresee the day when physiological chemistry will not only 
make extensive use of the natural enzymes as agents, but when it will also prepare synthetic 
ferments for its purposes.”60  
This dream of E. Fischer, which he envisioned in his Nobel lecture in 1902, made him one of 
the first chemists thinking of the artificial preparation of large biological active 
macromolecules. However, it took until the early 1950s when Vigneaud et al. initiated a new 
era in biology and chemistry by the isolation, determination of structure and, most important, 
synthesis of oxytocin and analogues.61 The work in this field was also honoured with the 
Nobel price in 1955. During this period more and more peptides were characterized but could 
be isolated often enough only in small quantities. This development, and in addition the need 
of peptide analogues to study structure-activity-relationships (SAR), made it necessary to 
synthesise these desired compounds. With increasing intricacy of the peptides the classical 
method of solution phase peptide synthesis met its limits, since the coupling reactions gave 
only moderate overall yields which were often contaminated with side products. These 
problems stimulated many scientists to think of more sophisticated techniques to produce 
peptides. The breakthrough was the work of R. B. Merrifield who conceived and elaborated 
the solid-phase alternative. In his approach the synthesis is still carried out in solution but the 
growing peptide chain is anchored on an insoluble solid support. The improved yields are due 
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to high excess of soluble reagents which can be removed simply by washing and filtration 
retaining the nascent peptide on the solid support. 
The protection of the amino acids that are attached stepwise need a special orthogonal 
protection scheme. Two kinds of protection groups are required, on the one hand a temporary 
protection group which can be removed after each coupling step to free a reactive group that 
can then undergo the next coupling. On the other hand, there is a need for ‘permanent’ 
protection groups for the side chains of the amino acids which are stable to the coupling 
conditions but can be selectively cleaved at the end of the synthesis to gain the free peptide. 
Most established is the Fmoc/tBu chemistry,62 what means that the amino group that needs to 
be coupled is protected with the base labile Fmoc group and can be easily removed in situ by 
using piperidine. Therefore, the side chains of the amino acids having reactive functional 
groups demand a base stable protecting group. Generally, acid labile protecting groups are 
chosen (e.g. tBu and Boc) to afford the free peptide in one step contemporaneous to the 
cleavage from the resin which can be achieved under acidic conditions as well. This mild 
Fmoc strategy is favoured over the Boc SPPS since the repetitive TFA acidolysis of the Boc 
group can lead to decomposition or alterations of sensitive peptides. Furthermore, this 
approach often needs dangerous HF for deprotection and cleavage from the resin. 
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Scheme 29. General scheme of SPPS.63 
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The solid support resins for SPPS need to be of small, low cross-linked particles which can 
swell more then 6-fold in volume giving the possibility for a fast diffusion of reagents. The 
simplest used resins are polystyrenes like chloro- or aminomethylpolystyrene which are 
crosslinked (~ 1% cross-linked) with divinylbenzene. However, these materials where 
supplanted by polystyrene-polyethylene glycol graft polymers (PEG-PS, TentaGel or 
NovaSyn® TG) and polyethylene glycol dimethyl acrylamide co-polymers (PEGA) with a 
loading capacity between 0.2 and 0.8 mmol per g depending on the degree of branching.  
For SPPS these polymers need to be functionalised with different linkers depending on the 
applied requirements and coupling strategy.  For the Fmoc/tBu strategy the commonly used 
resins can be divided into four subgroups:64  
 
a. The Wang linker (4-Alkoxybenzyl alcohol resin)  
b. The more acid-labile SASRINTM linker (2-Methoxy-4-alkoxybenzyl alcohol resin) 
having the same structure like the Wang resin but with the addition of a methoxy 
group, which leads to the free peptide acids. 
c. Fmoc-amide resin (2,4-Dimethoxy-4’-[carboxymethyloxy]-benzhydrylamine linked to 
amino methyl resin) and the Rink amide linker which lead to C-terminal amidated 
peptides. 
d. Traceless linker like the silyl linkers, which gained their name from the fact, that the 
final compound does not reveal the point of linkage to the solid phase. 
 
As a matter of course many combinations and subtypes of these basic subtypes are 
commercially available. 
The coupling of the amino acids to the resin starts with the modification of the resin and 
linker respectively in a way that a free accessible functionality is gained whereon the first (C-
terminal activated) Fmoc-amino acid is coupled. After this initial step the N-terminal Fmoc 
group is removed by treatment of solutions of piperidine and/or DBU to free the amino group 
which is then prone to the attachment of the next Fmoc-amino acid. Activation of these amino 
acids can be accomplished by using carbodiimides, preformed symmetrical anhydrides or 
active esters like OBt or OPfp esters. However, the most commonly used strategy in SPPS is 
the in situ activation of the carboxylic acids. For this process a wide range of activation 
reagents is known (Figure 14). These reagents are extremely helpful in forming HOBt, 
succinimidyl or other active esters.  
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Figure 14. Coupling reagents in SPPS. 
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The abovementioned β-amino acids were investigated concerning their behaviour in peptides. 
Therefore, some of the cispentacin analogues were coupled in a SPPS approach.  
The primarily approach was the synthesis of a α-β-alternating peptide of 91 and (L)-Ala 
(Figure 15). 
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Figure 15. α-β-Alternating peptide from 65 and (L)-Ala. 
 
 
 
This sequence was chosen to examine the coupling performance of 91 in SPPS and as 
potential new foldamers building block akin to the α-β-peptides of β-ACC which were shown 
to adopt a helical conformation (Figure 16).65  
 
Figure 16. Helical conformation of short (L)-Ala-β-ACC peptide. 
 
 
 
Fortunately, this synthesis showed that the standard coupling procedures for SPPS could be 
applied and no racemisation or ring opening of the lactone occurred. The synthesis was 
performed on the commercially available Fmoc-protected Rink amide MBHA resin with a 
loading of 0.64 mmol/g (Scheme 29). Cleavage of the Fmoc group with piperidine provided 
the free amine which was subsequently coupled with the first amino acid, Fmoc-Tyr(OtBu)-
OH. In the following steps the same deprotection-coupling protocol was applied. Finally the 
peptide was removed from the resin with a ‘cleavage cocktail’ (TFA/TIS/H2O 90:5:5) 
providing the three differently N-terminal modified peptides of 103.  
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Scheme 29. Synthesis of α-β-alternating peptides. 
 
 
 
Reagents and conditions: (a) (i) 40% Piperidine in DMF/NMP (80:20), (2 x 5 min). (ii) Fmoc-Tyr(OtBu)-OH (5 
equiv), HBTU (5 equiv), DIPEA (10 equiv), DMF, 1 hr. (b) (i) 40% Piperidine in DMF/NMP (80:20), (2 x 5 
min). (ii) Fmoc-Gly-OH (5 equiv), HBTU (5 equiv), DIPEA (10 equiv), DMF, 1 hr. (c) (i) 40% Piperidine in 
DMF/NMP (80:20), (2 x 5 min). (ii) Fmoc-Acp-OH (3 equiv), HBTU (3 equiv), DIPEA (6 equiv), DMF, 1.5 hr. 
(e) (i) 40% Piperidine in DMF/NMP (80:20), (2 x 5 min). (ii) Fmoc-Ala-OH (5 equiv), HBTU (5 equiv), DIPEA 
(10 equiv), DMF, 1 hr. (iii) repeat (c) and (d) twice. (f) TFA/TIS/H2O, 1.5 hr.  
 
 
1. 4. 2. Structural investigations of α-β-peptides and biological activity of NPY analogues 
 
All of the three peptides were purified by preparative HPLC and subsequently investigated by 
CD- as well as two-dimensional NMR spectroscopy.  
CD spectroscopy is a common method to investigate secondary structures in peptides and 
proteins. Circular polarised light interacts with optically active molecules depending on their 
secondary structure. When the optical active chromophore interacts with planar polarised 
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light, consisting of left and right circular polarised light, some parts of the spectrum are 
absorbed resulting in elliptically polarised light. The extent of this ellipticity can be measured 
after recombination of the left and right polarised light. The absorbance values of peptidic 
chromophores are due to a low energy npi* transition centred around 220 nm and a higher 
energy pipi* transition around 190 nm.66  
The typical CD spectra for α-peptides are shown in Figure 17. 
 
Figure 17. CD spectra of the common secondary structures seen for α-peptides.67 
 
 
The CD spectra of α-peptides and proteins are well established but there are of course also 
examples for CD spectra of α-β-alternating and unnatural amino acid containing peptides 
respectively.65 
The three investigated peptides showed to be quite similar concerning their CD profile 
(Figure 18). The shapes of the graphs are comparable to the spectra of (L)-Ala-β-ACC 
alternating hepta- and nonapeptides which were shown to have a 313 helical fold.68 Moreover, 
the structure seems to be quite independent of the solvent having similar shapes in methanol, 
water and the helix promoting solvent TFE. 
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Figure 18. CD spectra of the three differently N-terminal modified α-β-peptides. 
 
 
 
 
 
 
 
However, the quite high variability of the temperature coefficient (∆δ/∆T) of the amide 
protons as well as the most prominent long range couplings in NOE spectroscopy (Figure 19) 
suggest that a well ordered structure was not present in this α-β-peptide. 
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In the same way like shown in Scheme 29 some NPY analogues were prepared. In this 
context, similar to β-ACC containing NPY analogues like 106 the cispentacin containing β-
amino acids were incorporated into the peptide, namely in position 34 and 32 (in terms of the 
numbering of the natural peptide; 104 and 105). These positions are of high importance since 
they are adjacent to the Arg33 and Arg35 which were shown to be highly important for 
activity as well as selectivity.24 The substitution or removal of the C-terminal arginines were 
shown to be detrimental or resulted in complete loss of activity.  
 
Figure 20. NPY analogues containing cispentacin derivative 65 (left) and containing β-ACC 
(right). 
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All cispentacin containing peptides were tested at the Department of 
Pharmaceutical/Medicinal Chemistry II, University of Regensburg concerning their affinity 
towards Y1, Y4 and Y5 receptors using Ca2+ assay as well as fluorescence activated cell 
sorting (FACS). Unfortunately, their affinities were found to be only in a high micromolar 
range and therefore are not useful for any further pharmacological experiments.  
Ultimately, the lactone fused and other cispentacin derivatives seem to have neither a similar 
nor beneficial effect when compared to β-ACCs. 
 
 
B. 2. Preparation of a bicyclic β-proline derivative as potential new organocatalyst 
 
B. 2. 1. Introduction 
 
Since the pioneering work of List et al.69 in the field of organocatalysis using proline in aldol 
reactions this field has emerged tremendously. Ever since, not only proline but an enormous 
number of amino acids and related compounds were utilised for various transformations in 
synthetic chemistry.70 However, not only α-amino acid derivatives but also β-amino acids 
have attracted chemists and were successfully applied. 
Interesting examples are the glycosyl-β-amino (107) acids derived from sugars which were 
applied in aldol reactions.71 Moreover, the organocatalytic properties of (S)-homoproline 
(108),72 homoproline tetrazole (109)73 and homoproline sulfonamides74 derivatives in various 
reactions are under investigation by several groups. Very recently, the constrained β-proline 
analogue and 110 was applied in organocatalytic Aldol reactions by Armstrong et al.75 In their 
work they studied the influence of the acid geometry in the aforementioned reactions. 
Even cispentacin (57) was shown to be a highly active and selective catalyst in the Hajos-
Perrish-Sauer-Eder-Wiechert reaction.76 The activity of the lactone cis-fused cispentacin 
derived from 66b, which is described in this work, was also investigated in a quite limited 
preliminary study concerning its catalytic behaviour in this reaction and showed comparable 
results. Therefore, the lactone moiety blocking one side of the molecule did not show any 
effect to improve this reaction. 
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Figure 21. β-Amino acids in organocatalysis. 
 
 
 
 
Nevertheless, restricting and sterically shielding fragments in organocatalysts are envisioned 
to be valuable for selectivity in catalysis.          
 
 
B. 2. 2. Synthesis of bicyclic homoproline 
 
The substantial capability of the nitrone cycloaddition product 66a was already shown for 
cispentacin derivatives with different side chains. Moreover, not only cycloadduct 66a but 
also the second diastereomer 66b is a quite versatile building block. It can give rise to similar 
β-amino acids as shown in the abovementioned examples with an all-cis configuration.  
However, 66b is only be obtained as a minor diastereomer in the cycloaddition reaction under 
the herein applied conditions. 
Hence, methods need to be developed to increase the amount of the minor diastereomer. In 
this regard, Jäger et al. could show that the ratio of syn- to anti-cyclopentanoisoxazolidines 
112 and 113 in the cycloaddition of 111 depends strongly on the choice of solvent.77 In polar 
solvents like methanol the syn-tricycle was preferred whereas nonpolar solvents like 
chloroform favoured the formation of the anti isomer. The values for these reactions ranged 
from 87:13 to a complete inverse ratio of 5:95 (syn/anti).  
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Scheme 30. Intramolecular nitrone cycloaddition step in the synthesis of 
amino(hydroxymethyl)cyclopentanetriols according to Jäger et al.77 
 
 
 
Moreover, it was shown by M. Kuhn78 that the diastereomeric ratio in the case of γ-
butyrolactone nitrones can be modified by the use of a different solvent as well as the addition 
of acids or bases. This accidental result was observed in attempts to alkylate the nitrone in the 
presence of zinc(II)-triflate and Hünig’s base in dichloromethane (Scheme 31). In these 
reactions the desired alkylation product was not formed, but inter- and intramolecular 
cycloaddition products 115 and 66a/b instead. Here, the correlation changed from about 3:1 in 
benzene to 2:1 under the conditions of this reaction. This result suggests that it is possible to 
alter the diastereomeric ratio of this transformation by using different solvents and/or other 
additives. The influence of the aforementioned factors still needs to be examined in detail. 
 
Scheme 31. Unanticipated results in the attempts to alkylate the nitrone in 84. 
 
 
Reagents and conditions: (a) Zinc(II)-triflate (10 mol%), DIPEA (25 mol%), CH2Cl2, r.t. for 48 h then 50 °C for 
16 h, 28% for 115, 37% for 66a/66b (dr 2:1). 
 
In contrast to 66a, the stereochemical correlations in 66b can give rise to different 
transformation pathways like a rearrangement of the lactone moiety to the corresponding 
lactame. To obtain lactame 116 the N-O bond of the isoxazolidine needs to be cleaved. In the 
present case it can be achieved using the Zn/Cu(OAc)2 system in acetic acid at elaborate 
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temperatures. These conditions allow an opening of the heterocycle without removing the 
benzyl group on the amine and are frequently applied for breaking N-O bonds in nitrones and 
isoxazolidines.79 During the course of the reaction the formation of the desired product as well 
as of a secondary product was observed. This ‘by-product’ was identified as the lactame 
rearrangement product. After purification on silica gel the two products were obtained as a 
mixture of lactone and rearranged lactame in varying ratios. The remaining benzyl amino 
alcohol lactone 87 was then subjected to basic conditions to be rearranged to lactame 116.  
These N-O acyl migrations are already known since the early 20th century. This is especially 
true for the transformation from lactones to lactames (Scheme 32). Sometimes it was shown, 
that this rearrangement is in a pH dependent equilibrium and was utilised in several natural 
product syntheses.80  
 
Scheme 32. First example of the rearrangement from lactones to lactames by Walton and 
Green81. 
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For this transformation from lactone to the lactame different basic conditions with inorganic 
bases like LiOH and organic bases like triethylamine in different solvent mixtures were 
screened. However, the best base proved to be DBU, what was already shown for similar 
lactone rearrangements by G. Geyer82 (Scheme 33).  
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Scheme 33. Hydrogenolytic cleavage of the N-O bond and rearrangement from lactone 87 to 
lactame 116. 
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Reagents and conditions: (a) Zn/Cu(OAc)2, AcOH, ∆, 2 hr, quant. (mixture of 87 and 116). (b) DBU, MeOH, 5 
hr, 0°C - r.t., 81%. 
 
Lactame 116 now needs to be reduced to the corresponding amine. The most commonly used 
reagent for this reduction is LAH83 but also other reagents and methods were applied like 
DIBALH84, rhodium- and platinum-catalysed silane reductions85 or lithium 
aminoborohydrides.86 In this synthesis another classical method was employed, namely the 
use of boranes.87 The BH3.DMS complex in THF was successfully applied in the conversion 
of the lactame to amine 117 in excellent yield. However, due to quite long reaction times, 
LAH was used affording 117 in 81% yield. 
The diol of the benzylated amino alcohol now needs to be properly orthogonally protected to 
be prepared for further modifications. For that reason the primary alcohol was protected in a 
similar way as in the syntheses of the previous amino acids by TBDMS chloride in the 
presence of triethylamine to give 118. The secondary alcohol can now be variously altered by 
SN reactions or oxidations and further transformations. This position would of course also 
allow a ether formation with propargyl bromide which then could arise the possibility of 
immobilisation on various solid supports using ‘click-chemistry’. 
However, it was decided to protect the alcohol by methylation. This was again achieved by 
the use of iodomethane in presence of NaH yielding 119. Finally, the conversion of the 
primary silyl ether was necessary. Deprotection and in situ oxidation to the carboxylic acid 
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was performed under the acidic conditions of a Jones oxidation following a slightly modified 
protocol of Evans et al.88 to give 120 in good yield. This method was preferred over the 
method by Liu and Han89 who additionally used potassium fluoride, which was shown to be 
superfluous.  
 
Scheme 34. Final steps in the synthesis of β-proline analogue 119. 
 
 
Reagents and conditions: (a) LAH, THF, r.t., 81%. (b) TBDMSCl, NEt3, DMAP, CH2Cl2, 18 h, 79%. (c) MeI, 
NaH, THF, 12 h, 77%. (c) Jones reagent, acetone, 0 °C – r.t., 83%. 
 
The application of this reaction in aldol as well as in conjugate additions is currently under 
investigation in the Reiser group.  
 
 
B. 3. Conformationally restricted γ-amino acids 
 
B. 3. 1. Introduction 
 
γ-Amino acids are undoubted a very important class of amino acids and were intensively 
studied with the intent to generate new GABA analogues, turn inducing building blocks in 
peptides or peptidomimetics and to study their properties in foldamers.90  
However, γ-peptides are comparatively not so well studied like their β- and, of course,          
α-peptide counterparts. Nevertheless, they also show an ability to fold into defined secondary 
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structures which are reported to have interesting biologic activities.91 Therefore, over the last 
few years the stereoselective synthesis of new linear as well as cyclic γ-amino acids and their 
application as GABA analogues as well as in γ-peptides gained significant interest.90b As 
already outlined in the introduction of this work there are quite a number of different 
approaches towards various γ-amino acids. This includes also the synthesis of cyclic γ-amino 
acid derivatives (Cnα,β, Cnα,γ and Cnβ,γ; n indicates the ring size and the Greek letters indicate 
the position of the junction atoms of the cycle).90b An interesting approach was published by 
Mohapatra starting from trans-cinnamyl alcohol to trans-C3α,β amino acids (rct 1; Scheme 
35). Another synthesis of cyclopropane containing compounds was described by Ley et al. 92 
who applied an enzymatic desymmetrisation of cyclopropane dicarbonic acid methyl ester 
using pig liver esterase yielding cis-C3α,β amino acids (rct 2; Scheme 35). Furthermore, there 
are also a various number of syntheses for C4α,γ and C5α,γ amino acids.  
 
Scheme 35. Syntheses of different C3α,β amino acids. 
 
 
 
In this context, López et al. recently described a stereoselective synthesis of cyclobutane 
containing amino acids starting from commercially available α-pinene (rct. 1; Scheme 36).93 
The synthesis of cis and trans-cyclopentane γ-amino acids is also reported starting from        
2-azabicyclo[2.2.1]hept-5-en-3-one or simple norbornene (rct.2 and 3; Scheme 36).94 
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Scheme 36. Syntheses of different C4α,γ and C5α,γ amino acids. 
 
 
 
However, the synthesis of foldamers from cyclic γ-amino acids remains quite neglected and 
only view examples are known.95 A remarkable synthesis was reported by Smith et al. who 
described γ-peptides which fold into parallel sheet structures as well as into bend-ribbons 
(Figure 22). The building blocks used in these syntheses are C5α,β (120) a C3α,β (121) amino 
acids. 
 
Figure 22. Foldamers of cyclic γ-amino acids according to Smith et al.  
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B. 3. 2. Synthesis of new trans C5β,γ amino acids 
 
As mentioned in the previous chapter there are quite a number of syntheses for γ-amino acids. 
However, the construction of C5β,γ scaffolds is not as well investigated like for the other 
frameworks. One possibility was shown by Pätzel et al. who derived cyclopropane γ-amino 
acids from optically active nitroalkenes.96 In their approach, nitroethane was added to an 
acetonide of (R)-glyceraldehyde (122) affording the nitroaldol adduct 123, which can be 
dehydrated to nitroalkene 124. Cyclopropanation of 125 using a diphenylsulfur ylide gave the 
cyclopropane derivative 126, which by catalytic hydrogenation and N-protection with TFAA 
yielded 127. Finally, the cleavage of the acetonide was followed by an oxidation of the 
primary alcohol and a TFA deprotection affording α-hydroxy-γ-amino acid 128. 
 
Scheme 37. Synthesis of γ-amino acids from the acetonide of (R)-glyceraldehyde 122. 
 
 
Reagents and conditions: (a) Nitroethane, KF (cat.), neat, r. t., 18 h, 62-95% (b) DCC (1.2 equiv), CuCl(cat.), 
Et2O, r. t., 24–100 h; 14–70%. (c) PhS-CMe2 (1.2 equiv), DME, -70°C – r.t., 18 h; 74%, d.r. 94:6. (d) (i) H2 (10–
15bar), Pd–C (cat.), MeOH, r. t., 48 h; 74%; (ii) TFAO2 (e) p-TsOH.1H2O (cat.) MeOH/H2O (10:1), r. t., 18 h, 
97%. (f) (i) Et3SiCl (3.0 equiv), NEt3 (4.0 equiv), CH2Cl2, DMAP (cat.), -18°C – r. t., 18 h, 97%. (ii Swern 
oxidation, 77%. (iii) NaOCl2 (1.4 equiv), H2O (1.05 equiv), NaH2PO4 (cat.), MeCN/H2O (2:1), 0°C to r. t., 1 h, 
42%; (iv) Ba(OH)2.8H2O (4.8 equiv), MeOH, r. t. for 24 h then reflux for 2 h, 96%.  
 
A different synthetic approach towards cyclobutane γ-amino acids was reported by Baldwin et 
al.97 Here, 2-(dibenzylamino)-cyclobutanone 129 was reacted with tert-butyl bromoacetate 
under Reformatsky conditions affording the racemic mixture of 130 and 131 (8:1). 
Debenzylation gave the corresponding amino alcohol 132 which upon coupling with Boc-(S)-
valine in the presence of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) yielded a 
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diastereomeric mixture of 134 and 136. After separation of the diastereomers the final 
treatment under acidic conditions afforded 1-hydroxy-2-aminocyclobutane-1-acetic acids 135 
and 137. 
 
Scheme 38. Synthesis of γ-amino acids from 2-(dibenzylamino)-cyclobutanone 129. 
 
 
 
Reagents and conditions: (a) BrCH2CO2tBu, Zn, THF, reflux, 1.5 h, 70%. (b) Pd/C, H2 (1 atm), MeOH, r. t., 
78%. (c) EEDQ, CH2Cl2, 24 h, 69 %. (d) 2 N HCl, reflux, 10-20 h. 
 
However, until today - to the best of knowledge of the author - there is no synthesis reported 
for trans or cis C5β,γ γ-amino acids. A new approach towards these γ-amino acids highlights 
once again the versatility of cycloadducts 66a and 66b. The before described doubly protected 
diol intermediate 94 can be deprotected and oxidised in one pot under Jones oxidation 
conditions yielding carboxylic acid 138. During this reaction the acidic conditions will 
initially provoke a cleavage of the silyl ether which is then followed by the Cr(IV) mediated 
oxidation. Subsequently, the isoxazoline moiety of 138 is opened by a reduction using 
hydrogen at atmospheric pressure catalysed by Pd(OH)2-C which once again also removes the 
benzyl group of the amine. The resulting free amine can now be protected by FmocOSu under 
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basic conditions affording the γ-amino acid 139 with a free hydroxyl group which gives the 
possibility for further derivatisation obtaining differently substituted γ-amino acids     
(Scheme 39). 
 
Scheme 39. Synthetic scheme towards the trans C5β,γ γ-amino acid  
 
Reagents and conditions: (a) Jones oxidation, acetone, 0°C – r. t., 86%. (b) (i) Pd(OH)2-C, H2, MeOH, overnight, 
86%. (ii) FmocOSu, NaHCO3, acetone/water, 24 h, 58%. 
 
It is worth mentioning, that the preparation of the cis analogue 141 of this γ-amino acid failed 
using selfsame synthetic route. In the case of 140, Jones oxidation afforded the tricyclic 
intermediate 142 which was inert towards further oxidation and conversion to 141. 
 
Scheme 40. Failure in the attempt to synthesise 141 due to formation of inert intermediate 
142 (left); X-ray structure of tricyclic oxidation intermediate 142 (right). 
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The behaviour of 139 in Homo- and Heteropolymers as well as in other peptides is currently 
under in investigation in the Reiser group. 
 
 
B. 4. Preparation of Diketopiperazine (DKP) amino acids and their application in 
organocatalysis 
  
B. 4. 1. Introduction 
 
DKPs are cyclic dipeptides composed of two α-amino acids. These scaffolds are a common 
motif in natural products and have a broad range of applications in various fields. Their 
structure was first reported by Corey in 1938 who elucidated them via X-ray 
crystallography.98 Especially, many of their chemical features make them highly beneficial for 
medicinal chemistry, such as high resistance to proteolysis, the possibility of mimicking 
peptidic pharmacophoric groups, conformational rigidity, their quite simple preparation and 
many others.99 Hence, they have been used as PAI-1 inhibitors (143), antiarrhythmic agents 
for the treatment of cardiovascular dysfunctions (144), as analogues of pyrimidinic bases in 
antiviral agents (145) and also showed activity in antimicrobial testing (146) (Figure 23). 
 
Figure 23. Various biologically active compounds containing a DKP motif. 
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Furthermore, DKPs were successfully applied as peptidomimetics by Piarulli et al.100 who 
used a new bifunctional diketopiperazine scaffold as a β-hairpin inducer, and in selective 
B.   Main part  61 
peptide recognition using DKP receptors by Wennemers et al.101 Another application is the 
introductorily mentioned Schöllkopf synthesis which allows an intra-annular chirality transfer 
in the synthesis of natural and unnatural α-amino acids. All these results are an encouraging 
starting point for further investigations. 
 
 
B. 4. 2. Synthesis of trans-DKP scaffold 
 
The scaffold which was chosen for different new applications is a DKP composed of (R)-2,3-
diaminopropionic acid and (L)-aspartic acid. This combination gives rise to a cyclic β2/β3 
amino acid having the amino functionality and the carboxylic acid in a trans configuration 
(Figure 24). 
 
Figure 24. Structure of trans-DKP 147. 
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The synthesis of 155 was accomplished similar to a known strategy.100,30 (D)-Serine (148) 
was converted to its methyl ester followed by a benzyl protection of the amine functionality 
under reductive amination conditions using benzaldehyde to yield 149. In the second amino 
acid, (L)-aspartic acid (150), the carboxylic acid of the side chain could be selectively 
protected as an allyl ester, followed by a N-Boc protection under standard conditions to form 
151. These two orthogonally protected amino acids were then coupled to form dipeptide 152 
using HBTU. After Boc deprotection of 152 with trifluoroacetic acid the corresponding TFA 
salt was stirred in a 1:1 mixture of ethyl acetate and saturated NaHCO3, leading to cyclisation 
and formation of DKP 153.  Introduction of the azide functionality to 154 was accomplished 
under Mitsunobu conditions using hydrazoic acid. Subsequently, azide 154 can be converted 
to a Boc protected amine in a one pot reaction applying a Staudinger reduction in the presence 
of BocON [2-(tert-butoxycarbonyloxyimino)-2-phenyl-acetonitile] to yield 155.  
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Scheme 41. Preparation of Boc-trans-DKP-OAllyl. 
 
 
 
Reagents and conditions: (a) (i) AcCl, MeOH, 65%. (ii) PhCHO, NEt3, MeOH, then NaBH4, 71%. (b) (i) 
Allylalcohol, AcCl, 71%. (ii) NEt3, Boc2O, dioxane/H2O, 88%. (c) HBTU, DIPEA, DCM, 78%. (d) (i)TFA, 
DCM. (ii) Sat. NaHCO3, EtOAc, 87% over two steps. (e) HN3.toluene, PPh3, DIAD, toluene/DCM, -20 °C, 91%. 
(f) Me3P, Boc-ON, toluene, -20 °C, 79%.  
 
 
B. 4. 3. Pro-trans-DKP esters and amides in organocatalysis 
 
Not only amino acids - as already addressed in chapter B. 2. 1. of this work – but also 
peptides are highly useful organocatalysts. Thanks to the recent investigations of Wennemers 
et al. this field has becoming increasingly popular.102 The Wennemers group was able to 
identify new organocatalysts from a pool of almost 3500 tripeptides using a catalyst-substrate 
coimmobilisation in split-and-mix libraries.103 These tripeptide scaffolds, and particular the 
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H-Pro-Pro-Asp-NH2 sequence, showed to be highly effective concerning yield and selectivity 
in the aldol condensation of acetone and aromatic and aliphatic aldehydes104- as well as in 
conjugate additions105 showing its enormous potential. The secondary amine of proline at the 
N-terminus and the carboxylic acid functionality of the aspartic acid side chain are crucial for 
the catalytic activity suggesting that the mechanism is similar to enamine activation proposed 
for proline catalysis. Moreover, a defined turn structure within the peptide was demonstrated 
to be essential.106 The importance of these features was also demonstrated by the Reiser group 
by introduction of the turn inducing β-ACC in between to proline units which was 
successfully applied in aldol reactions.107 
Even though these results show that there is a quite limited space of variation in the peptide 
sequence and substitution pattern, these results led to the hypothesis that coupling of proline 
to DKP scaffolds 153 or 155 (after N-deprotection) might lead to interesting organocatalysts. 
In fact, the Pro-DKP derivatives provide the secondary amine of the proline moiety and a free 
carboxylic acid connected by a shape inducing element, the DKP itself. In this way up to four 
different organocatalyst precursors could be formed by coupling either enantiomer of Boc-
proline with in turn the hydroxy-derived DKP 153 and the amino functionalised DKP 155. 
The Pro-DKP esters were prepared by esterification of Boc-Pro-OH to the hydroxyl 
functionality of DKP 153 using a standard EDC, HOBt protocol. After deallylation of 156 
Boc-Pro-DKP (157) esters were obtained (Scheme 42).  
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Scheme 42. Preparation of Boc-Pro-O-DKP esters. 
 
 
Reagents and conditions: (a) Boc-Pro-OH, EDC, HOBt, DMAP, DCM/THF, 5 h, 0°C – r. t., 96 % (for (D)-Pro). 
(b) Pd(Ph3)4, PPh3, pyrrolidine, DCM, 3 h, 0°C – r.t., 77% (for Boc-(L)-Pro-O-DKP-OH) and 98% (for Boc-(D)-
Pro-O-DKP-OH).  
 
The analogous Pro-DKP amides were prepared by a peptide coupling of Boc-Pro-OH to Boc 
deprotected 155 using HBTU to yield 158. Again, deallylation afforded the Boc protected 
organocatalyst precursor 159 (Scheme 43). 
 
Scheme 43. Preparation of Boc-Pro-DKP amides. 
 
 
Reagents and conditions: (a) (i) TFA/DCM (1:1), 0°C – r.t., 30 min. (ii) Boc-Pro-OH, HBTU, collidine, MeCN, 
overnight, 0°C – r. t., 98% (for (L)-Pro) and 97% (for (D)-Pro). (b) Pd(Ph3)4, PPh3, pyrrolidine, DCM, 3 h, 0°C – 
r.t., 74% (for Boc-(L)-Pro-O-DKP-OH) and 93% (for Boc-(D)-Pro-O-DKP-OH).  
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In this regard, it should be mentioned that both enantiomers of proline were applied in the 
synthesis. In addition, also the cis-DKP counterparts of the aforementioned DKP esters and 
peptides were synthesised in the Piarulli group in order to have a small library of compounds 
for the testing of their catalytic activity. 
The final Boc deprotection of the amide and ester precursors gave the TFA salts of catalysts 
160, 161, 162 and 163. 
 
Figure 25. Applied catalysts in addition of aldehydes and ketones to β-nitrostyrene. 
 
 
As a benchmark reaction to test the effectiveness of all these catalysts, the conjugate addition 
of propanal and β-nitrosytrene was chosen. The reaction conditions and the results are 
summarised in Table 3. 
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Table 3. Addition of propanal to β-nitro styrene using DKP catalysts. 
  
 
 
Entry Cat. Solvent t [h] yield [%] syn:anti ee [%] Abs. Conf. 
1 (L)-Pro CH2Cl2 24 88 4:1 23 (R, S) 
2 A a (10 mol%) CH2Cl2 24 49 11:1 52 (S, R) 
3 B a (10 mol%) CH2Cl2 24 62 20:1 83 (S, R) 
4 C a (10 mol%) CH2Cl2 24 63 4:1 30 (R, S) 
5 D a (10 mol%) CH2Cl2 12 95 3:1 60 (R, S) 
6 A a (10 mol%) CHCl3/iPrOH (9:1) 5 96 n.d. 53 (S, R) 
7 B a (10 mol%) CHCl3/iPrOH (9:1) 4 98 n.d. 89 (S, R) 
8 C a (10 mol%) CHCl3/iPrOH (9:1) 5 95 n.d. 29 (R, S) 
9 D a (10 mol%) CHCl3/iPrOH (9:1) 4 89 n.d. 86 (R, S) 
10 b B a (10 mol%) CHCl3/iPrOH (9:1) 9 93 n.d. 89 (S, R) 
11 b D a (10 mol%) CHCl3/iPrOH (9:1) 9 95 n.d. 91 (R, S) 
12 b B a (5 mol%) CHCl3/iPrOH (9:1) 24 93 n.d. 91 (S, R) 
13 b D a (5 mol%) CHCl3/iPrOH (9:1) 24 91 20:1 84 (R, S) 
 
(a) An equal amount of N-methylmorpholine was added to the reaction mixture as the trifluoroacetate of the 
catalyst was used; (b) reactions were carried out at 0 °C. 
 
The scope of this reaction was further investigated using other aldehydes. The ‘amide’ 
catalysts 161 and 163 were used, due to their higher activity and selectivity in the reaction 
with propanal.  
Some preliminary results in these reactions show the high potential of both (L)-Pro-DKP and 
(D)-Pro-DKP in the addition of aldehydes to nitroolefins giving the opposite absolute 
configuration. The amount of catalyst can be reduced to only 5 mol% giving high yields with 
a fast conversion and excellent selectivity already at 20°C. 
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The scope and the universal application of the reactions between various aldehydes and 
nitroolefins is under investigation in Piarulli group at the moment. 
 
However, not only the addition of aldehydes but also the addition of ketones to nitroolefines 
is an extremely interesting transformation which recently showed good results in selected 
cases.108 For that purpose, again β-nitrostyrene was chosen and reacted with acetone and 
cyclohexanone. The first attempts using neat acetone showed a quite fast conversion (12 h) 
with a very low stereoinduction for the Pro-DKP esters. Interestingly, both diastereomeric 
catalysts gave the same enantiomer. 
On the other hand, the Pro-DKP amides showed a very slow conversion and only moderate 
yields. Furthermore, also here the selectivity was very low. 
 
 
Entry Cat. t [h] Conv. [%] ee [%] 
1 A (10 mol%) 12 quant.a 6 
2 B (10 mol%) 12 42 -6 
3 C (10 mol%) 72 quant.a -6 
4 D (10 mol%) 72 42 0 
 
(a) full consumption of starting material on TLC. 
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Entry Cat. t [h] Conv. [%] ee [%] 
1 A (10 mol%) 72 92 15 
2 B (10 mol%) 72 49 2 
3 C (10 mol%) 72 97 -7 
4 D (10 mol%) 72 41 2 
 
In summary, Pro-DKP peptides were shown to be quite active and selective catalysts in the 
conjugate addition of aliphatic or β-branched aldehydes to nitroolefins. Some preliminary 
experiments suggest that α-branched aldehydes need a higher catalyst loading and were 
extremely slow at temperatures lower than room temperature. 
The conjugate addition of ketones to nitroolefins did show only a low stereoinduction with 
moderate to good yields. However, it should be mentioned that the DKP-ester catalysts are 
more active and also selective compared to DKP-amides, which might be due to lower 
solubility. Hence, further studies on this unexpected result need to be carried out in order to 
understand this observation. The scope of these catalysts is currently under further 
investigation in the Piarulli group. 
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Instruments and general techniques 
 
1H-NMR spectra were recorded on Bruker Avance 300 (300 MHz), Bruker Avance 400 (400 
MHz) and Bruker Avance 600 (600 MHz). The chemical shifts are reporter in δ (ppm) 
relative to chloroform (CDCl3, 7.26 ppm), dimethylsulfoxide (DMSO-d6, 2.49 ppm), 
methanol-d3 or methanol-d4 (CD3OH, 3.34 ppm). The spectra were analysed by first order, 
the coupling constant (J) are reported in Hertz (Hz). Characterisation of signals: s = singlet,  
bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bm = broad multiplet, dd 
= double doublet, dt = double triplet, ddd = double double doublet. Integration is determined 
as the relative number of atoms. Diastereomeric ratios were determined by comparing the 
integrals of corresponding protons in the 1H-NMR spectra. 
 
13C-NMR spectra were recorded on Bruker AC 250 (62.9 MHz), Bruker Avance 300 (75.5 
MHz), Bruker Avance 400 (100.6 MHz) and Bruker Avance 600 (150.9 MHz). The chemical 
shifts are reported in δ (ppm) relative to chloroform (CDCl3, 77 ppm), dimethylsulfoxide 
(DMSO-d6, 39.52 ppm), methanol-d3 or methanol-d4 (CD3OH, 49 ppm). 
 
2D-NMR spectra (COSY, NOESY, ROESY, TOCSY, HETCORR, HMBC, HSQC) were 
recorded on Bruker Avance 400 (400 MHz) and Bruker Avance 600 (600 MHz). 
 
IR spectra were recorded with a Bio-Rad Excalibur series FT-IR. 
 
MS spectra were recorded in the mass spectroscopy department of the University of 
Regensburg. 
 
Optical rotations were measured on a Perkin-Elmer-polarimeter 241 with sodium lamp at 
589 nm in the specified solvent. Concentration is indicated as [g/100ml]. 
 
CD spectra were measured on a JASCO model J-710/720 at the Institute of Analytical 
Chemistry of the University of Regensburg at 21°C between 250 and 190 nm in the specified 
solvent, with 10 scans. The length of the rectangular cuvette was 0.1 mm, the resolution was 
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0.2 nm, the band width 1.0 nm, the sensitivity 10-20 mdeg, the response 2.0 s, the speed 10 
nm/min. The background was substracted for each spectrum. The absorption value is 
measured as molar ellipticity per residue (deg.cm2.dmol-1). The spectra were smoothed by 
adjacent averaging algorithm or FFT filter with the Origin 6.0 program. 
 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel 
(Merck silica gel 60 F 254, layer thickness 0.2 mm) or glass plates coated with flash 
chromatography silica gel (Merck silica gel 60 F 254, layer thickness 0.25 mm). Visualisation 
was accomplished by UV light (wavelength λ= 254 nm), permanganate solution, 
ninhydrin/acetic acid solution, vanillin/H2SO4 solution, anisaldehyde solution or 
Draggendorf-Munier reagent. 
 
HPLC-chromatography analytical and preparative reverse Phase HPLC was performed on 
Agilent equipment (Böblingen, Germany) by using the columns: Luna C18(2), 3 µm, 4.60 x 
150 mm and the Luna C18(2), 90 µm, 21.2 x 250 mm (Phenomenex, Aschaffenburg, 
Germany). The flow rate was 1 mL/min for the analytical HPLC runs and 21 mL/min for 
preparative applications. The binary solvent system (A/B) was: (A) ACN, (B) 0.0059% TFA 
in water. The absorbance was detected at 220 nm. 
 
 
BF3•Et2O was distilled under nitrogen and stored in a Schlenk flask under nitrogen in the 
refrigerator. Diethyl ether, dichloromethane and THF were purified by a solvent purification 
system apparatus. In Como, all dry solvents were obtained from sealed bottles under 
nitrogen purchased from Aldrich.  
 
 
Solid phase peptide synthesis 
General procedure for the preparation of peptides on a Rink-amide resin 
The syntheses were carried out by manual coupling using Fmoc/tBu strategy on the acid labile 
HMPA-AM resin pre-modified with an Fmoc protecting group (loading 0.64 mmol/g). The 
Fmoc group was removed by treatment with 20% piperidine in DMF, one cycle of and one of 
15 minutes. The first amino acid (5 equiv), was attached activating the carboxylic function 
with HBTU (5 equiv) and HOBt (5 equiv) in the presence of DIPEA (10 equiv) in NMP/DMF 
for 2 hours. This deprotection/coupling strategy was applied for each step, besides the amount 
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of the unnatural amino acids (3 equiv) and the amount of coupling reagents respectively. The 
cleavage of the peptide from the resin with simultaneous side chains deprotection was 
achieved by treatment with a TFA/water/TIS mixture (95:5:5) for 2.5 hours. The peptide was 
precipitated from ice-cold diethyl ether and recovered by centrifugation. The purification was 
achieved by using RP-preparative HPLC and the products were characterized by analytical 
HPLC and MALDI-MS spectroscopy. 
 
 
Catalysis 
General procedure for addition of aldehydes to nitroolefins 
The catalyst (5 mol%, 10 mol%) was dissolved in the appropriate solvent (500 µl, 1 ml; 
solvent contained equal amount of N-methylmorpholine corresponding to the catalyst (TFA 
salt)) and stirred for 5 minutes. To that solution was added the nitroolefin (1 equiv) and the 
aldehyde (3 equiv) and stirred for the indicated time. Purification was accomplished using 
flash column chromatography on flash silica gel eluting with mixtures of hexanes and EtOAc. 
The d.r. was determined by NMR and the e.e. was determined by HPLC (for propanal 
Hexane/iPropanol 99.3:0.7, flow 0.6 ml/min on Chiracel AD-H. The isomeric products were 
detected at 254 nm at 36.3 and 42.1 min) 
 
General procedure for addition of ketones to nitroolefins 
The catalyst (10 mol%) was dissolved in the appropriate ketone (1 ml; solvent contained 
equal amount of N-methylmorpholine corresponding to the catalyst (TFA salt)) and stirred for 
5 minutes. To that solution was added the nitroolefin (1 equiv) stirred for the indicated time. 
Purification was accomplished using flash column chromatography on flash silica gel eluting 
with mixtures of hexanes and EtOAc. 
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(E)-N-(((2R,3R)-2-allyl-5-oxotetrahydrofuran-3-yl)methylene)-1-phenylmethanamine 
oxide (84) 
 
A mixture of (2R,3S)-2-Ally-5-oxo-tetrahydro-furan-3-carbaldehyde 67 (0.5 g, 3.24 mmol, 1 
equiv), NaOAc·3H2O (1.32 g, 9.73 mmol, 3 equiv) and N-benzylhydroxylamine 
hydrochloride (0.78 g, 4.86 mmol, 1.5 equiv) in 10 ml of an 80% ethanol/water mixture was 
stirred at room temperature for 1 hour (TLC control). Ethanol was removed under reduced 
pressure, the aqueous solution was extracted with CH2Cl2 (3 x 10 ml) and the combined 
organic layers were washed with saturated aq. NaHCO3, dried over MgSO4 and evaporated to 
give a brown sticky oil (710 mg, 2.74 mmol, 85 %) which was used for the next step without 
further purification.  
 
Rf = 0.17 (hexanes/ethyl acetate 1:1). – 1H NMR (300 MHz, CDCl3): δH = 2.50 (m, 2H), 2.54 
(dd, J = 17.9, 7.5 Hz, 1H), 2.84 (dd, 1H, J = 17.8, 9.4 Hz), 3.55 (m, 1H), 4.47 (dd, 1H, J = 
12.2, 5.9 Hz), 4.87 (s, 2H), 5.07-5.14 (m, 1H), 5.14-5.23 (m, 1H), 5.66-5.80 (m, 1H), 6.72 (d, 
1H, J = 6.31 Hz), 7.30-7.44 (m, 5H). – 13C NMR (75.5 MHz, CDCl3): δC = 31.96 (-, 1C), 
37.97 (+, 1C), 39.17 (-, 1C), 69.58 (-, 1C), 81.38 (+, 1C), 119.76 (-, 1C), 129.15 (+, 1C), 
129.35 (+, 2C), 131.30 (+, 2C), 132.22 (1C), 135.94 (+, 1C), 175.14 (1C). – IR (film): ~ν = 
3366, 3273, 3078, 2934, 1775, 1639, 1602, 1495, 1450, 1422, 1205, 1169, 995, 915, 703. 
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(3aR,4aR,7aS,7bR)-1-benzyloctahydro-6H-furo[2',3':4,5]cyclopenta[1,2-c]isoxazol-6-one 
(66a; major) 
 
(3aS,4aR,7aS,7bS)-1-benzyloctahydro-6H-furo[2',3':4,5]cyclopenta[1,2-c]isoxazol-6-one 
(66b; minor) 
 
A solution of crude nitrone 84 (710 mg, 2.74 mmol, 1 equiv) in 20 ml anhydrous benzene was 
refluxed for 20 hours under nitrogen (TLC). After coming to room temperature benzene was 
removed under reduced pressure to give a black sticky oil. The two isomers where seperated 
by chromatography on silica gel (5-20 % ethyl acetate in hexanes) yielding a yellowish oil 
which was crystallized from ethylacetate/hexane giving a colourless crystalline solid (508 mg, 
1.96 mmol, 55 %, dr (major/minor) = 78:22). 
 
66a; major: 
Rf = 0.37 (hexanes/ethyl acetate 1:1). – [α]20 = +26.3 (c = 0.13, CH2Cl2). – mp: +78 °C. – 1H 
NMR (600 MHz, CDCl3): δH = 2.02 (m, 1H), 2.15 (dd, 1H, J = 1.5, 18.0 Hz), 2.41 (dd, 1H, J 
= 8.2, 14.7 Hz), 2.60 (dd, 1H, J = 9.3, 18.0 Hz), 2.74 (m, 1H), 3.21 (dd, 1H, J = 3.0, 7.9 Hz), 
3.34 (dq, 1H, J = 3.1, 8.3 Hz), 3.71 (dd, 1H, J = 3.0, 8.6 Hz), 3.80 (d, 1H, J = 12.6 Hz), 4.12 
(d, 1H, J = 12.6 Hz), 4.20 (m, 1 H), 5.02 (t, 1H, J = 5.1 Hz), 7.35 (m, 5H). – 13C NMR (150.9 
MHz, CDCl3): δC = 34.76 (-, 1C), 37.76 (-, 1C), 45.54 (+, 1C), 47.88 (+, 1C), 61.17 (+, 1C), 
71.75 (+, 1C), 78.49 (+, 1C), 88.48 (+, 1C),127.81 (+, 1C), 128.57 (+, 2C), 129.18 (+, 2C), 
136.26 (1C), 176.33 (1C). – IR (KBr) = ~ν = 3503, 3440, 3028, 2940, 2874, 2360, 1762, 1360, 
1171, 1028, 754, 702. – MS (EI-MS): m/z (%) = 91.1 (100) [C7H7+], 259 (17) [M+.]. – HRMS 
(HR-EI, 70 eV): 259.1206 (C15H17NO3 [M+.]: calcd. 259.1208). – Elemental analysis calcd. 
(%) for C15H27NO3 (259.12): C 69.48, H 6.61, N 5.40, found C 69.42, H 6.61, N 5.35. 
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66b; minor: 
Rf = 0.29 (hexanes/ethyl acetate 1:1). – [α]20 = -36.0 (c = 0.11, CH2Cl2). – mp: +108 °C. – 1H 
NMR (400 MHz, CDCl3): δH = 1.97 (ddd, 1H, J = 5.0, 7.6, 13.1 Hz), 2.31 (d, 1H, J = 15.3 
Hz), 2.46 (dd, 1H, J = 9.5, 17.6 Hz), 2.80 (ddt, 1H, J = 1.1, 5.9, 9.6 Hz), 3.17 (dd, 1H, J = 1.0, 
17.6 Hz), 3.33 (m, 1H), 3.66-3.72 (m, 1H), 3.66-3.76 (m, 1H), 3.72 (d, 1H, J = 12.8 Hz), 4.05 
(d, 1H, J = 12.8 Hz), 4.15 (m, 1H), 4.88 (t, 1H, J = 5.3 Hz), 7.31-7.37 (m, 5H). – 13C NMR 
(100.6 MHz, CDCl3): δC = 29.71 (-, 1C), 30.58 (-, 1C), 42.45 (+, 1C), 46.65 (+, 1C), 60.12 (-, 
1C), 70.31 (+, 1C), 70.99 (-, 1C), 86.30 (+, 1C), 127.56 (+, 1C), 128.50 (+, 2C), 128.90 (+, 
2C), 136.99 (1C), 177.53 (1C). – IR (KBr): ~ν = 3353, 3030, 2956, 2878, 1960, 1753, 1495, 
1452, 1360, 1331, 1200, 1165, 1203, 974, 913, 893, 724, 698 656. – MS (EI-MS): m/z (%) = 
91.1 (100) [C7H7+], 259.1 (24) [M+.]. – HRMS (HR-EI, 70 eV): 259.121 (C15H17NO3 [M+.]: 
calcd. 259.1208). – Elemental analysis calcd. (%) for C15H17NO3 (259.12): C 69.48, H 6.61, 
N 5.40, found C 69.31, H 6.93, N 5.36. 
 
 
 
 
(3aS,4R,5R,6aR)-4-amino-5-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
(86) 
 
To a solution of (3aR,4aR,7aS,7bR)-1-benzyloctahydro-6H-furo[2',3':4,5]cyclopenta[1,2-
c]isoxazol-6-one (66a, 250 mg, 0.96 mmol, 1 equiv) in 18 ml anhydrous MeOH was added 
10% Pd/C (40 mg) and ammonium formate (304 mg, 4.82 mmol, 5 equiv). After refluxing for 
2 hours the solution was filtered through celite yielding a slightly yellow sticky solid (164 mg, 
0.96 mmol, quant. yield). 
 
Rf = 0.84 (DCM/MeOH 9:1). – [α]20 = +4.8 (c = 0.03, MeOH). – 1H NMR (300 MHz, 
CDCl3): δH = 2.00 (broad m, 5H), 2.23-2.32 (m, 1H), 2.38 (dd, 1H, J = 3.1, 18.4 Hz), 2.68 
(ddd, 1H, J = 3.3, 6.7, 10.4 Hz), 2.85 (dd, 1H, J = 10.7, 18.3 Hz), 3.37 (dd, 1H, J = 3.4, 5.6 
Hz), 3.64-3.72 (m, 1H), 3.83 (dd, 1H, J = 4.4, 11.1 Hz), 5.08 (td, 1H, J = 3.7, 7.2 Hz). – 13C 
NMR (75.5 MHz, CDCl3): δC = 33.35 (-, 1C), 34.16 (-, 1C), 42.68 (+, 1C), 47.85 (+, 1C), 
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60.52 (+, 1C), 62.05 (-, 1C), 84.84 (+, 1C), 177.01 (1C). – IR (film): ~ν = 3353, 3300, 2931, 
1760, 1643, 1555, 1359, 1187, 1017, 753. – MS (CI-MS): m/z (%) = 172.1 (100) [MH+], 
189.1 (39) [M+NH4+]. – HRMS (HR-EI, 70 eV): 171.0894 (C8H13NO3 [M+.]: calcd. 
171.0895). 
 
 
 
 
tert-butyl[(3aS,4R,5R,6aR)-5-(hydroxymethyl)-2-oxohexahydro-2H-cyclopenta[b]furan-
4-yl]carbamate (88) 
 
Procedure A: (3aS, 4R, 5R, 6aR)-4-Amino-5-(hydroxymethyl)hexahydro-2H-
cyclopenta[b]furan-2-one (66a) (96 mg, 0.56 mmol, 1 equiv) was dissolved in 5 ml dry 
MeOH under nitrogen. To that solution di-tert-butyl dicarbonate (132 µl, 0.62 mmol, 1.1 
equiv) and a catalytic amount of 4-dimethylamino pyridine (6 mg, 0.05 mmol, 0.1 equiv) was 
added. After stirring for 2 h the reaction mixture was added 2 ml 1N HCl and extracted with 
CH2Cl2 (3 x 5 ml). The combined organic layers were dried over MgSO4, filtered and 
concentrated. Chromatography on silica gel eluting with 60 % ethyl acetate in hexanes gave a 
colourless solid (114 mg, 0.42 mmol, 75%).  
Procedure B: Cycloadduct 66a (500 mg, 1.93 mmol, 1 equiv) was dissolved in 20 ml dry 
MeOH under nitrogen. To that solution di-tert-butyl dicarbonate (631 mg, 2.89 mmol, 1.5 
equiv) and Pd(OH)2-C (150 mg) was added. After stirring overnight under a hydrogen 
atmosphere the reaction mixture was filtered through celite. The solution was concentrated 
under reduced pressure. Chromatography on silica gel eluting with 60 % ethyl acetate in 
hexanes gave a colourless solid (396 mg, 1.46 mmol, 76%). 
 
Rf = 0.66 (DCM/MeOH 9:1). – [α]20 = - 8.4 (c = 0.7, MeOH). – mp: +137 °C. – 1H NMR 
(300 MHz, D2O): δH = 1.27 (s, 9H), 1.60-1.78 (m, 1H), 1.96 (dd, 1H, J = 6.6, 14.8 Hz), 2.27 
(tt, 1H, J = 6.5, 12.8 Hz), 2.41 (dd, 1H, J = 2.5, 18.1 Hz), 2.75-2.85 (m, 1H), 2.90 (dd, 1H, J = 
11.1, 18.1 Hz), 3.42 (dd, 1H, J = 6.6, 11.3 Hz), 3.50 (dd, 1H, J = 8.4, 15.4 Hz), 3.75 (m, 1H), 
5.06 (t, 1H, J = 6.1 Hz). – 13C NMR (75.5 MHz, CDCl3): δC = 28.29 (+, 3C), 33.18 (-, 1C), 
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34.24 (-, 1C), 42.83 (+, 1C), 45.56 (+, 1C), 59.57 (+, 1C), 60.89 (-, 1C), 80.65 (1C), 83.62 (+, 
1C), 156.57 (1C), 176.38 (1C). – IR (KBr): ~ν = 3349, 3272, 3047, 2974, 2932, 2360, 1801, 
1674, 1553, 1186, 1024. – MS (ES-MS): m/z (%) = 272.1 [MH+], 289.1 [M+NH4+], 543.4 
(2MH+), 560.4 (2M+NH4+), 565.4 (2M+Na+). – Elemental analysis calcd. (%) for 
C13H23NO6 (289.32): C 57.55, H 7.80, N 5.16, found C 57.63, H 7.90, N 4.74. 
 
 
 
 
 
 
(3aS,4S,5R,6aR)-4-[(tert-butoxycarbonyl)amino]-2-oxohexahydro-2H-
cyclopenta[b]furan-5-carboxylic acid (89) 
 
Aminoalcohol 88 (92 mg, 0.32 mmol) was dissolved in a 1:1:2 mixture of CCl4-CH3CN-H2O 
and cooled to 0°C. After addition of RuCl3.3H2O (3.3 mg, 0.02 mmol, 5mol%) and NaIO4 
(340 mg, 1.59 mmol, 5 equiv) the mixture was stirred for 19 h at room temperature. The 
mixture was quenched with H2O and extracted with CH2Cl2 (4x10ml). The resulting black 
sticky oil was recrystallized from ethyl acetate/hexane giving a white solid (83 mg, 0.29 
mmol, 90%). 
 
Rf = 0.18 (DCM/MeOH 9:1). – [α]20 = - 33.9 (c = 0.53, MeOH). – mp: +161 °C. – 1H NMR 
(300 MHz, CDCl3): δH = 1.45 (s, 9H), 2.18 (ddd, 1H, J = 2.26, 8.16, 15.44 Hz), 2.45-2.61 (m, 
2H), 2.85 (dd, 1H, J = 9.06, 17.84 Hz), 2.84 (m, 1H), 3.32 (dt, 1H, J = 3.91, 11.34 Hz), 3.87 
(m, 1H), 5.06 (dt, 1H, J = 2.47, 6.72 Hz), 7.06 (d, 1H, J = 7.68 Hz), 10.50-13.00 (1H, bs). – 
13C NMR (75.5 MHz, CDCl3): δC = 28.17 (+, 3C), 33.98 (-, 1C), 34.02 (+, 1C), 44.48 (+, 
1C), 47.06 (+, 1C), 59.93 (+, 1C), 82.95 (-, 1C), 83.42 (+, 1C), 158.30 (1C), 175.96 (1C), 
177.59 (1C).– IR (KBr): ~ν = 3397, 3226, 2980, 2938, 1757, 1728, 1697, 1530, 1163,1001, 
924, 775, 596. – MS (CI-MS): m/z (%) = 247.1 (100) [M+NH+-C4H8], 286.1 (4) [MH+], 
303.1 (73) [2M+NH4+]. – Elemental analysis calcd. (%) for C13H23NO6 (289.32): C 54.73, H 
6.71, N 4.91, found C 54.83, H 6.71, N 4.92. 
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(9H-fluoren-9-yl)methyl (3aS,4R,5R,6aR)-5-(hydroxymethyl)-2-oxohexahydro-2H-
cyclopenta[b]furan-4-ylcarbamate (90) 
 
66a (600 mg, 2.31 mmol, 1 equiv) was dissolved in 20 ml anhydrous methanol, 150 mg of 
Pd(OH)2-C were added and the resulting suspension was stirred under hydrogen atmosphere 
overnight. After filtration through celite the methanol was removed under reduced pressure 
giving the crude amino alcohol in quantitative yield. The crude intermediate was dissolved in 
10 ml of an acetone/water mixture (1:1) and subsequently NaHCO3 (1.94 g, 23.14 mmol, 10 
equiv) and FmocOSu (1.64 mg, 4.86 mmol, 2.1 equiv) were added. After stirring for 24 h 
acetone was removed under reduced, 5 ml of saturated NH4Cl solution was added and the 
aqueous solution was extracted with ethyl acetate (3 x 30 ml). The organic layer was dried 
over MgSO4 and concentrated under reduced pressure. Chromatography on silica gel eluting 
with 5% MeOH in dichloromethane gave a white solid (663 mg, 1.69 mmol, 73 %).  
 
Rf = 0.65 (DCM/MeOH 9:1). – [α]20 = - 8.4 (c = 0.7, MeOH). – mp: +158 °C. – 1H NMR 
(300 MHz, CDCl3): δH = 1.81-1.97 (m, 2H), 2.19 (m, 1H), 2.41 (dd, 1H, J = 16.91, 1.65 Hz), 
2.70-2.94 (m, 2H), 3.20-3.54 (m, 3H), 3.80 (m, 1H), 4.17-4.59 (broad m, 4H), 4.98 (m, 1H), 
7.30-7.46 (m, 4H), 7.64-7.73 (m, 2H), 7.86-7.94 (m, 2H). – 13C NMR (75.5 MHz, CDCl3): δC 
= 33.53 (-, 1C), 33.81 (-, 1C), 42.47 (+, 1C), 44.70 (+, 1C), 46.65 (+, 1C), 58.80 (+, 1C), 
59.87 (-, 1C), 65.27 (-, 1C), 83.60 (-, 1C), 120.04 (+, 2C), 125.02 (+, 2C), 126.97 (+, 2C), 
127.53 (+, 2C), 140.65 (2C), 143.72 (2C), 155.84 (1C), 176.76 (1C). – IR (KBr): ~ν = 3266, 
1790, 1684, 1561, 1449, 1272, 1252, 1147, 1012. – MS (EI-MS): m/z (%) = 178.0 (100) 
[C14H10+.], 393.1 (0.5) [M+.]. – HRMS (EI-MS): 393.1569 (C23H23NO5 [M+.]: calcd. 
393.1576). 
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(3aS,4S,5R,6aR)-4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-2-oxohexahydro-2H-
cyclopenta[b]furan-5-carboxylic acid (91) 
 
Procedure A: 89 (605 mg, 2.12 mmol) was dissolved in ethyl acetate saturated with HCl at 
0°C and stirred for 1 h (TLC control). After removing the solvent under reduced pressure the 
hydrochloride salt of (3aS,4S,5R,6aR)-4-amino-2-oxohexahydro-2H-cyclopenta[b]furan-5-
carboxylic acid was isolated as a white solid. The hydrochloride salt was then dissolved in a 
2:1 mixture of acetone/water and cooled to 0°C. After addition of NaHCO3 (1.07 g, 12.7 
mmol, 6 equiv) and N-(9-Fluorenylmethoxycarbonyloxy)-succinimide (720 mg, 2.12 mmol, 1 
equiv) the mixture was stirred for 2 h at 0°C and then for 24 h at room temperature. Acetone 
was removed under reduced pressure and 60 ml water and 60 ml diethyl ether were added and 
additionally stirred for 1 h. The layers were separated and the aqueous layer was extracted 
with 50 ml of diethyl ether. The aqueous layer was adjusted to pH 2 and extracted with ethyl 
acetate (4 x 80 ml). The combined organic layers were washed with 30 ml 1N HCl and brine, 
dried over MgSO4 filtered and concentrated. Chromatography on silica gel eluting with 10 % 
methanol in chloroform gave a white foaming solid (805 mg, 1.98 mmol, 93%). 
 
Procedure B: Aminoalcohol 90 (92 mg, 0.32 mmol) was dissolved in a 1:1:2 mixture of 
CCl4-CH3CN-H2O and cooled to 0°C. After addition of RuCl3.3H2O (3.3 mg, 0.02 mmol, 5 
mol%) and NaIO4 (340 mg, 1.59 mmol, 5 equiv) the mixture was stirred for 19 h at room 
temperature. The mixture was added H2O and extracted with CH2Cl2 (4x10ml). The resulting 
black foam was purified by chromatography on silica gel eluting with 5% MeOH in 
dichloromethane gave a white solid (78 mg, 0.27 mmol, 72%) 
 
Rf = 0.28 (DCM/MeOH 9:1). – [α]20 = - 13.2 (c = 0.83, MeOH). – mp: +173 °C. – 1H NMR 
(300 MHz, DMSO): δH = 1.93 (m, 1H), 2.29-2.56 (m, 2H), 2.77-2.95 (m, 2H), 3.07 (m, 1H), 
4.07 (m, 1H), 4.13-4.36 (m, 3H), 5.03 (m, 1H), 7.29-7.95 (m, 9H), 12.24 (1H, bs). – 13C 
NMR (75.5 MHz, DMSO): δC = 33.14 (-, 1C), 33.25 (-, 1C), 44.25 (+, 1C), 45.60 (+, 1C), 
46.55 (+, 1C), 59.10 (+, 1C), 65.50 (-, 1C), 82.99 (+, 1C), 120.02 (+, 2C), 125.10 (+, 2C), 
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126.99 (+, 2C), 127.54 (+, 2C), 140.60 (2C), 143.59 (1C), 143.85 (1C), 155.47 (2C), 172.72 
(1C), 176.72 (1C).– IR (KBr): ~ν = 3368, 3068, 2959, 2363, 2200, 1752, 1695, 1560, 1541, 
1416, 1244, 1161, 1032, 736. – MS (NI-LSIMS) (MeOH/glycerol): m/z (%) = 406.1 [(M-H+)-
], 498.3 [(M-H+)-+Gly.], 590.2 [(M-H+)-+2Gly.]. – HRMS (NI-LSIMS): 406.1285 
(C23H21NO6 [M+.]: calcd. 406.1291). 
 
 
 
 
(3aR,5R,6S,6aR)-1-benzyl-6-(2-hydroxyethyl)hexahydro-1H-cyclopenta[c]isoxazol-5-ol 
(92) 
 
To a solution of LAH (77 mg, 2.0 mmol, 5 equiv) in 10 ml anhydrous THF under nitrogen 
was slowly added 66a (105 mg, 0.4 mmol) in 5 ml anhydrous THF at -10 °C. After stirring 
for 30 min the reaction mixture was quenched with 6 ml EtOAc. The reaction mixture was 
filtered through celite and concentrated under reduced pressure yielding a colourless solid 
(103 mg, 0.39 mmol, 98%). 
 
Rf = 0.40 (DCM/MeOH 9:1). – [α]20 = -8.2 (c = 0.11, CH2Cl2). – mp: +83 °C. – 1H NMR 
(300 MHz, MeOD): δH = 1.48 (m, 1H), 1.55-167 (m, 2H), 1.69-1.80 (m, 1H), 2.10 (ddd, 1H, J 
= 1.5, 8.6, 13.6 Hz), 3.24-3.37 (m, 1H), 3.43-3.53 (m, 3H), 3.58 (dd, 1H, J = 2.2, 8.8 Hz), 
3.75 (d, 1H, J = 12.6 Hz), 3.97 (d, 1H, J = 12.6 Hz), 4.16 (m, 1H), 4.23 (dd, 1H, J = 7.4, 8.8 
Hz), 7.20-7.39 (m, 5H). – 13C NMR (75.5 MHz, MeOD): δC = 31.84 (-, 1C), 42.02 (-, 1C), 
45.61 (+, 1C), 49.34 (+, 1C) 61.04 (-, 1C), 61.70 (-, 1C), 73.04 (-, 8C), 75.82 (+, 5C), 76.65 
(+, 1C), 128.65 (+, 1C), 129.42 (+, 2C), 130.85 (+, 2C), 138.22 (1C), 177.53 (1C). – IR 
(film): ~ν = 3420, 2932, 2390, 2221, 1580, 1427, 1078, 1039, 868, 731, 509. – MS (EI-MS): 
m/z (%) = 91.1 (100) [C7H7+], 263.3 (24) [M+.]. – HRMS (HR-EI, 70 eV): 263.15208 
(C15H17NO3 [M+.]: calcd. 263.1521).  
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(3aR,5R,6S,6aR)-1-benzyl-6-[2-(tert-butyldimethylsiloxy)ethyl]hexahydro-1H-
cyclopenta[c]isoxazol-5-ol (93) 
 
Diol 92 (3.5g, 13.30 mmol) was dissolved 180 ml DCM and tert-butyltrimethylsilyl chloride 
(2.20g, 14.62 mmol, 1.1 equiv), triethylamine (2.3 ml, 15.95 mmol, 1.2 equiv) and DMAP 
(0.16 g, 1.33 mmol, 0.1 equiv) were added and stirred overnight (18 h). After addition of 10 
ml saturated NH4Cl solution the layers were separated and the aqueous layer was extracted 
with DCM (3 x 10 ml). The combined organic layers were dried over MgSO4, filtered and 
concentrated. Chromatography on silica gel eluting with ethyl acetate in hexanes (2:1) gave a 
colourless oil (4.6 g, 12.18 mmol, 92 %). 
 
Rf = 0.43 (hexanes/ethyl acetate 1:1). – [α]20 = - 18.6 (c = 0.54, MeOH). – 1H NMR (300 
MHz, CDCl3): δH = 0.05 (s, 3H), 0.06 (s, 3H), 0.89 (s, 9H), 1.49 (m, 1H), 1.62 (dt, 1H, J = 
2.3, 5.0 Hz), 1.68 (m, 1H), 1.81 (m, 1H), 2.21 (m, 1H), 3.18 (s, 1H), 3.32 (m, 1H), 3.40 (m, 
1H), 3.52 (m, 1H), 3.64 (m, 2H), 3.71 (d, 1H, J = 12.3 Hz), 4.05 (d, 1H, J = 12.3 Hz), 4.23 
(m, 1H), 4.31 (m, 1H), 7.26-7.39 (m, 5H). – 13C NMR (75.5 MHz, CDCl3): δC = -5.64 (+, 
1C), -5.59 (+, 1C), 18.14 (1C), 25.85 (+, 3C), 31.03 (-, 1C), 39.96 (-, 1C), 44.59 (+, 1C), 
50.99 (+, 1C), 60.52 (-, 1C), 62.60 (-, 1C), 72.47 (-, 1C), 75.15 (+, 1C), 75.58 (+, 1C), 127.44 
(+, 1C), 128.36 (+, 1C), 129.41 (+, 1C), 137.16 (1C).– IR (film): ~ν = 3437, 3031, 2954, 2858, 
2200, 1463, 1254, 1087, 1005, 835, 777. – MS (EI-MS): m/z (%) = 91.1 (100) [C7H7+], 106.1 
(21), 320.2 (21) [M+-C4H9], 377.2 (10) [M+]. – HRMS (HR-EI, 70 eV): 377.2384 
(C21H35NO3Si [M+.]: calcd. 377.2386). 
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(3aR,5R,6S,6aR)-1-benzyl-6-[2-(tert-butyldimethylsiloxy)ethyl]-5-methoxyhexahydro-
1H-cyclopenta[c]isoxazole (94) 
 
To a solution of alcohol 93 (4.36 g, 11.55 mmol) in 100 ml anhydrous THF was added NaH 
(60 % suspension in paraffin oil, 0.51 g, 12.71 mmol, 1.1 eq) at 0 °C. After stirring for 1 hour 
methyl iodide (3.6 ml, 57.73 mmol, 5 equiv) was added and stirred overnight (14 h). 
Subsequently 10 ml of saturated NH4Cl solution was added and the layers were separated. 
The aqueous phase was extracted with ethyl acetate (3 x 10 ml) and the combined organic 
layers were were dried over MgSO4, filtered and concentrated. Chromatography on silica gel 
eluting with ethyl acetate in hexanes (1:10) gave a colourless oil (3.9 g, 9.96 mmol, 86 %). 
 
Rf = 0.64 (hexanes/ethyl acetate 1:1). – [α]20 = - 29.4 (c = 0.38, MeOH). – 1H NMR (300 
MHz, CDCl3): δH = 0.00 (s, 3H), 0.01 (s, 3H), 0.85 (s, 9H), 1.35-151 (m, 2H), 1.63 (m, 1H), 
1.84 (m, 1H), 2.16 (ddd, 1H, J = 3.16, 8.64, 13.58 Hz), 3.10 (m, 1H), 3.22 (s, 3H), 3.29 (m, 
1H), 3.55 (m, 3H), 3.71 (d, 1H, J = 12.90), 3.75 (m, 1H), 3.94 (d, 1H, J = 12.90), 4.13 (m, 
1H), 7.18-7.36 (m, 5H). – 13C NMR (75.5 MHz, CDCl3): δC = -5.20 (+, 1C), -5.17 (+, 1C), 
18.39 (1C), 26.04 (+, 1C), 30.42 (-, 1C), 35.74 (-, 1C), 44.14 (+, 1C), 45.82 (+, 1C), 56.69 (+, 
1C), 60.39 (-, 1C), 62.36 (-, 1C), 72.05 (-, 1C), 77.50 (+, 1C), 83.61 (+, 1C), 127.35 (+, 1C), 
128.35 (+, 2C), 129.18 (+, 2C), 137.39 (1C).– IR (film): ~ν = 3030, 2951, 2928, 2857, 2200, 
1462, 1358, 1252, 1090, 835, 776, 728, 697. – MS (EI-MS): m/z (%) = 91.1 (100) [C7H7+], 
334.2 (28) [MH.+-C4H9], 360.2 (4) [MH.+-OMe], 376.3 (6) [MH.+-CH3], 391.3 (22) [MH.+]. – 
HRMS (HR-EI, 70 eV): 391.2547 (C22H37NO3Si [M+.]: calcd. 391.2543). 
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(9H-fluoren-9-yl)methyl (1R,2S,3R,5R)-2-(2-(tert-butyldimethylsilyloxy)ethyl)-5-
(hydroxymethyl)-3-methoxycyclopentylcarbamate (96) 
 
94 (500 mg, 1.28 mmol, 1 equiv) was dissolved in 20 ml anhydrous methanol, 100 mg of 
Pd(OH)2-C were added and the resulting suspension was stirred under hydrogen atmosphere 
overnight. After filtration through celite the methanol was removed under reduced pressure 
giving the crude amino alcohol in quantitative yield. The crude intermediate was dissolved in 
10 ml of an acetone/water mixture (1:1) and subsequently NaHCO3 (1.08 g, 12.80 mmol, 10 
equiv) and FmocOSu (907 mg, 2.69 mmol, 2.1 equiv) were added. After stirring for 24 h 
acetone was removed under reduced, 5 ml of saturated NH4Cl solution was added and the 
aqueous solution was extracted with ethyl acetate (3 x 20 ml). The organic layer was dried 
over MgSO4 and concentrated under reduced pressure. Chromatography on silica gel eluting 
with 2% MeOH in dichloromethane gave a white solid (580 mg, 1.10 mmol, 86 %).  
 
Rf = 0.48 (DCM/MeOH 95:5). – [α]20 = - 45.6 (c = 0.10, MeOH). mp = 87 °C. – 1H NMR 
(300 MHz, CDCl3): δH = 0.05 (s, 3H), 0.05 (s, 3H), 0.89 (s, 9H), 1.50-1.70 (m, 2H), 1.73-1.93 
(m, 2H), 1.99 (ddd, 1H, , J = 13.86, 8.37, 0.99 Hz), 2.28 (broad s, 1H), 2.48 (m, 1H), 3.26 (s, 
3H), 3.47-3.77 (m, 5H), 4.00 (m, 1H), 4.22 (m, 1H), 4.33-4.55 (m, 2H), 5.26 (d, 1H, J = 8.23 
Hz), 7.27-7.44 (m, 4H), 7.60 (m, 2H), 7.76 (m, 2H). – 13C NMR (75.5 MHz, CDCl3): δC = -
5.27 (+, 1C), -5.23 (+, 1C), 18.35 (1C), 26.01 (+, 3C), 30.22 (-, 1C), 31.16 (-, 1C), 40.13 (+, 
1C), 47.36 (+, 1C), 47.68 (+, 1C), 56.49 (+, 1C), 56.89 (+, 1C), 61.70 (-, 1C), 62.51 (-, 1C), 
66.62 (-, 1C), 80.56 (+, 1C), 119.95 (+, 1C), 119.98 (+, 1C), 125.03 (+, 1C), 125.10 (+, 1C), 
127.07 (+, 2C), 127.86 (+, 2C), 141.34 (2C), 143.99 (2C), 157.23 (1C).– IR (film): ~ν = 3307, 
2933, 2859, 1969, 1686, 1547, 1258, 1081. – MS (PI-LSIMS): m/z (%) = 526.6 [MH+], 304.4 
[MH+-Fmoc]. – HRMS (HR-FAB): 526.29775 (C22H37NO3Si [M+.]: calcd. 391.2989). 
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(1R,2S,3S,4R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-(tert-
butyldimethylsilyloxy)ethyl)-4-methoxycyclopentanecarboxylic acid (97) 
 
RuCl3 hydrate (35-40 % Ru; 17 mg, 0.03 mmol, 5 mol%) and NaIO4 (610 mg, 2.85 mmol, 5 
equiv) were dissolved in 14 ml of a CCl4/CH3CN/water (2:2:3) mixture and cooled to 0 °C. 
To that solution 96 (300 mg, 0.57 mmol, 1 equiv) in 3 ml CH3CN was added and stirred at 
0°C until the starting material was consumed (TLC control). After addition of 10 ml of 
diethylether and 5 ml of brine the layers were separated and the aqueous layer was extracted 
with diethylether (5 x 10 ml). The combined organic layers were dried over MgSO4, filtered 
and concentrated. Chromatography on silica gel eluting with 5% MeOH in dichloromethane 
gave a white solid (228 mg, 0.42 mmol, 74 %). 
 
Rf = 0.16 (DCM/MeOH 95:5). – [α]20 = - 59.3 (c = 0.78, MeOH). mp: 115 °C. – 1H NMR 
(300 MHz, CDCl3): δH = 0.07 (s, 6H), 0.91 (s, 9H), 1.70 (m, 1H), 1.83 (m, 1H), 2.00 (m, 1H), 
2.06-2.21 (m, 2H), 3.26 (m, 1H), 3.31 (s, 3H), 3.70 (m, 3H), 4.16-4.46 (m, 4H), 5.51 (d, 1H, J 
= 5.50 Hz), 7.27-7.45 (m, 4H), 7.58-7.44 (m, 2H), 7.74 (m, 2H). – 13C NMR (75.5 MHz, 
CDCl3): δC = -5.31 (+, 1C), -5.22 (+, 1C), 18.37 (1C), 26.04 (+, 3C), 29.39 (-, 1C), 31.51 (-, 
1C), 44.37 (+, 1C), 45.88 (+, 1C), 47.01 (+, 1C), 56.49 (+, 1C), 57.79 (+, 1C), 62.02 (-, 1C), 
68.20 (-, 1C), 80.53 (+, 1C), 119.95 (+, 2C), 125.19 (+, 1C), 125.30 (+, 1C), 127.09 (+, 2C), 
127.67 (+, 2C), 141.27 (2C), 143.69 (2C), 143.94 (1C), 158.96 (1C), 178.04 (q).– IR (film): ~ν 
= 2857, 1704, 1661, 1420, 1336, 1082. – MS (PI-LSIMS): m/z (%) = 540.5 [MH+], 318.4 
[MH+-Fmoc]. – HRMS (HR-FAB): 540.27908 (C22H37NO3Si [M+.]: calcd. 540.2781). 
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2-[(3aR,5R,6S,6aR)-1-benzyl-5-methoxyhexahydro-1H-cyclopenta[c]isoxazol-6-
yl]ethanol (98) 
 
To solution of 94 (1.94 g, 4.95 mmol, 1 equiv) in 9 ml THF was added 18 ml of water and the 
solution was cooled to 0°C. Subsequently, 36 ml of AcOH were slowly added and the 
resulting mixture was allowed to come to ambient temperature and stirred for 6 hours. The 
solvent mixture was removed under reduced pressure and the residue was chromatographed 
on silica gel eluting with ethyl acetate in hexanes (2:1) giving a colourless solid (1.21 g, 4.36 
mmol, 88%). 
 
Rf = 0.12 (ethyl acetate/hexanes 1:1). – [α]20 = - 4.7 (c = 0.74, CH2Cl2). mp: 57 °C. – 1H 
NMR (300 MHz, CDCl3): δH = 1.49 (dddd, 1H, J = 13.98, 7.58, 3.70, 0.35 Hz), 1.63 (m, 1H), 
1.81 (m, 1H), 1.99 (m, 1H), 2.41 (ddd, 1H, J = 13.86, 8.92, 0.96 Hz), 3.16-3.30 (m, 1H), 3.27 
(s, 3H), 3.47 (m, 1H), 3.54-3.66 (m, 3H), 3.70 (m, 1H), 3.75 (d, 1H, J = 12.91 Hz), 3.99 (d, 
1H, J = 12.90 Hz), 4.21 (m, 1H), 7.23-7.40 (m, 5H). – 13C NMR (75.5 MHz, CDCl3): δC = 
30.70 (-, 1C), 36.30 (-, 1C), 43.94 (+, 1C), 47.45 (+, 1C), 56.62 (+, 1C), 59.62 (-, 1C), 61.13 
(-, 1C), 72.09 (-, 1C), 75.28 (+, 1C), 85.59 (+, 1C), 127.70 (+, 1C), 128.51 (+, 2C), 129.39 (+, 
2C), 136.40 (1C).– IR (film): ~ν = 3267, 2927, 2882, 1735, 1455,1440, 1077, 1053. – MS (EI-
MS): m/z (%) = 277.2 [MH+.], 262 [MH+-CH3], 246.2 [MH+-OCH3], 91.0 [C7H7+]. – HRMS 
(EI-MS, 70 eV): 277.16747 (C22H37NO3Si [M+.]: calcd. 277.1678). 
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tert-butyl {(Z)-amino[{2-[(3aR,5R,6S,6aR)1-benzyl-5-methoxyhexahydro-1H-cyclopenta 
[c]isoxazol-6-yl]ethyl}(tert-butoxycarbonyl)amino]methylidene}carbamate (99) 
 
Alcohol 98 (1.7 g, 6.13 mmol), PPh3 (2.41 g, 9.19 mmol, 1.5 equiv) and tert-butyl {(Z)-
amino[(tert-butoxycarbonyl)amino]methylidene}carbamate (2.38 g, 9.19 mmol, 1.5 equiv) 
were dissolved in 80 ml anhydrous THF and cooled to 0 °C. To the solution was slowly added 
DEAD (1.45 ml, 9.19 mmol, 1.5 equiv) in 10 ml anhydrous THF and the resulting mixture 
was stirred overnight. The solvent was removed under reduced pressure and the residue was 
treated with 200 ml of pentane/ethyl acetate (9:1) mixture, filtered through celite and 
concentrated. Chromatography on silica gel eluting with ethyl acetate in hexanes (gradient 
from 10% - 30 % ethyl acetate) gave a colourless oil (2.42 g, 4.66 mmol, 76 %). 
 
Rf = 0.50 (ethyl acetate/hexanes 1:1). – [α]20 = - 7.7 (c = 1.2, CH2Cl2).-  1H NMR (300 MHz, 
CDCl3): δH = 1.43 (s, 9H), 1.45-1.53 (m, 2H), 1.51 (s, 9H), 1.66-1.89 (m, 2H), 2.25 (ddd, 1H, 
J = 13.58, 8.78, 2.88 Hz), 3.17 (m, 1H), 3.29 (s, 3H), 3.48 (m, 1H), 3.59 (dd, 1H, J = 8.78, 
2.47 Hz), 3.77-3.89 (m, 2H), 3.93 (d, 2H, J = 5.21 Hz), 4.06 (m, 1H), 4.16 (m, 1H), 7.19-7.41 
(m, 5H), 9.24 (broad s, 1H). – 13C NMR (75.5 MHz, CDCl3): δC = 26.76 (-, 1C), 28.07 (+, 3 
C), 28.28 (+, 3C), 35.92 (-, 1C), 43.58 (-, 1C), 44.45 (+, 1C), 46.98 (+, 1C), 56.75 (+, 1C), 
59.97 (-, 1C), 71.56 (-, 1C), 75.66 (+, 1C), 78.31 (1C), 83.43 (1C), 83.83 (+, 1C), 127.19 (+, 
1C), 128.25 (+, 2C), 129.39 (+,2C), 137.80 (1C), 155.13 (1C), 160.51 (1C), 163.83 (1C).– IR 
(film): ~ν = 3383, 2975, 2932, 1710, 1607,1270, 1249, 1143, 1116. – MS (LSIMS): m/z (%) = 
519.3 [MH+], 419.3 [MH+-Boc], 319.3 [MH+-2Boc]. – HRMS (LSIMS): 519.31685 
(C22H37NO3Si [M+.]: calcd. 519.3183). 
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Tert-butoxy-(1R,2S,3R,5R)-2-(2-(1-(tert-butoxycarbonyl)-2-(9H-fluoren-9-yl)-guanidino) 
ethyl)-5-(hydroxymethyl)-3-methoxycyclopentylcarbamate (101) 
 
99 (3.25 g, 6.27 mmol, 1 equiv) was dissolved in 60 ml anhydrous methanol, 600 mg of 
Pd(OH)2-C was added and the resulting suspension was stirred under hydrogen atmosphere 
for 9 hours. After filtration through celite methanol was removed under reduced pressure 
giving the crude amino alcohol in quantitative yield. The crude intermediate was dissolved in 
120 ml of an acetone/water mixture (1:1) and subsequently NaHCO3 (5.27 g, 62.70 mmol, 10 
equiv) and FmocOSu (4.44 g, 13.17 mmol, 2.1 equiv) were added. After stirring for 24 h 
acetone was removed under reduced pressure, 15 ml of saturated NH4Cl solution was added 
and the aqueous solution was extracted with ethyl acetate (4 x 60 ml). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure. Chromatography on 
silica gel eluting with ethyl acetate in hexanes (1:2) gave a white solid foam (2.82 g, 4.31 
mmol, 69 %). 
  
NMR spectra showed a mixture of rotamers (92:8, assigned by ratio of amide peaks at 
8.27 and 8.49); High temperature NMR experiments failed due to decomposition 
Assignment was possible only for the major isomer)  
 
Rf = 0.30 (ethyl acetate/hexanes 1:1). – [α]20 = - 28.8 (c = 0.8, CH2Cl2). – mp: ~88 °C 
(decomposition). – 1H NMR (300 MHz, CDCl3): δH = 1.44 (s, 9H), 1.47-1.55 (m, 1H), 1.51 
(s, 9H), 1.61-1.68 (m, 1H), 1.85-2.04 (m, 3H), 2.65 (m, 1H), 3.13-3.26 (m, 2H), 3.31 (s, 3H), 
3.55 (m, 1H), 3.64 (m, 1H), 3.80 (m, 1H), 4.25-4.34 (m, 3H), 4.41 (m, 1H), 4.76 (broad s, 
1H), 7.28-7.42 (m, 4H), 7.66 (m, 2H), 7.55 (m, 2H), 8.50 (d, 1H, J = 7.9), 9.39 (broad s, 1H), 
11.37 (s, 1H). – 13C NMR (75.5 MHz, CDCl3): δC = 28.02 (+, 3C ), 28.23 (-, 1C), 28.43 (+, 
3C), 31.14 (-, 1C), 39.70 (-, 1C), 42.10 (+, 1C), 47.10 (+, 1C), 50.02 (+, 1C), 56.54 (+, 1C), 
57.37 (+, 1C), 61.80 (-, 1C), 67.81 (-, 1C), 78.98 (1C), 80.23 (+, 1C), 83.92 (1C), 119.84 (+, 
2C), 125.40 (+, 1C), 125.48 (+, 1C), 127.11 (+, 1C), 127.15 (+, 1C), 127.59 (+, 2C), 141.17 
(1C), 141.22 (1C), 144.10 (1C), 144.13 (1C), 153.14 (1C), 156.03 (1C), 156.91 (1C), 163.30 
(1C).– IR (film): ~ν = 3370, 3321, 2977, 2935, 2364, 1713, 1612, 1249, 1148, 1108. – MS 
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(LSIMS): m/z (%) = 653.4 [MH+], 553.4 [MH+-Boc], 453.4 [MH+-2Boc], 431.5 [MH+-
Fmoc]. – HRMS (LSIMS): 653.35464 (C22H37NO3Si [M+.]: calcd. 653.3550). 
 
 
 
 
(1R,2S,3S,4R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-(2,3-bis(tert-
butoxycarbonyl)guanidino)ethyl)-4-methoxycyclopentanecarboxylic acid (102) 
 
RuCl3.H2O (35 mg, 0.06 mmol, 5mol%) was dissolved in 3ml CCl4 and cooled in an ice bath. 
To this solution were subsequently added NaIO4 (1.26 g, 5.87 mmol, 5 equiv) in 7 ml H2O 
and alcohol 101 (767 mg, 1.17 mmol, 1 equiv) in 5 ml of a CH3CN and the resulting mixture 
was stirred for 5 h. Addition of 5 ml of water as followed by extraction with CH2Cl2 (4 x 20 
ml). The combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. A quick chromatography on silica gel eluting with CH2Cl2/ethyl acetate (5:1) was 
performed, which was followed by chromatography on neutral alumina eluting with 
CH2Cl2/MeOH/H2O (75:20:5) giving a white foam (568 mg, 0.85 mmol, 73%). 
 
Rf = 0.12 (CH2Cl2/MeOH 95:5). – [α]20 = - 39.0 (c = 0.8, MeOH). – mp: ~99 °C. – 1H NMR 
(600 MHz Kryo, MeOD): δH = 1.41 (s, 9H), 1.50 (s, 9H), 1.58 (m, 1H), 1.78 (m, 1H), 2.08-
2.16 (m, 2H), 2.24 (m, 1H), 3.03-3.17 (m, 2H), 3.27 (m, 1H), 3.32 (s, 3H), 3.85 (m, 1H), 4.24-
4.38 (m, 3H), 4.73 (m, 1H), 7.30 (m, 2H), 7.37 (m, 2H), 7.66 (m, 2H), 7.78 (m, 2H). – 13C 
NMR (150.9 MHz Kryo, MeOD): δC = 27.82 (1C), 28.24 (3C), 28.82 (3C), 34.04 (1C), 39.94 
(1C), 45.85 (1C), 48.32 (1C), 48.47 (1C), 56.84 (1C), 57.22 (1C), 69.24 (1C), 79.88 (1C), 
81.22 (1C), 84.83 (1C), 120.90 (1C), 120.91 (1C), 126.32 (1C), 126.39 (1C), 128.16 (2C), 
128.72 (1C), 128.74 (1C), 142.52 (1C), 142.56 (1C), 145.41 (1C), 145.47 (1C), 153.89 (1C), 
158.22 (1C), 158.53 (1C), 164.97 (1C), 178.06 (1C).– IR (film): ~ν 3350, 2976, 2933, 1710, 
1609, 1249, 1108. – MS (ESIMS): m/z (%) = 667.2 [MH+], 576.3 [MH+-Boc], 467.1 [MH+-
2Boc], 2 isomers due to Boc migration at 13.34 min and 13.93 min. 
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(3aS,4R,6S,6aS)-1-benzyl-4-hydroxy-6-(hydroxymethyl)hexahydrocyclopenta[b]pyrrol-
2(1H)-one (116) 
 
A mixture of zinc dust (1.16 g, 17.7 mmol, 5 equiv) in 5ml acetic acid was added copper(II) 
acetate (5.5 mg, 0.03 mmol, 0.8 mol%) and stirred for 15 minutes. To that mixture was added 
66b (879 mg, 3.39 mmol, 1 equiv) in 3 ml AcOH/H2O (2:1) and the solution was heated to  
80°C until starting material was consumed (TLC control). After cooling to room temperature 
EDTA (0.4 g) were added and stirred for additional 15 minutes. Upon addition of 4M NaOH 
the pH of the solution was adjusted to pH 10 and subsequently extracted with DCM. The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude mixture (900 mg) was obtained as a mixture of 87 and 116 was therefore 
used in the next step without further purification. The crude mixture was dissolved in 5 ml 
MeOH, upon addition of DBU (1.5 ml, 10.17 mmol, 3equiv) the mixture was stirred 
overnight. After addition of EtOAc the organic layers were washed with KHSO4 solution, 
dried over MgSO4, filtered and concentrated under reduced pressure. Chromatography on 
silica gel eluting with 5% MeOH in CH2Cl2 gave white solid foam (712 g, 2.75 mmol, 81 %). 
   
Rf = 0.27 (CH2Cl2/MeOH 9:1). – [α]20 = - 48.2 (c = 0.8, MeOH).– 1H NMR (300 MHz, 
CDCl3): δH = 1.67 (m, 1H), 1.99 (m, 1H), 2.20 (m, 1H), 2.36 (dd, 1H, J = 13.3, 19.9 Hz), 2.85 
(m, 1H), 3.68 (dd, 1H, J = 6.2, 10.8 Hz), 3.77 (dd, 1H, J = 4.4, 10.8 Hz), 3.90 (m, 1H), 4.04 
(d, 1H, J = 14.7 Hz), 4.21 (m, 1H), 5.22 (d, 1H, J = 14.7 Hz), 7.23-7.35 (m, 5H). – 13C NMR 
(75.5 MHz, CDCl3): δC = 30.02 (-, 1C), 36.94 (+, 1C), 40.17 (-, 1C), 43.05 (-, 1C), 46.28 (+, 
1C), 61.67 (+, 1C), 62.00 (-, 1C), 70.67 (+, 1C), 127.64 (+, 1C), 128.31 (+, 2C), 128.71 (+, 
2C), 136. 63 (q, 1C), 176.86 (q, 1C).– IR: ~ν = 3399, 2892, 2977, 1651, 1451, 1423, 1255, 
1074, 1052, 1014. – MS (EI-MS): m/z (%) = 261.1 (23.7) [M+.], 244.1 (7.4) [M+.–OH], 91.1 
(100) [C7H7+]. – HRMS (EI-MS): 261.1366 (C15H19NO3 [M+.]: calcd. 261.1368). 
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(3aS,4R,6S,6aS)-1-benzyl-6-(hydroxymethyl)octahydrocyclopenta[b]pyrrol-4-ol (117) 
 
To a solution of LAH (241 mg, 6.36 mmol, 3 equiv) in 15 ml anhydrous THF under nitrogen 
was slowly added 116 (554 mg, 2.12 mmol, 1 equiv) in 10 ml anhydrous THF at 0 °C. After 
stirring for 45 min the reaction mixture was quenched with 10 ml EtOAc. The reaction 
mixture was filtered through celite and concentrated under reduced pressure yielding a 
colourless solid (422 mg, 1.71 mmol, 81%). 
 
Rf = 0.14 (CH2Cl2/MeOH 9:1). – [α]20 = - 41.1 (c = 0.3, MeOH). – 1H NMR (300 MHz, 
CDCl3): δH = 1.68 (m, 1H), 1.98 (m, 1H), 2.19 (m, 1H), 2.34 (dd, 1H, J = 13.3, 19.9 Hz), 2.83 
(m, 2H), 3.62-3.77 (m, 3H), 3.88 (m, 1H), 4.02 (d, 1H, J = 14.8 Hz), 4.18 (m, 2H), 5.17 (d, 
1H, J = 14.8 Hz), 7.22-7.34 (m, 5H) . – 13C NMR (75.5 MHz, CDCl3): δC = 23.39 (-, 1C), 
39.63 (+, 1C), 39.85 (-, 1C), 49.38 (+, 1C), 56.52 (-, 1C), 62.04 (-, 1C), 63.46 (-, 1C), 71.13 
(+, 1C), 71.69 (+, 1C), 127.54 (+, 1C), 128.59 (+, 2C), 129.16 (+, 2C), 137.95 (1C).– IR 
(film): ~ν = 3290, 3267, 2922, 2849, 2785, 1728, 1453, 1331, 1050, 1029, 1002, 751. – MS 
(EI-MS): m/z (%) = 247.2 [M+.], 230.2 [M+.-OH.], 91.1 [C7H7+]. – HRMS (EI-MS): 247.1566 
(C15H21NO2 [M+.]: calcd. 247.1572). 
 
 
 
 
(3aS,4R,6S,6aS)-1-benzyl-6-((tert-butyldimethylsilyloxy)methyl)octahydrocyclopenta 
[b]pyrrol-4-ol (118) 
 
Diol 117 (600 mg, 2.43 mmol, 1 equiv) was dissolved in 20 ml DCM and tert-
butyltrimethylsilyl chloride (403 mg, 2.67 mmol, 1.1 equiv), triethylamine (406 µl, 2.92 
mmol, 1.2 equiv) and DMAP (30 mg, 0.24 mmol, 0.1 equiv) were added and stirred overnight 
(18 h). After addition of 5 ml saturated NH4Cl solution the layers were separated and the 
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aqueous layer was extracted with DCM (3 x 10 ml). The combined organic layers were dried 
over MgSO4, filtered and concentrated. Chromatography on silica gel eluting with 5% MeOH 
in CH2Cl2 gave a colourless oil (690 mg, 1.91 mmol, 79 %). 
 
Rf = 0.27 (ethyl acetate/hexanes 1:1). – 1H NMR (300 MHz, CDCl3): δH = -0.06 (s, 3H), 0.00 
(s, 9H), 1.54 (m, 2H), 1.77 (m, 2H), 1.93 (m, 2H), 2.09 (m, 1H), 2.73 (p, 1H, J = 8.5 Hz), 2.92 
(m, 1H), 3.15 (m, 2H), 3.68 (dd, 1H, J = 5.6, 10.0 Hz), 3.98 (m, 1H), 4.08 (ddd, 1H, J = 5.8, 
7.9, 9.5 Hz), 4.31 (d, 1H, J = 13.6 Hz), 7.17-7.31 (m, 5H). – 13C NMR (75.5 MHz, CDCl3): 
δC = -5.37 (+, 2C), 18.22 (1C), 24.56 (-, 1C), 25.90 (+, 3C), 35.02 (-, 1C), 43.50 (+, 1C), 
47.46 (+, 1C), 55.20 (-, 1C), 62.59 (-, 1C), 68.16 (+, 1C), 72.89 (+, 1C), 128.16 (4C), 128.48 
(2C). – IR (film): ~ν = 3289, 2856, 2791, 1453, 1253, 1089, 1059, 833. – MS (ESIMS): m/z = 
376.1 [MH+]. – HRMS (EI-MS): 375.2588 (C22H37NO2Si [M+.]: calcd. 375.2594). 
 
 
 
 
(3aS,4R,6S,6aS)-1-benzyl-6-((tert-butyldimethylsilyloxy)methyl)-4-
methoxyoctahydrocyclopenta[b]pyrrole (118) 
 
To a solution of alcohol 118 (20 mg, 0.05 mmol, 1 equiv) in 5 ml anhydrous THF was added 
NaH (60 % suspension in paraffin oil, 5 mg, 0.11 mmol, 2.2 equiv). After stirring for 1 hour 
methyl iodide (16 µl, 0.25 mmol, 5 equiv) was added and stirred overnight (18 h). 
Subsequently 2 ml of half saturated NH4Cl solution was and the layers were separated. The 
aqueous phase was extracted with ethyl acetate (3 x 5 ml) and the combined organic layers 
were dried over MgSO4, filtered and concentrated. Chromatography on silica gel eluting with 
ethyl acetate in hexanes (1:10) gave a colourless oil (14 mg, 0.04 mmol, 77 %). 
 
Rf = 0.53 (ethyl acetate/hexanes 1:1). – 1H NMR (300 MHz, CDCl3): δH = -0.06 (s, 3H), 0.00 
(s, 3H), 0.83 (s, 9H), 1.44 (m, 1H), 1.59 (m, 1H), 1.69-1.94 (m, 3H), 2.02 (ddd, 1H, J = 5.5, 
8.7, 12.0 Hz), 2.82 (m, 2H), 3.08 (dd, 1H, J = 6.0, 8.4 Hz), 3.16 (d, 1H, J = 13.7 Hz), 3.30 (s, 
3H), 3.63 (m, 2H), 4.00 (dd, 1H, J = 8.2, 9.8 Hz), 4.29 (d, 1H, J = 13.7 Hz), 7.17-7.32 (m, 
5H). – 13C NMR (75.5 MHz, CDCl3): δC = -5.37 (+, 2C), 18.22 (1C), 24.89 (-, 1C), 25.91 (+, 
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3C), 31.15 (-, 1C), 43.37 (+, 1C), 44.80 (+, 1C), 54.95 (-, 1C), 57.32 (+, 1C), 60.53 (-, 1C), 
62.58 (-, 1C), 67.39 (+, 1C), 81.57 (+, 1C), 126.46 (+, 1C), 128.10 (+, 2C), 128.43 (+, 2C), 
140.51 (1C).– IR (film): ~ν = 2927, 2855, 2791, 1462, 1357, 1253, 1091, 836. – MS (ESIMS): 
m/z  = 362.1 [MH+]. – HRMS (ES-MS): 361.2431 (C21H35NO2Si [M+.]: calcd. 361.2437). 
 
 
 
 
(3aS,4R,6S,6aR)-1-benzyl-4-methoxyoctahydrocyclopenta[b]pyrrole-6-carboxylic acid 
(119) 
 
To a solution of 118 (200 mg, 0.53 mmol, 1 equiv) in 5 ml acetone was added 1 ml of Jones 
reagent at 0°C and stirred for 5 hours at room temperature. After addition of 2 ml isopropanol 
and 30 ml of ethylacetate the mixture of organic solvents was washed with water and brine. 
The organic layer was dried over MgSO4 and the solvent was removed under reduced 
pressure. The residue was chromatographed on silica gel eluting with 2% MeOH in DCM 
giving a colourless solid (120 mg, 0.44 mmol, 83 %). 
 
Rf = 0.18 (CH2Cl2/MeOH 1:1). – [α]20 = - 2.6 (c = 0.3, MeOH). – 1H NMR (300 MHz, 
MeOD): δH = 1.94-2.21 (m, 4H), 2.68 (m, 1H), 3.11-3.26 (m, 2H), 3.29 (s, 1H), 3.77 (m, 1H), 
4.07 (m, 1H), 4.16 (d, 1H, J = 12.8 Hz), 4.38 (d, 1H, J = 12.8 Hz), 7.43 (m, 3H), 7.53 (m, 
2H). – 13C NMR (75.5 MHz, MeOD): δC = 24.40 (-, 1C), 36.48 (-, 1C), 42.24 (+, 1C), 47.46 
(+, 1C), 55.34 (-, 1C), 57.62 (+, 1C), 59.98 (-, 1C), 71.94 (+, 1C), 81.25 (+, 1C), 130.37 (+, 
2C), 130.71 (+, 1C), 131.45 (+, 2C), 133.14 (1C), 180.08 (1C).– IR (neat): ~ν = 3412, 2977, 
2934, 1602, 1457, 1370, 1205, 1107, 1205, 1107, 1041, 936, 762. – MS (EI-MS): m/z (%) = 
275.1 (11.9) [M+.], 91.0 (100) [C7H7+]. – HRMS (EI-MS, 70 eV): 275.1514 (C16H21NO4 
[M+.]: calcd. 275.1521). 
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[(3aR,5R,6S,6aR)-1-benzyl-5-methoxyhexahydro-1H-cyclopenta[c]isoxazol-6-yl]acetic 
acid (138) 
 
To a solution of 94 (550 mg, 1.40 mmol, 1 equiv) in 10 ml acetone was added 2 ml of Jones 
reagent at 0°C and stirred for 2 hours at room temperature. After addition of 5ml isopropanol 
and 60 ml of ethylacetate the mixture of organic solvents was washed with water and brine. 
The organic layer was dried over MgSO4 and the solvent was removed under reduced 
pressure. The residue was chromatographed on silica gel eluting with 2% MeOH in DCM 
giving an colorless oil (350 mg, 1.20 mmol, 86 %). 
 
Rf = 0.14 (ethyl acetate). – [α]20 = - 44.1 (c = 0.07, MeOH). – 1H NMR (300 MHz, CDCl3): 
δH = 1.57 (ddd, 1H, J = 4.1, 6.8, 14.0 Hz), 2.26 (m, 3H), 2.57 (dd, 1H, J = 6.6, 16.5 Hz), 3.16 
(m, 1H), 3.25 (s, 3H), 3.46 (m, 2H), 3.64 (dd, 1H, J = 2.9, 8.9 Hz), 3.77 (d, 1H, J = 12.8 Hz), 
3.85 (m, 1H), 3.99 (d, 1H, J = 12.8 Hz), 4.21 (m, 1H), 7.27-7.37 (m, 5H). – 13C NMR (75.5 
MHz, CDCl3): δC = 32.98 (-, 1 C ), 35.77 (-, 1 C), 43.70 (+, 1 C), 44.66 (+, 1 C), 56.81 (+, 1 
C), 59.78 (-, 1 C), 72.66 (-, 1 C), 74.95 (+, 1 C), 83.78 (+, 1 C), 127.78 (+, 1 C), 128.54 (+, 2 
C), 129.30 (+, 2 C), 136.10 (1 C), 176.96 (1 C).– IR (film): ~ν = 2932, 2882, 1706, 1455, 
1255, 1177, 1131, 1083. – MS (EI-MS): m/z (%) = 291.1 (22.4) [M+.], 276.1 (13.7) [M+-
CH3], 260.1 (4.3), [M+-COOH], 246.1 (3.1) [M+-OCH3], 91.0 (100)[C7H7+]. – HRMS (EI-
MS, 70 eV): 291.1469 (C16H21NO4 [M+.]: calcd. 291.1481). 
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2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(hydroxymethyl)-5-
methoxycyclopentyl)acetic acid (139) 
 
138 (1.1 g, 3.78 mmol, 1 equiv) was dissolved in 25 ml anhydrous methanol, 150 mg of 
Pd(OH)2-C were added and the resulting suspension was stirred under hydrogen atmosphere 
overnight. After filtration through celite the methanol was removed under reduced pressure 
giving the crude amino alcohol in quantitative yield. The crude intermediate was dissolved in 
20 ml of an acetone/water mixture (1:1) and subsequently NaHCO3 (2.95 g, 37.80 mmol, 10 
equiv) and FmocOSu (2.67 g, 7.94 mmol, 2.1 equiv) were added. After stirring for 24 h 
acetone was removed under reduced, 15 ml of saturated NH4Cl solution was added and the 
aqueous solution was extracted with ethyl acetate (3 x 50 ml). The combined organic layers 
were washed with brine, dried over MgSO4 and concentrated under reduced pressure. 
Chromatography on silica gel eluting with 5% MeOH in dichloromethane gave a white solid 
(930 mg, 2.19 mmol, 58 %).  
 
Rf = 0.25 (DCM/MeOH 95:5). – [α]20 = - 55.7 (c = 0.73, MeOH). mp: 133 °C. – 1H NMR 
(300 MHz, DMSO): δH = 1.63 (m, 1H), 1.95 (m, 1H), 2.10-2.35 (m, 2H), 2.38 (m, 1H), 3.13 
(s, 3H), 3.28-3.49 (m, 2H), 3.76 (m, 2H), 4.19-4.45 (m, 3H), 7.05 (d, 1H, J = 5.35 Hz), 7.33-
7.50 (m, 4H), 7.75 (m, 2H), 7.93 (m, 1H). – 13C NMR (75.5 MHz, DMSO): δC = 31.40 (-, 1 
C), 31.73 (-, 1 C), 39.01 (+, 1 C), 44.99 (+, 1 C), 46.69 (+, 1 C), 55.43 (+, 1 C), 55.93 (+, 1 
C), 61.24 (-, 1 C), 65.22 (-, 1 C), 79.40 (+, 1 C), 120.01 (+, 2 C), 125.11 (+, 2 C), 126.93 (+, 2 
C), 127.52 (+, 2 C), 140.61 (2 C), 143.70 (1 C), 143.83 (1 C), 150.89 (1 C), 173.97 (1 C).– IR 
(film): ~ν = 3312, 2935, 2361, 1683, 1539,1450, 1262, 1082, 1021. – MS (PI-LSIMS): m/z = 
426.3 [MH+], 851.3 [2 x MH+]. – HRMS (PI-LSIMS): 426.1915 (C24H27NO6 [MH+]: calcd. 
426.1913).  
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(R)-2-((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-yl)methyl 1-
tert-butyl pyrrolidine-1,2-dicarboxylate (156a) 
 
Under nitrogen at 0 °C were dissolved Boc-(D)-Pro (320 mg, 1.53 mmol, 1.5 equiv), EDC 
(270 µl, 1.53 mmol, 1.5 equiv), HOBt (201 mg, 1.53 mmol, 1.5 equiv) and DMAP (364 mg, 
3.05 mmol, 3 equiv) in 14 ml DCM/THF (5:2). After 30 minutes were added alcohol 153 (330 
mg, 1.02 mmol, 1 equiv) and the reaction was stirred at room temperature for 5 hours. The 
reaction mixture was poured into 100 ml EtOAc and washed successively with 1 M KHSO4, 
sat. NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified by flash chromatography eluting with 1 % 
MeOH in DCM to afford 156a (510 mg, 0.70 mmol, 96 %).  
 
NMR spectra showed a double set of signal for most proton peaks and carbon peaks 
respectively. 
 
Rf = 0.52 (ethyl acetate). – 1H NMR (400 MHz, CDCl3): δH = 1.40+1.46 (s, 9H), 1.70 (broad 
s, 1H), 1.92 (broad m, 3H), 2.20 (m, 1H), 2.80 (m, 1H), 3.28-3.57 (m, 3H), 4.04 (m, 2H), 
4.21-4.70 (m, 6H), 5.32 (m, 2H), 5.91 (m, 1H), 7.30 (bs, 1H), 7.23-7.36 (m, 5H). – 13C NMR 
(100.6 MHz, CDCl3): δC = 23.77+24.51 (1C), 28.29+28.42 (3C), 29.97+30.97 (1C), 
37.34+37.38 (1C), 46.35+46.64 (1C), 47.40 (1C), 50.91 (1C), 58.16+58.43 (1C), 58.75+58.93 
(1C), 62.79+63.03 (1C), 65.94+66.03 (1C), 80.18+80.32 (1C), 119.09+119.13 (1C), 
128.21+128.39 (2C), 129.11+129.15 (2C), 131.39+46 (1C), 134.80+134.93 (1C), 
153.56+154.36 (1C), 165.48+165.69 (1C), 165.78+165.87 (1C), 170.59+170.86 (1C), 
172.31+172.68 (1C). 
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(S)-2-((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-yl)methyl 1-tert-
butyl pyrrolidine-1,2-dicarboxylate (156b) 
 
Under nitrogen at 0 °C were dissolved Boc-(L)-Pro (162 mg, 0.75 mmol, 1.5 equiv), DCC 
(156 mg, 0.75 mmol, 1.5 equiv), HOBt (103 mg, 0.75 mmol, 1.5 equiv) and DMAP (184 mg, 
1.5 mmol, 3 equiv) in 7ml DCM/THF (5:2). After 30 minutes were added alcohol 153 (165 
mg, 0.50 mmol, 1 equiv) and the reaction was stirred at room temperature for 5 hours. The 
reaction mixture was poured into 80 ml EtOAc and washed successively with 1 M KHSO4, 
sat. NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified by flash chromatography eluting with 2 % 
MeOH in DCM to afford 156b (370 mg, 0.70 mmol, 140 %). Even after chormoatography the 
NMR spectra showed the presence of DCU which could not be removed and therefore the 
mixture was used for the next step without further purification. 
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(R)-tert-butyl 2-(((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-
yl)methylcarbamoyl)pyrrolidine-1-carboxylate (158a) 
 
155 (320 mg, 0.74 mmol, 1 equiv) was dissolved in 7 ml DCM and added 7 ml TFA at 0°C 
and stirred for 30 minutes. The solution was concentrated under reduced pressure and the 
residue was treated with EtO2 to provoke precipitation of the TFA salt. Boc-(D)-Pro (230 mg, 
1.11 mmol, 1.5 equiv) was dissolved in 15 ml acetonitrile and added HBTU (406 mg, 1.11 
mmol, 1.5 equiv) and collidine (0.38 ml, 2.97 mmol, 4 equiv) at 0°C under N2. After stirring 
for 30 minutes the TFA salt was added and the mixture was continued stirring for overnight at 
room temperature. The reaction mixture was poured in to 100 ml of EtOAc and washed with 1 
M KHSO4, sat. NaHCO3 and brine. The organic layer was dried over NaSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography eluting with 1 % MeOH in DCM to yield 158a (380 mg, 0.72 mmol, 97 %). 
 
Rf = 0.26 (ethyl acetate). – 1H NMR (400 MHz, CDCl3): δH = 1.46 (s, 9H), 1.86 (broad m, 
2H), 2.34 (broad s, 1H), 2.60 (s, 1H), 2.79 (m, 1H) 3.26 (dd, 1H, J = 17.52, 1.52 Hz), 3.31–
3.52 (broad m, 3H), 3.86 (broad s, 1H), 4.05-4.75 (broad m, 3H), 4.61-4.80 (m, 3 H), 5.28 (m, 
2H), 5.50 (m, 1H), 5.89 (m, 1H), 6.72 (broad s, 1H), 7.18 (broad s, 1H), 7.25 – 7.41 (m, 5H). 
– 
13C NMR (100.6 MHz, CDCl3): δC = 24.50 (1C), 28.40 (3C), 28.58 (1C), 37.78 (1C), 38.61 
(1C), 39.21 (1C), 47.03 (1C), 47.36 (1C), 50.80 (1C), 58.61 (1C), 60.31 (1C), 65.86 (1C), 
80.66 (1C), 119.00 (1C), 128.02 (1C), 128.38 (2C), 128.68 (2C), 131.47 (1C), 135.43 (1C), 
165.00 (1C), 166.68 (1C), 170.71 (1C), 173.15 (1C). 
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(S)-tert-butyl2-(((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-
yl)methylcarbamoyl)pyrrolidine-1-carboxylate (158b)  
 
155 (325 mg, 0.75 mmol, 1 equiv) was dissolved in 6 ml DCM and added 6ml TFA at 0°C 
and stirred for 30 minutes. The solution was concentrated under reduced pressure and the 
residue was treated with EtO2 to provoke precipitation of the TFA salt. Boc-(L)-Pro (230 mg, 
1.11 mmol, 1.5 equiv) was dissolved in 15 ml acetonitrile and added HBTU (406 mg, 1.11 
mmol, 1.5 equiv) and collidine (0.38 ml, 2.97 mmol, 4 equiv) at 0°C under N2. After stirring 
for 30 minutes the TFA salt was added and the mixture was continued stirring for overnight at 
room temperature. The reaction mixture was poured in to 100 ml of EtOAc and washed with 1 
M KHSO4, sat. NaHCO3 and brine. The organic layer was dried over NaSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography eluting with 2 % MeOH in DCM to yield 158b (390 mg, 0.74 mmol, 98%).  
 
Rf = 0.26 (ethyl acetate). – 1H NMR (400 MHz, CDCl3): δH = 1.47 (s, 9H), 1.88 (broad m, 
2H), 2.08 (broad m, 1H), 2.81 (broad m, 2H), 3.22 (dd, 1H, J = 17.57, 3.12 Hz), 3.33 (broad 
m, 1H), 3.41 (broad m, 1H), 3.58 (broad m, 1H), 3.88 (broad s, 1H), 3.95 (broad m, 1H), 4.21 
(d, 1H, J = 15.17 Hz), 4.30 (broad s, 1H), 4.55-4.63 (m, 3 H), 5.28 (ddd, 2H, J = 30.17, 17.20, 
1.16 Hz), 5.43 (d, 1H, J = 15.16 Hz), 5.89 (m, 1H), 6.97 (broad s, 1H), 7.27 – 7.35 (m, 5H), 
7.51 (broad m, 1H). – 13C NMR (151 MHz, CDCl3): δC = 24.54 (-, 1C), 28.40 (+, 3C), 28.62 
(-, 1C), 37.55  (-, 1C), 39.21 (-, 1C), 47.06 (-, 1C), 47.44 (-, 1C), 50.69 (+, 1C), 59.04 (+, 1C), 
59.84 (+, 1C), 65.81 (-, 1C), 80.63 (1C), 118.92 (-, 1C), 127.93 (+, 1C), 128.43 (+, 2C), 
128.90 (+, 2C), 131.48 (+, 1C), 135.61 (1C), 164.81 (1C), 167.03 (1C), 170.68 (1C), 173.85 
(1C). 
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2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((R)-pyrrolidine-2-carbonyloxy)methyl)piperazin-2-
yl)acetic acid (160) 
 
To a solution of 156a (490 mg, 0.67 mmol, 1 equiv) in 7 ml of DCM were subsequently 
added pyrrolidine (91 µl, 0.81 mmol, 1.2 equiv), PPh3 (44 mg, 0.12 mmol, 0.18 equiv) and 
Pd(PPh3)4 (44 mg, 0.03 mmol, 0.04 equiv) at 0 °C and additionally stirred at room 
temperature for 2-3 hours. The reaction mixture was poured into 120 ml of EtOAc and 
extracted with ml of sat. NaHCO3. The organic layers were discarded and the pH of the 
aqueous solution was carefully adjusted to 2 by addition of 1 M KHSO4. The acidified 
aqueous solution was extracted with DCM (3 x) and the combined organic layers were dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography eluting with 5 % MeOH in DCM to yield 157a. 
Subsequently, 157a was dissolved in 5 ml DCM and added 5 ml TFA to yield TFA salt 160 
(321 mg, 0.66 mmol, 98 %). 
 
Rf ≈ 0.05 (CH2Cl2/MeOH). – 1H NMR (300 MHz, D2O): δH = 1.78-1.96 (m, 3H), 2.28 (m, 
1H), 2.82 (dd, 1H, J = 4.9, 17.8 Hz), 3.01 (dd, 1H, J = 4.4, 17.7 Hz), 3.24 (m, 2H), 4.31-4.40 
(m, 3H), 4.46-4.51 (m, 3H), 4.70 (d, 1H, J = 15.5 Hz), 7.19-7.30 (m, 5H). – 13C NMR (75.5 
MHz, D2O): δC = 23.36 (-, 1C), 28.12 (-, 1C), 35.84 (-, 1C), 46.25 (-, 1C), 48.67 (-, 1C), 50.81 
(+, 1C), 59.06 (+, 1C), 59.53 (+, 1C), 64.87 (-, 1C), 127.71 (+, 2C), 128.16 (+, 1C), 129.04 
(+, 2C), 135.43 (1C), 167.49 (1C), 168.32 (1C), 169.09 (1C), 173.66 (1C). 
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2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((R)-pyrrolidine-2-carboxamido)methyl)piperazin-2-
yl)acetic acid (161) 
 
To a solution of 158a (370 mg, 0.70 mmol, 1 equiv) in 6 ml of DCM were subsequently 
added pyrrolidine (70 µl, 0.84 mmol, 1.2 equiv), PPh3 (33 mg, 0.13 mmol, 0.18 equiv) and 
Pd(PPh3)4 (33 mg, 0.03 mmol, 0.04 equiv) at 0 °C and additionally stirred at room 
temperature for 2-3 hours. The reaction mixture was poured into ml of EtOAc and extracted 
with ml of sat. NaHCO3. The organic layers were discarded and the pH of the aqueous 
solution was carefully adjusted to 2 by addition of 1 M KHSO4. The acidified aqueous 
solution was extracted with DCM (3 x) and the combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography eluting with 5 % MeOH in DCM to yield 159a. Subsequently, 
159a was dissolved in 5 ml DCM and added 5 ml TFA to yield TFA salt 161 (315 mg, 0.65 
mmol, 93 %). 
 
Rf ≈ 0.05 (CH2Cl2/MeOH). – 1H NMR (300 MHz, D2O): δH = 1.69-2.10 (m, 3H), 2.33 (m, 
1H), 2.83 (dd, 1H, J = 4.8, 17.7 Hz), 3.02 (dd, 1H, J = 4.4, 17.7 Hz), 3.31 (m, 2H), 3.57 (dd, 
1H, J = 2.4, 14.1 Hz), 4.00 (m, 2H), 4.14 (d, 1H, J = 15.5 Hz), 4.24 (t, 1H, J = 7.8 Hz), 4.41 
(t, 1H, J = 4.5 Hz), 5.13 (d, 1H, J = 15.5 Hz), 7.24-7.35 (m, 5H). – 13C NMR (75.5 MHz, 
D2O): δC = 23.71 (-, 1C), 29.66 (-, 1C), 35.83 (-, 1C), 39.50 (-, 1C), 46.73 (-, 1C), 47.76 (-, 
1C), 50.71 (+, 1C), 59.24 (+, 1C), 59.76 (+, 1C), 127.83 (+, 2C), 128.17 (+, 1C), 129.02 (+, 
2C), 129.07 (1C), 167.88 (1C), 168.18 (1C), 170.17 (1C), 173.56 (1C). 
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2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((S)-pyrrolidine-2-carbonyloxy)methyl)piperazin-2-
yl)acetic acid (162) 
 
To a solution of crude 156b (370 mg, 0.70 mmol, 1 equiv) in 6 ml of DCM were subsequently 
added pyrrolidine (70 µl, 0.84 mmol, 1.2 equiv), PPh3 (33 mg, 0.13 mmol, 0.18 equiv) and 
Pd(PPh3)4 (33 mg, 0.03 mmol, 0.04 equiv) at 0 °C and additionally stirred at room 
temperature for 2-3 hours. The reaction mixture was poured into 100 ml of EtOAc and 
extracted with ml of sat. NaHCO3. The organic layers were discarded and the pH of the 
aqueous solution was carefully adjusted to 2 by addition of 1 M KHSO4. The acidified 
aqueous solution was extracted with DCM (3 x) and the combined organic layers were dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography eluting with 5 % MeOH in DCM to yield 162. 
Subsequently, 157b was dissolved in 4 ml DCM and added 4 ml TFA to yield TFA salt 162 
(238 mg, 0.49 mmol, 77 %). 
 
Rf ≈ 0.05 (CH2Cl2/MeOH). – 1H NMR (300 MHz, D2O): δH = 1.90-2.06 (m, 3H), 2.33 (m, 
1H), 2.88 (dd, 1H, J = 4.7, 17.8 Hz), 3.07 (dd, 1H, J = 4.5, 17.8 Hz), 3.30 (m, 2H), 4.33-4.55 
(m, 6H), 4.86 (d, 1H, J = 15.8 Hz), 7.22-7.35 (m, 5H). – 13C NMR (75.5 MHz, D2O): δC = 
23.31 (-, 1C), 28.02 (-, 1C), 35.88 (-, 1C), 46.28 (-, 1C), 48.26 (-, 1C), 50.76 (+, 1C), 59.11 
(+, 1C), 59.28 (+, 1C), 64.75 (-, 1C), 127.55 (+, 2C), 128.11 (+, 1C), 128.99 (+, 2C), 135.21 
(1C), 167.33 (1C), 168.20 (1C), 169.05 (1C), 173.69 (1C). 
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2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((S)-pyrrolidine-2-carboxamido)methyl)piperazin-2-
yl)acetic acid (163) 
 
To a solution of 158b (350 mg, 0.66 mmol, 1 equiv) in 5 ml of DCM were subsequently 
added pyrrolidine (65 µl, 0.79 mmol, 1.2 equiv), PPh3 (32 mg, 0.12 mmol, 0.18 equiv) and 
Pd(PPh3)4 (32 mg, 0.03 mmol, 0.04 equiv) at 0 °C and additionally stirred at room 
temperature for 2-3 hours. The reaction mixture was poured into ml of EtOAc and extracted 
with ml of sat. NaHCO3. The organic layers were discarded and the pH of the aqueous 
solution was carefully adjusted to 2 by addition of 1 M KHSO4. The acidified aqueous 
solution was extracted with DCM (3 x) and the combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography eluting with 5 % MeOH in DCM to yield 159b. Subsequently, 
159b was dissolved in 5 ml DCM and added 5 ml TFA to yield TFA salt 163 (237 mg, 0.49 
mmol, 74 %). 
 
Rf ≈ 0.05 (CH2Cl2/MeOH). – 1H NMR (300 MHz, D2O): δH = 1.83-2.01 (m, 3H), 2.34 (m, 
1H), 2.83 (dd, 1H, J = 4.8, 17.8 Hz), 3.03 (dd, 1H, J = 4.4, 17.8 Hz), 3.30 (m, 2H), 3.80 (dd, 
1H, J = 5.0, 14.7 Hz), 3.71 (dd, 1H, J = 3.4, 14.7 Hz), 4.03 (t, 1H, J = 3.9 Hz), 4.13 (d, 1H, J 
= 15.5 Hz), 4.24 (m, 1H), 4.42 (t, 1H, J = 4.5 Hz), 5.16 (d, 1H, J = 15.5 Hz), 7.30 (m, 5H). – 
13C NMR (75.5 MHz, D2O): δC = 23.77 (-, 1C), 29.64 (-, 1C), 35.94 (-, 1C), 39.49 (-, 1C), 
46.36 (-, 1C), 47.82 (-, 1C), 50.77 (+, 1C), 59.24 (+, 1C), 59.78 (+, 1C), 127.84 (+, 2C), 
128.15 (+, 1C), 129.01 (+, 2C), 134.91 (1C), 167.85 (1C), 168.19 (1C), 170.26 (1C), 173.57 
(1C). 
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D.    Summary 
 
The synthesis of different cispentacin derivatives (91, 97, 102 and 119) as well as of 
conformational restricted γ-amino acid 139 was accomplished starting from furan methyl ester 
(68) and the thereof derived trans-substituted γ-butyrolactone 67 respectively. 
The keystep in this synthetic approach is a [3+2]-nitrone-cycloaddition reaction affording the 
diastereomeric products 66a and 66b which were subsequently transformed in a 
straightforward manner. These amino acids have a broad range of potential applications like 
in the field of medicinal chemistry as new antiviral agents (cispentacin analogues), in  
organocatalysis, as constricting elements in peptides and as building blocks for foldamers. 
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Furthermore, four different proline-diketopiperazine esters (157a/157b) and the related 
amides (159a/159b) were prepared. In this course, differently protected Asp and Ser 
derivatives were condensed to DKP 153, which can be subsequently transformed to the 
corresponding DKP 155. Adducts of these to DKPs with (L)-and (D)-proline were applied as 
novel organocatalysts in the conjugate addition of aldehydes and ketones to nitroolefines.  
 
 
 
 
Especially, the proline DKP amides were shown to be highly active and selective in the 
reaction of aldehydes.  
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However, the addition of ketones (acetone and cyclohexanone respectively were utilised and 
also used as neat solvent) were achieved in reasonable to good yields with comparably low 
stereoinduction. The potentially beneficial effect of additives or other solvents was not 
investigated so far. 
Due to the promising results in the addition of aldehydes, the scope of these catalysts is 
currently under further investigation in the Piarulli group. 
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E. 1. NMR spectroscopic data 
 
 
Nuclei, solvents and type of experiment are indicated separately for each spectrum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E.   Appendix  112 
 (3aR,4aR,7aS,7bR)-1-benzyloctahydro-6H-furo[2',3':4,5]cyclopenta[1,2-c]isoxazol-6-one 
(66a) 
 
1H-NMR (300 MHz, CDCl3) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aS,4aR,7aS,7bS)-1-benzyloctahydro-6H-furo[2',3':4,5]cyclopenta[1,2-c]isoxazol-6-one 
(66b) 
 
1H-NMR (300 MHz, CDCl3) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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NOESY (400 MHz) 
 
ppm
2.02.53.03.54.04.55.05.56.06.57.07.5 ppm
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
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(E)-N-(((2R,3R)-2-allyl-5-oxotetrahydrofuran-3-yl)methylene)-1-phenylmethanamine 
oxide (84) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aS,4R,5R,6aR)-4-amino-5-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
(86) 
 
1H-NMR (300 MHz, CDCl3) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
(ppm)
0102030405060708090100110120130140150160170180190
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tert-butyl [(3aS,4R,5R,6aR)-5-(hydroxymethyl)-2-oxohexahydro-2H-cyclopenta[b]furan-
4-yl]carbamate (88) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aS,4S,5R,6aR)-4-[(tert-butoxycarbonyl)amino]-2-oxohexahydro-2H-
cyclopenta[b]furan-5-carboxylic acid (89) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
(ppm)
10111213
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(9H-fluoren-9-yl)methyl (3aS,4R,5R,6aR)-5-(hydroxymethyl)-2-oxohexahydro-2H-
cyclopenta[b]furan-4-ylcarbamate (90) 
 
1H-NMR (300 MHz, MeOD)  
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, MeOD) 
 
                                                                                                                          (ppm)
050100150
 
O
O
H
HFmocHN
HO
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(3aS,4S,5R,6aR)-4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-2-oxohexahydro-2H-
cyclopenta[b]furan-5-carboxylic acid (91) 
 
1H-NMR (300 MHz, DMSO+D2O) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, DMSO+D2O) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,5R,6S,6aR)-1-benzyl-6-(2-hydroxyethyl)hexahydro-1H-cyclopenta[c]isoxazol-5-ol 
(92) 
 
1H-NMR (300 MHz, MeOD)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, MeOD) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,5R,6S,6aR)-1-benzyl-6-[2-(tert-butyldimethylsiloxy)ethyl]hexahydro-1H-
cyclopenta[c]isoxazol-5-ol (93) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,5R,6S,6aR)-1-benzyl-6-[2-(tert-butyldimethylsiloxy)ethyl]-5-methoxyhexahydro-
1H-cyclopenta[c]isoxazole (94) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(9H-fluoren-9-yl)methyl (1R,2S,3R,5R)-2-(2-(tert-butyldimethylsilyloxy)ethyl)-5-
(hydroxymethyl)-3-methoxycyclopentylcarbamate (96) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(1R,2S,3S,4R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-(tert-
butyldimethylsilyloxy)ethyl)-4-methoxycyclopentanecarboxylic acid (97) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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2-[(3aR,5R,6S,6aR)-1-benzyl-5-methoxyhexahydro-1H-cyclopenta[c]isoxazol-6-
yl]ethanol (98) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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tert-butyl 2-((3aS,5R,6S,6aS)-1-benzyl-5-methoxyhexahydro-1H-cyclopenta[c]isoxazol-6-
yl)ethyl(N-(tert-butoxycarbonyl)carbamimidoyl)carbamate (99) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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tert-butyl (1R,2S,3R,5R)-2-(2-(3-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-
butylcarboxy)guanidino)ethyl)-5-(hydroxymethyl)-3-methoxycyclopentylcarbamate 
(101) 
 
1H-NMR (400 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
(ppm)
9.29.610.010.410.811.211.6
 
 
13C NMR (101 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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HSQC (400MHz)  
 
ppm
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5 ppm
10
20
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(1R,2S,3S,4R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-(1,2-bis(tert-
butoxycarbonyl)guanidino)ethyl)-4-methoxycyclopentanecarboxylic acid (102) 
 
1H-NMR (600 MHz, CDCl3)  
 
                                                                                                                          (ppm)
0.05.010.0
 
 
13C NMR (151 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
 
OMe
NH
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(3aS,4R,6S,6aS)-1-benzyl-4-hydroxy-6-(hydroxymethyl)hexahydrocyclopenta[b]pyrrol-
2(1H)-one (116) 
 
1H-NMR (300 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
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(3aS,4R,6S,6aS)-1-benzyl-6-(hydroxymethyl)octahydrocyclopenta[b]pyrrol-4-ol (117) 
 
1H-NMR (300 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
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(3aS,4R,6S,6aS)-1-benzyl-6-((tert-butyldimethylsilyloxy)methyl) 
octahydrocyclopenta[b]pyrrol-4-ol   
 
1H-NMR (300 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
 
 
BnN
OH
H
H
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(3aS,4R,6S,6aS)-1-benzyl-6-((tert-butyldimethylsilyloxy)methyl)-4-methoxy-
octahydrocyclopenta[b]pyrrole (118) 
 
1H-NMR (300 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150 1020304060708090110120130140160170180190
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(3aS,4R,6S,6aR)-1-benzyl-4-methoxyoctahydrocyclopenta[b]pyrrole-6-carboxylic acid 
(119) 
 
1H-NMR (300 MHz, MeOD) 
 
                                                                                                                      (ppm)
0.000.501.001.502.002.503.003.504.004.505.005.506.006.507.007.508.008.509.00
 
 
13C NMR (75.5 MHz, MeOD) 
 
                                                                                                                          (ppm)
050100150 1020304060708090110120130140160170180190
 
 
 
BnN
HOOC
OMe
H
H
E.   Appendix  136 
2-((3aR,5R,6S,6aR)-1-benzyl-5-methoxyhexahydro-1H-cyclopenta[c]isoxazol-6-yl)acetic 
acid (138) 
 
1H-NMR (300 MHz, CDCl3)  
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
(ppm)
9101112
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
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2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(hydroxymethyl)-5-
methoxycyclopentyl)acetic acid (139) 
 
1H-NMR (300 MHz, DMSO) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
 
 
13C NMR (75.5 MHz, CDCl3) 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
E.   Appendix  138 
(R)-2-((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-yl)methyl 1-
tert-butyl pyrrolidine-1,2-dicarboxylate (156a) 
 
1H-NMR (400 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (APT, 101 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
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(S)-tert-butyl-2-(((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-
yl)methylcarbamoyl)pyrrolidine-1-carboxylate (158a) 
 
1H-NMR (400 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (APT, 101 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
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(R)-tert-butyl 2-(((2R,5S)-5-(2-(allyloxy)-2-oxoethyl)-1-benzyl-3,6-dioxopiperazin-2-
yl)methylcarbamoyl)pyrrolidine-1-carboxylate (158b) 
 
1H-NMR (600 MHz, CDCl3) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (151 MHz, CDCl3) 
 
                                                                                                                          (ppm)
050100150
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2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((R)-pyrrolidine-2-carbonyloxy)methyl)piperazin-2-
yl)acetic acid (160) 
 
1H-NMR (300 MHz, D2O) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, D2O) 
 
                                                                                                                          (ppm)
050100150
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2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((R)-pyrrolidine-2-carboxamido)methyl)piperazin-2-
yl)acetic acid (161) 
 
1H-NMR (300 MHz, D2O) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (101 MHz, D2O) 
 
                                                                                                                          (ppm)
050100150
 
HN
BnN
NH
O
O
O
OH
O
N
H TFA
E.   Appendix  143 
2-((2S,5R)-4-benzyl-3,6-dioxo-5-(((S)-pyrrolidine-2-carbonyloxy)methyl)piperazin-2-
yl)acetic acid (162) 
 
1H-NMR (300 MHz, D2O) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, D2O) 
 
                                                                                                                          (ppm)
050100150
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2-((2S,5R)-4-benzyl-5-(((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxamido)methyl)-
3,6-dioxopiperazin-2-yl)acetic acid (163) 
 
1H-NMR (300 MHz, D2O) 
 
                                                                                                                          (ppm)
0.01.02.03.04.05.06.07.08.09.0
 
 
13C NMR (75.5 MHz, D2O) 
 
                                                                                                                          (ppm)
050100150
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E. 2. X-ray crystallographic data 
 
 
(3aR,4aR,7aS,7bR)-1-benzyloctahydro-6H-furo[2',3':4,5]cyclopenta[1,2-c]isoxazol-6-one 
(66a) 
 
  
Crystal data and structure refinement for 66a. 
 
Empirical formula  C15H17NO3  
Formula weight  259.30  
Crystal size  0.36 x 0.28 x 0.06 mm 
Crystal description  platelike 
Crystal colour  colourless  
Crystal system Orthorhombic  
Space group  P 21 21 21  
Unit cell dimensions              a = 9.7077(7) Å   alpha = 90 deg. 
                                        b = 9.8447(10) Å    beta = 90 deg. 
                                        c = 13.7934(10) Å   gamma = 90 deg. 
Volume  1318.23(19) Å3  
Z, Calculated density  4,  1.306 Mg/m3  
Absorption coefficient  0.091 mm-1  
F(000)  552 
Measurement device 
type  
STOE-IPDS diffractometer  
Measuremnet method  rotation  
Temperature  123(1) K  
Wavelength  0.71073 A  
Monochromator   graphite  
Theta range for data 
collection  
2.54 to 26.84 deg.  
Index ranges  -12<=h<=12,  
-12<=k<=12,  
-17<=l<=17 
Reflections collected / 
unique  
19567 / 2822 [R(int) = 0.0577] 
Reflections greater 
I>2\s(I) 
2581 
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Absorption correction  None  
Refinement method  Full-matrix least-squares on F2  
Data / restraints / 
parameters  
2822 / 0 / 172 
Goodness-of-fit on F2  1.092  
Final R indices 
[I>2sigma(I)]      
R1 = 0.0299, wR2 = 0.0775 
R indices (all data)           R1 = 0.0335, wR2 = 0.0792 
Absolute structure 
parameter  
-0.2(8) 
Largest diff. peak and 
hole  
0.196 and -0.141 e. Å -3  
 
 
Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å 2 x 103) for 
66a. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 x y z U(eq) 
     
O(1) 1476(1) 7241(1) 9334(1) 30(1)  
O(2) 3302(1) 5862(1) 9414(1) 36(1)  
O(3) 1535(1) 10624(1) 6415(1) 35(1)  
N(1) 2227(1) 10829(1) 7357(1) 26(1)  
C(1) 2847(1) 6996(1) 9315(1) 25(1)  
C(2) 3632(1) 8311(1) 9162(1) 24(1)  
C(3) 2536(1) 9323(1) 8828(1) 23(1)  
C(4) 2358(1) 9400(1) 7709(1) 24(1)  
C(5) 921(1) 8806(1) 7463(1) 30(1)  
C(6) 107(1) 8872(1) 8415(1) 33(1)  
C(7) 1174(1) 8695(1) 9210(1) 26(1)  
C(8) 394(2) 9752(2) 6651(1) 42(1)  
C(9) 3556(1) 11436(1) 7066(1) 30(1)  
C(10) 4457(1) 11729(1) 7935(1) 24(1)  
C(11) 4120(1) 12770(1) 8585(1) 26(1)  
C(12) 4942(1) 13025(1) 9390(1) 31(1)  
C(13) 6120(1) 12241(1) 9559(1) 33(1)  
C(14) 6468(1) 11207(1) 8918(1) 35(1)  
C(15) 5644(1) 10954(1) 8106(1) 30(1)  
O(1) 1476(1) 7241(1) 9334(1) 30(1)  
O(2) 3302(1) 5862(1) 9414(1) 36(1)  
O(3) 1535(1) 10624(1) 6415(1) 35(1)  
N(1) 2227(1) 10829(1) 7357(1) 26(1)  
C(1) 2847(1) 6996(1) 9315(1) 25(1)  
C(2) 3632(1) 8311(1) 9162(1) 24(1)  
C(3) 2536(1) 9323(1) 8828(1) 23(1)  
C(4) 2358(1) 9400(1) 7709(1) 24(1)  
C(5) 921(1) 8806(1) 7463(1) 30(1)  
C(6) 107(1) 8872(1) 8415(1) 33(1)  
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Bond lengths [Å] and angles [deg] for 66a. 
 
O(1)-C(1) 1.3534(15) 
O(1)-C(7) 1.4710(14) 
O(2)-C(1) 1.2082(14) 
O(3)-N(1) 1.4770(14) 
O(3)-C(8) 1.4388(19) 
N(1)-C(4) 1.4937(15) 
N(1)-C(9) 1.4771(17) 
C(1)-C(2) 1.5165(16) 
C(2)-C(3) 1.5293(16) 
C(3)-C(4) 1.5537(16) 
C(3)-C(7) 1.5519(16) 
C(4)-C(5) 1.5506(18) 
C(5)-C(6) 1.534(2) 
C(5)-C(8) 1.543(2) 
C(6)-C(7) 1.5182(19) 
C(9)-C(10) 1.5114(18) 
C(10)-C(11) 1.4013(17) 
C(10)-C(15) 1.4027(17) 
C(11)-C(12) 1.3905(19) 
C(12)-C(13) 1.3987(19) 
C(13)-C(14) 1.390(2) 
C(14)-C(15) 1.398(2) 
C(2)-H(2A) 0.9893 
C(2)-H(2B) 0.9897 
C(3)-H(3) 10.005 
C(4)-H(4) 10.003 
C(5)-H(5) 0.9994 
C(6)-H(6A) 0.9901 
C(6)-H(6B) 0.9901 
C(7)-H(7) 0.9995 
C(8)-H(8A) 0.9898 
C(8)-H(8B) 0.9894 
C(9)-H(9A) 0.9900 
C(9)-H(9B) 0.9902 
C(11)-H(11) 0.9504 
C(12)-H(12) 0.9501 
C(13)-H(13) 0.9502 
C(14)-H(14) 0.9506 
C(15)-H(15) 0.9493 
C(1)-O(1)-C(7) 111.54(9) 
N(1)-O(3)-C(8) 103.43(10) 
O(3)-N(1)-C(4) 101.31(8) 
O(3)-N(1)-C(9) 102.29(9) 
C(4)-N(1)-C(9) 113.29(10) 
O(1)-C(1)-O(2) 121.45(10) 
O(1)-C(1)-C(2) 110.16(9) 
O(2)-C(1)-C(2) 128.39(11) 
C(1)-C(2)-C(3) 104.40(9) 
C(2)-C(3)-C(4) 114.13(9) 
C(2)-C(3)-C(7) 103.33(9) 
C(4)-C(3)-C(7) 105.21(9) 
N(1)-C(4)-C(3) 112.24(9) 
N(1)-C(4)-C(5) 101.97(9) 
C(3)-C(4)-C(5) 107.41(9) 
C(4)-C(5)-C(6) 105.04(10) 
C(4)-C(5)-C(8) 103.28(10) 
C(6)-C(5)-C(8) 115.11(11) 
C(5)-C(6)-C(7) 105.19(10) 
O(1)-C(7)-C(3) 104.92(9) 
O(1)-C(7)-C(6) 109.38(10) 
C(3)-C(7)-C(6) 106.85(10) 
O(3)-C(8)-C(5) 105.62(12) 
N(1)-C(9)-C(10) 111.48(10) 
C(9)-C(10)-C(11) 120.81(11) 
C(9)-C(10)-C(15) 120.39(11) 
C(11)-C(10)-C(15) 118.80(11) 
C(10)-C(11)-C(12) 120.62(11) 
C(11)-C(12)-C(13) 120.19(12) 
C(12)-C(13)-C(14) 119.78(13) 
C(13)-C(14)-C(15) 120.06(12) 
C(10)-C(15)-C(14) 120.54(12) 
C(1)-C(2)-H(2A) 110.85 
C(1)-C(2)-H(2B) 110.89 
C(3)-C(2)-H(2A) 110.90 
C(3)-C(2)-H(2B) 110.88 
H(2A)-C(2)-H(2B) 108.89 
C(2)-C(3)-H(3) 111.24 
C(4)-C(3)-H(3) 111.25 
C(7)-C(3)-H(3) 111.24 
N(1)-C(4)-H(4) 111.59 
C(3)-C(4)-H(4) 111.59 
C(5)-C(4)-H(4) 111.60 
C(4)-C(5)-H(5) 110.99 
C(6)-C(5)-H(5) 110.97 
C(8)-C(5)-H(5) 111.01 
C(5)-C(6)-H(6A) 110.70 
C(5)-C(6)-H(6B) 110.67 
C(7)-C(6)-H(6A) 110.72 
C(7)-C(6)-H(6B) 110.74 
H(6A)-C(6)-H(6B) 108.81 
O(1)-C(7)-H(7) 111.78 
C(3)-C(7)-H(7) 111.78 
C(6)-C(7)-H(7) 111.80 
O(3)-C(8)-H(8A) 110.64 
O(3)-C(8)-H(8B) 110.60 
C(5)-C(8)-H(8A) 110.62 
C(5)-C(8)-H(8B) 110.64 
H(8A)-C(8)-H(8B) 108.71 
N(1)-C(9)-H(9A) 109.31 
N(1)-C(9)-H(9B) 109.31 
C(10)-C(9)-H(9A) 109.37 
C(10)-C(9)-H(9B) 109.32 
H(9A)-C(9)-H(9B) 107.97 
C(10)-C(11)-H(11) 119.66 
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C(12)-C(11)-H(11) 119.72 
C(11)-C(12)-H(12) 119.92 
C(13)-C(12)-H(12) 119.89 
C(12)-C(13)-H(13) 120.10 
C(14)-C(13)-H(13) 120.12 
C(13)-C(14)-H(14) 119.99 
C(15)-C(14)-H(14) 119.95 
C(10)-C(15)-H(15) 119.74 
C(14)-C(15)-H(15) 119.72 
O(1)-C(1) 1.3534(15) 
O(1)-C(7) 1.4710(14) 
O(2)-C(1) 1.2082(14) 
O(3)-N(1) 1.4770(14) 
O(3)-C(8) 1.4388(19) 
N(1)-C(4) 1.4937(15) 
N(1)-C(9) 1.4771(17) 
C(1)-C(2) 1.5165(16) 
C(2)-C(3) 1.5293(16) 
C(3)-C(4) 1.5537(16) 
C(3)-C(7) 1.5519(16) 
C(4)-C(5) 1.5506(18) 
C(5)-C(6) 1.534(2) 
C(5)-C(8) 1.543(2) 
C(6)-C(7) 1.5182(19) 
C(9)-C(10) 1.5114(18) 
C(10)-C(11) 1.4013(17) 
C(10)-C(15) 1.4027(17) 
C(11)-C(12) 1.3905(19) 
C(12)-C(13) 1.3987(19) 
C(13)-C(14) 1.390(2) 
C(14)-C(15) 1.398(2) 
C(2)-H(2A) 0.9893 
C(2)-H(2B) 0.9897 
C(3)-H(3) 1.0005 
C(4)-H(4) 1.0003 
C(5)-H(5) 0.9994 
C(6)-H(6A) 0.9901 
C(6)-H(6B) 0.9901 
C(7)-H(7) 0.9995 
C(8)-H(8A) 0.9898 
C(8)-H(8B) 0.9894 
C(9)-H(9A) 0.9900 
C(9)-H(9B) 0.9902 
C(11)-H(11) 0.9504 
C(12)-H(12) 0.9501 
C(13)-H(13) 0.9502 
C(14)-H(14) 0.9506 
C(15)-H(15) 0.9493 
C(1)-O(1)-C(7) 111.54(9) 
N(1)-O(3)-C(8) 103.43(10) 
O(3)-N(1)-C(4) 101.31(8) 
O(3)-N(1)-C(9) 102.29(9) 
C(4)-N(1)-C(9) 113.29(10) 
O(1)-C(1)-O(2) 121.45(10) 
O(1)-C(1)-C(2) 110.16(9) 
O(2)-C(1)-C(2) 128.39(11) 
C(1)-C(2)-C(3) 104.40(9) 
C(2)-C(3)-C(4) 114.13(9) 
C(2)-C(3)-C(7) 103.33(9) 
C(4)-C(3)-C(7) 105.21(9) 
N(1)-C(4)-C(3) 112.24(9) 
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Anisotropic displacement parameters (A2 x 103) for 66a. The anisotropic displacement factor 
exponent takes the form: -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
 
 U11 U22 U33 U23 U13 U12 
       
O(1) 26(1) 25(1) 38(1) 7(1) 1(1) -1(1) 
O(2) 41(1) 24(1) 44(1) 5(1) -4(1) 6(1) 
O(3) 43(1) 36(1) 25(1) 7(1) -12(1) -8(1) 
N(1) 30(1) 25(1) 22(1) 4(1) -6(1) -3(1) 
C(1) 27(1) 25(1) 22(1) 2(1) -1(1) 1(1) 
C(2) 25(1) 24(1) 23(1) 1(1) -1(1) 0(1) 
C(3) 26(1) 21(1) 21(1) -3(1) 1(1) 1(1) 
C(4) 28(1) 21(1) 22(1) -1(1) -1(1) 2(1) 
C(5) 34(1) 23(1) 32(1) 1(1) -7(1) -3(1) 
C(6) 25(1) 31(1) 42(1) 5(1) -1(1) 4(1) 
C(7) 26(1) 24(1) 29(1) 2(1) 6(1) 5(1) 
C(8) 46(1) 39(1) 40(1) 10(1) -21(1) -14(1) 
C(9) 33(1) 33(1) 24(1) 6(1) -1(1) -5(1) 
C(10) 26(1) 23(1) 24(1) 5(1) 2(1) -4(1) 
C(11) 26(1) 21(1) 32(1) 5(1) 3(1) -2(1) 
C(12) 38(1) 24(1) 32(1) -1(1) 4(1) -6(1) 
C(13) 33(1) 35(1) 31(1) 6(1) -7(1) -8(1) 
C(14) 27(1) 33(1) 45(1) 9(1) -2(1) 2(1) 
C(15) 30(1) 25(1) 35(1) 1(1) 5(1) 2(1) 
 
 
Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2 x 103) for 66a. 
 
 x y z U(eq) 
     
H(2A) 4354 8197 8663 29 
H(2B) 4068 8617 9773 29 
H(3) 2698 10244 9112 27 
H(4) 3111 8903 7364 28 
H(5) 1000 7849 7227 36 
H(6A) -367 9758 8479 39 
H(6B) -589 8138 8442 39 
H(7) 873 9125 9831 32 
H(8A) 107 9218 6078 50 
H(8B) -401 10293 6880 50 
H(9A) 3382 12291 6708 36 
H(9B) 4043 10805 6624 36 
H(11) 3322 13308 8474 32 
H(12) 4703 13733 9827 37 
H(13) 6680 12416 10110 40 
H(14) 7266 10671 9032 42 
H(15) 5891 10251 7668 35 
H(2A) 4354 8197 8663 29 
H(2B) 4068 8617 9773 29 
H(3) 2698 10244 9112 27 
H(4) 3111 8903 7364 28 
H(5) 1000 7849 7227 36 
H(6A) -367 9758 8479 39 
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H(6B) -589 8138 8442 39 
H(7) 873 9125 9831 32 
H(8A) 107 9218 6078 50 
H(8B) -401 10293 6880 50 
 
 
Torsion angles [deg] for 66a. 
 
C(1)-O(1)-C(7)-C(6) 129.33(11) 
C(1)-O(1)-C(7)-C(3) 15.02(12) 
C(7)-O(1)-C(1)-O(2) 179.31(11) 
C(7)-O(1)-C(1)-C(2) -0.51(13) 
N(1)-O(3)-C(8)-C(5) -34.84(13) 
C(8)-O(3)-N(1)-C(9) 166.94(10) 
C(8)-O(3)-N(1)-C(4) 49.80(11) 
C(4)-N(1)-C(9)-C(10) -71.41(12) 
O(3)-N(1)-C(4)-C(5) -43.59(10) 
O(3)-N(1)-C(9)-C(10) -179.60(10) 
C(9)-N(1)-C(4)-C(5) -152.40(10) 
O(3)-N(1)-C(4)-C(3) -158.24(9) 
C(9)-N(1)-C(4)-C(3) 92.95(11) 
O(2)-C(1)-C(2)-C(3) 165.80(12) 
O(1)-C(1)-C(2)-C(3) -14.40(12) 
C(1)-C(2)-C(3)-C(7) 22.23(11) 
C(1)-C(2)-C(3)-C(4) -91.45(11) 
C(2)-C(3)-C(4)-C(5) 111.86(11) 
C(2)-C(3)-C(7)-O(1) -22.75(11) 
C(7)-C(3)-C(4)-C(5) -0.69(11) 
C(2)-C(3)-C(4)-N(1) -136.85(10) 
C(4)-C(3)-C(7)-C(6) -18.83(12) 
C(7)-C(3)-C(4)-N(1) 110.59(10) 
C(4)-C(3)-C(7)-O(1) 97.23(10) 
C(2)-C(3)-C(7)-C(6) -138.82(10) 
N(1)-C(4)-C(5)-C(6) -98.58(10) 
C(3)-C(4)-C(5)-C(6) 19.58(12) 
C(3)-C(4)-C(5)-C(8) 140.57(10) 
N(1)-C(4)-C(5)-C(8) 22.41(12) 
C(4)-C(5)-C(8)-O(3) 7.26(13) 
C(8)-C(5)-C(6)-C(7) -144.12(11) 
C(4)-C(5)-C(6)-C(7) -31.25(12) 
C(6)-C(5)-C(8)-O(3) 121.16(12) 
C(5)-C(6)-C(7)-C(3) 31.36(12) 
C(5)-C(6)-C(7)-O(1) -81.69(12) 
N(1)-C(9)-C(10)-C(11) -70.30(15) 
N(1)-C(9)-C(10)-C(15) 109.38(13) 
C(11)-C(10)-C(15)-C(14) 0.73(18) 
C(9)-C(10)-C(11)-C(12) 179.18(12) 
C(15)-C(10)-C(11)-C(12) -0.49(18) 
C(9)-C(10)-C(15)-C(14) -178.94(12) 
C(10)-C(11)-C(12)-C(13) 0.09(19) 
C(11)-C(12)-C(13)-C(14) 0.07(19) 
C(12)-C(13)-C(14)-C(15) 0.2(2) 
C(13)-C(14)-C(15)-C(10) -0.6(2) 
C(1)-O(1)-C(7)-C(6) 129.33(11) 
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C(1)-O(1)-C(7)-C(3) 15.02(12) 
C(7)-O(1)-C(1)-O(2) 179.31(11) 
C(7)-O(1)-C(1)-C(2) -0.51(13) 
N(1)-O(3)-C(8)-C(5) -34.84(13) 
C(8)-O(3)-N(1)-C(9) 166.94(10) 
C(8)-O(3)-N(1)-C(4) 49.80(11) 
C(4)-N(1)-C(9)-C(10) -71.41(12) 
O(3)-N(1)-C(4)-C(5) -43.59(10) 
O(3)-N(1)-C(9)-C(10) -179.60(10) 
 
 
Hydrogen-bonds for 66a [Å and deg.]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
 C(2)-H(2B)...O(3)#1  0.9900 24.600 
 
3.2831(16) 
 141.00  
 C(12)-H(12)...O(2)#2  0.9500 25.600 
 
3.2151(16)  126.00  
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tert-butyl (3aS,4S,5R,6aR)-5-((R)-1-(4-chlorophenyl)ethylcarbamoyl)-2-oxohexahydro-
2H-cyclopenta[b]furan-4-ylcarbamate (85) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal data and structure refinement for 85. 
 
Empirical formula  C21H27ClN2O5  
Formula weight  422.90  
Crystal size  0.42 x 0.22 x 0.06 mm  
Crystal description  flat prism  
Crystal colour  colourless  
Crystal system Orthorhombic  
Space group  P 21 21 21  
Unit cell dimensions              a = 5.1731(4) Å   alpha = 90 deg.  
                                        b = 18.9784(15) Å    beta = 90 deg.  
                                        c = 21.737(2) Å   gamma = 90 deg.  
Volume  2134.1(3) Å3  
Z, Calculated density  4,  1.316 Mg/m3  
Absorption coefficient  0.213 mm-1  
F(000)  896 
Measurement device 
type  
STOE-IPDS diffractometer  
Measuremnet method  rotation  
Temperature  123(1) K  
Wavelength  0.71073 A  
Monochromator   graphite  
Theta range for data 
collection  
2.15 to 26.88 deg.  
Index ranges  -6<=h<=6,  
-24<=k<=24,  
-27<=l<=27 
Reflections collected / 
unique  
31067 / 4589 [R(int) = 0.0545]  
Reflections greater 
I>2\s(I) 
3794 
Absorption correction  None  
Refinement method  Full-matrix least-squares on F2  
Data / restraints / 
parameters  
4589 / 0 / 266  
O
O
H
HBocHN
O
NH
Cl
85
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Goodness-of-fit on F^2  0.931  
Final R indices 
[I>2sigma(I)]      
R1 = 0.0337, wR2 = 0.0667  
R indices (all data)              R1 = 0.0447, wR2 = 0.0689  
Absolute structure 
parameter  
0.02(5)  
Largest diff. peak and 
hole  
0.251 and -0.153 e. Å -3  
 
 
Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å 2 x 103) for 
85. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 x y z U(eq) 
     
Cl(1) 1415(1) 4150(1) -378(1) 36(1) 
O(11) -3293(2) 2603(1) 2682(1) 26(1) 
O(15) -1216(3) 3174(1) 4844(1) 32(1) 
O(17) -594(3) 4177(1) 5362(1) 54(1) 
O(23) 3408(2) 4325(1) 2873(1) 28(1) 
O(24) 377(2) 4819(1) 2241(1) 22(1) 
N(9) 814(3) 2436(1) 2340(1) 24(1) 
N(21) -880(3) 4122(1) 2999(1) 20(1) 
C(1) 1064(4) 3565(1) 241(1) 25(1) 
C(2) 2895(3) 3043(1) 324(1) 24(1) 
C(3) 2604(3) 2576(1) 812(1) 23(1) 
C(4) 530(3) 2627(1) 1216(1) 22(1) 
C(5) -1267(4) 3167(1) 1122(1) 26(1) 
C(6) -1029(4) 3637(1) 635(1) 26(1) 
C(7) 120(4) 2111(1) 1747(1) 24(1) 
C(8) 1571(4) 1414(1) 1675(1) 30(1) 
C(10) -941(3) 2632(1) 2762(1) 20(1) 
C(12) 226(4) 2879(1) 3370(1) 21(1) 
C(13) -878(4) 2447(1) 3917(1) 32(1) 
C(14) -2587(4) 2937(1) 4291(1) 25(1) 
C(16) -1522(4) 3880(1) 4927(1) 32(1) 
C(18) -3135(4) 4182(1) 4410(1) 27(1) 
C(19) -2986(3) 3610(1) 3917(1) 20(1) 
C(20) -534(3) 3655(1) 3523(1) 17(1) 
C(22) 1184(3) 4414(1) 2713(1) 20(1) 
C(25) 2282(3) 5140(1) 1811(1) 21(1) 
C(26) 541(4) 5469(1) 1326(1) 29(1) 
C(27) 3989(3) 4574(1) 1528(1) 22(1) 
C(28) 3843(4) 5704(1) 2146(1) 28(1) 
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Bond lengths [Å] and angles [deg] for 85. 
 
Cl(1)-C(1) 1.7538(17) 
O(11)-C(10) 1.2304(19) 
O(15)-C(14) 1.467(2) 
O(15)-C(16) 1.360(2) 
O(17)-C(16) 1.201(2) 
O(23)-C(22) 1.2136(19) 
O(24)-C(22) 1.3468(19) 
O(24)-C(25) 1.4890(19) 
N(9)-C(7) 1.472(2) 
N(9)-C(10) 1.344(2) 
N(21)-C(20) 1.454(2) 
N(21)-C(22) 1.355(2) 
N(9)-H(9) 0.8800 
N(21)-H(21) 0.8800 
C(1)-C(2) 1.383(2) 
C(1)-C(6) 1.386(3) 
C(2)-C(3) 1.389(2) 
C(3)-C(4) 1.391(2) 
C(4)-C(7) 1.528(2) 
C(4)-C(5) 1.398(3) 
C(5)-C(6) 1.391(3) 
C(7)-C(8) 1.529(3) 
C(10)-C(12) 1.526(2) 
C(12)-C(13) 1.553(2) 
C(12)-C(20) 1.562(2) 
C(13)-C(14) 1.519(3) 
C(14)-C(19) 1.529(2) 
C(16)-C(18) 1.512(3) 
C(18)-C(19) 1.527(2) 
C(19)-C(20) 1.533(2) 
C(25)-C(28) 1.524(2) 
C(25)-C(26) 1.520(2) 
C(25)-C(27) 1.521(2) 
C(2)-H(2) 0.9500 
C(3)-H(3) 0.9500 
C(5)-H(5) 0.9500 
C(6)-H(6) 0.9500 
C(7)-H(7) 1.0000 
C(8)-H(8A) 0.9800 
C(8)-H(8B) 0.9800 
C(8)-H(8C) 0.9800 
C(12)-H(12) 1.0000 
C(13)-H(13A) 0.9900 
C(13)-H(13B) 0.9900 
C(14)-H(14) 1.0000 
C(18)-H(18A) 0.9900 
C(18)-H(18B) 0.9900 
C(19)-H(19) 1.0000 
C(20)-H(20) 1.0000 
C(26)-H(26A) 0.9800 
C(26)-H(26B) 0.9800 
C(26)-H(26C) 0.9800 
C(27)-H(27A) 0.9800 
C(27)-H(27B) 0.9800 
C(27)-H(27C) 0.9800 
C(28)-H(28A) 0.9800 
C(28)-H(28B) 0.9800 
C(28)-H(28C) 0.9800 
C(14)-O(15)-C(16) 110.74(14) 
C(22)-O(24)-C(25) 120.41(12) 
C(7)-N(9)-C(10) 123.31(15) 
C(20)-N(21)-C(22) 120.82(14) 
C(7)-N(9)-H(9) 118.00 
C(10)-N(9)-H(9) 118.00 
C(22)-N(21)-H(21) 120.00 
C(20)-N(21)-H(21) 120.00 
Cl(1)-C(1)-C(6) 119.50(14) 
C(2)-C(1)-C(6) 121.65(16) 
Cl(1)-C(1)-C(2) 118.85(14) 
C(1)-C(2)-C(3) 118.81(15) 
C(2)-C(3)-C(4) 121.47(15) 
C(3)-C(4)-C(5) 118.12(16) 
C(3)-C(4)-C(7) 122.72(16) 
C(5)-C(4)-C(7) 119.16(15) 
C(4)-C(5)-C(6) 121.47(17) 
C(1)-C(6)-C(5) 118.48(18) 
N(9)-C(7)-C(4) 111.07(15) 
C(4)-C(7)-C(8) 114.11(14) 
N(9)-C(7)-C(8) 109.37(14) 
O(11)-C(10)-C(12) 121.85(14) 
N(9)-C(10)-C(12) 114.16(14) 
O(11)-C(10)-N(9) 123.97(14) 
C(10)-C(12)-C(20) 111.96(14) 
C(13)-C(12)-C(20) 104.01(13) 
C(10)-C(12)-C(13) 110.86(15) 
C(12)-C(13)-C(14) 107.54(14) 
O(15)-C(14)-C(13) 110.22(16) 
O(15)-C(14)-C(19) 104.18(14) 
C(13)-C(14)-C(19) 107.76(13) 
O(15)-C(16)-C(18) 109.83(15) 
O(17)-C(16)-C(18) 128.9(2) 
O(15)-C(16)-O(17) 121.30(18) 
C(16)-C(18)-C(19) 102.99(15) 
C(18)-C(19)-C(20) 113.23(14) 
C(14)-C(19)-C(18) 103.09(13) 
C(14)-C(19)-C(20) 103.42(14) 
N(21)-C(20)-C(19) 111.69(13) 
C(12)-C(20)-C(19) 105.96(14) 
N(21)-C(20)-C(12) 116.03(13) 
O(23)-C(22)-O(24) 126.24(14) 
O(23)-C(22)-N(21) 123.96(15) 
O(24)-C(22)-N(21) 109.80(13) 
C(26)-C(25)-C(28) 110.91(15) 
C(27)-C(25)-C(28) 112.40(14) 
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C(26)-C(25)-C(27) 110.63(13) 
O(24)-C(25)-C(26) 102.20(13) 
O(24)-C(25)-C(27) 110.43(13) 
O(24)-C(25)-C(28) 109.83(13) 
C(1)-C(2)-H(2) 121.00 
C(3)-C(2)-H(2) 121.00 
C(2)-C(3)-H(3) 119.00 
C(4)-C(3)-H(3) 119.00 
C(4)-C(5)-H(5) 119.00 
C(6)-C(5)-H(5) 119.00 
C(1)-C(6)-H(6) 121.00 
C(5)-C(6)-H(6) 121.00 
N(9)-C(7)-H(7) 107.00 
C(4)-C(7)-H(7) 107.00 
C(8)-C(7)-H(7) 107.00 
C(7)-C(8)-H(8A) 109.00 
C(7)-C(8)-H(8B) 109.00 
C(7)-C(8)-H(8C) 109.00 
H(8A)-C(8)-H(8B) 109.00 
H(8A)-C(8)-H(8C) 110.00 
H(8B)-C(8)-H(8C) 109.00 
C(10)-C(12)-H(12) 110.00 
C(13)-C(12)-H(12) 110.00 
C(20)-C(12)-H(12) 110.00 
C(12)-C(13)-H(13A) 110.00 
C(12)-C(13)-H(13B) 110.00 
C(14)-C(13)-H(13A) 110.00 
C(14)-C(13)-H(13B) 110.00 
H(13A)-C(13)-H(13B) 108.00 
O(15)-C(14)-H(14) 111.00 
C(13)-C(14)-H(14) 111.00 
C(19)-C(14)-H(14) 111.00 
C(16)-C(18)-H(18A) 111.00 
C(16)-C(18)-H(18B) 111.00 
C(19)-C(18)-H(18A) 111.00 
C(19)-C(18)-H(18B) 111.00 
H(18A)-C(18)-H(18B) 109.00 
C(14)-C(19)-H(19) 112.00 
C(18)-C(19)-H(19) 112.00 
C(20)-C(19)-H(19) 112.00 
N(21)-C(20)-H(20) 108.00 
C(12)-C(20)-H(20) 108.00 
C(19)-C(20)-H(20) 108.00 
C(25)-C(26)-H(26A) 110.00 
C(25)-C(26)-H(26B) 109.00 
C(25)-C(26)-H(26C) 109.00 
H(26A)-C(26)-H(26B) 109.00 
H(26A)-C(26)-H(26C) 109.00 
H(26B)-C(26)-H(26C) 109.00 
C(25)-C(27)-H(27A) 110.00 
C(25)-C(27)-H(27B) 110.00 
C(25)-C(27)-H(27C) 109.00 
H(27A)-C(27)-H(27B) 109.00 
H(27A)-C(27)-H(27C) 110.00 
H(27B)-C(27)-H(27C) 109.00 
C(25)-C(28)-H(28A) 109.00 
C(25)-C(28)-H(28B) 109.00 
C(25)-C(28)-H(28C) 109.00 
H(28A)-C(28)-H(28B) 109.00 
H(28A)-C(28)-H(28C) 109.00 
H(28B)-C(28)-H(28C) 109.00 
 
 
Anisotropic displacement parameters (A2 x 103) for 85. The anisotropic displacement factor 
exponent takes the form: -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
 
 
U11 
 
U22 
 
U33 
 
U23 
 
U13 
 
U12 
 
Cl(1) 45(1) 28(1) 36(1) 6(1) -3(1) 1(1) 
O(11) 19(1) 33(1) 25(1) -6(1) -1(1) 0(1) 
O(15) 40(1) 41(1) 16(1) 1(1) -5(1) 9(1) 
O(17) 56(1) 72(1) 33(1) -25(1) -11(1) 3(1) 
O(23) 17(1) 40(1) 29(1) 12(1) -2(1) 1(1) 
O(24) 16(1) 27(1) 23(1) 9(1) 2(1) 0(1) 
N(9) 18(1) 36(1) 19(1) -6(1) -1(1) -2(1) 
N(21) 15(1) 24(1) 20(1) 5(1) -2(1) 2(1) 
C(1) 30(1) 22(1) 23(1) -4(1) -6(1) -4(1) 
C(2) 22(1) 29(1) 22(1) -8(1) 1(1) 0(1) 
C(3) 20(1) 29(1) 20(1) -6(1) -3(1) 3(1) 
C(4) 20(1) 27(1) 20(1) -9(1) -4(1) -2(1) 
C(5) 18(1) 31(1) 27(1) -12(1) 2(1) -1(1) 
C(6) 22(1) 23(1) 34(1) -9(1) -7(1) 4(1) 
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C(7) 19(1) 33(1) 19(1) -5(1) 1(1) -3(1) 
C(8) 35(1) 31(1) 24(1) -1(1) 4(1) 1(1) 
C(10) 22(1) 18(1) 19(1) 1(1) -2(1) 1(1) 
C(12) 23(1) 22(1) 19(1) 0(1) -3(1) 4(1) 
C(13) 55(1) 20(1) 22(1) 4(1) -2(1) 4(1) 
C(14) 30(1) 28(1) 18(1) 5(1) -2(1) -6(1) 
C(16) 29(1) 47(1) 22(1) -10(1) 3(1) 4(1) 
C(18) 27(1) 30(1) 25(1) -3(1) 5(1) 4(1) 
C(19) 17(1) 24(1) 18(1) 2(1) -3(1) -2(1) 
C(20) 17(1) 19(1) 17(1) 1(1) -2(1) 0(1) 
C(22) 20(1) 20(1) 19(1) 1(1) 1(1) 1(1) 
C(25) 17(1) 22(1) 24(1) 5(1) 4(1) -1(1) 
C(26) 23(1) 32(1) 31(1) 14(1) 6(1) 2(1) 
C(27) 21(1) 22(1) 23(1) 1(1) 0(1) -1(1) 
C(28) 25(1) 23(1) 37(1) -4(1) 6(1) -2(1) 
 
 
Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2 x 103) for 85. 
 
 x y z U(eq) 
     
H(2) 4326 3004 52 29 
H(3) 3850 2215 870 27 
H(5) -2682 3214 1398 31 
H(6) -2273 3998 572 32 
H(7) -1768 1999 1763 29 
H(8A) 3435 1500 1701 36 
H(8B) 1158 1206 1274 36 
H(8C) 1048 1090 2003 36 
H(9) 2461 2504 2422 29 
H(12) 2151 2831 3356 25 
H(13A) -1898 2043 3763 38 
H(13B) 549 2263 4175 38 
H(14) -4273 2709 4397 30 
H(18A) -2403 4631 4260 33 
H(18B) -4942 4261 4543 33 
H(19) -4589 3590 3660 24 
H(20) 868 3858 3786 21 
H(21) -2450 4215 2866 24 
H(26A) -498 5100 1130 34 
H(26B) 1605 5704 1015 34 
H(26C) -605 5814 1521 34 
H(27A) 5312 4431 1825 27 
H(27B) 4826 4761 1158 27 
H(27C) 2928 4166 1417 27 
H(28A) 2663 6048 2330 34 
H(28B) 4985 5942 1852 34 
H(28C) 4883 5483 2469 34 
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Torsion angles [deg] for 85. 
 
C(16)-O(15)-C(14)-C(19) 19.45(19)  
C(16)-O(15)-C(14)-C(13) 134.81(16)  
C(14)-O(15)-C(16)-O(17) 178.43(18)  
C(14)-O(15)-C(16)-C(18) -1.1(2)  
C(22)-O(24)-C(25)-C(27) 56.14(17)  
C(25)-O(24)-C(22)-O(23) 7.4(2)  
C(25)-O(24)-C(22)-N(21) -173.60(13)  
C(22)-O(24)-C(25)-C(28) -68.37(18)  
C(22)-O(24)-C(25)-C(26) 173.86(13)  
C(7)-N(9)-C(10)-C(12) 173.37(15)  
C(10)-N(9)-C(7)-C(8) -125.69(18)  
C(7)-N(9)-C(10)-O(11) -4.7(3)  
C(10)-N(9)-C(7)-C(4) 107.48(18)  
C(22)-N(21)-C(20)-C(19) 158.46(14)  
C(20)-N(21)-C(22)-O(24) 179.51(13)  
C(20)-N(21)-C(22)-O(23) -1.5(2)  
C(22)-N(21)-C(20)-C(12) -79.97(19)  
C(6)-C(1)-C(2)-C(3) 0.5(3)  
C(2)-C(1)-C(6)-C(5) 0.0(3)  
Cl(1)-C(1)-C(2)-C(3) -179.49(13)  
Cl(1)-C(1)-C(6)-C(5) -179.98(14)  
C(1)-C(2)-C(3)-C(4) -0.3(3)  
C(2)-C(3)-C(4)-C(5) -0.4(2)  
C(2)-C(3)-C(4)-C(7) 178.46(16)  
C(3)-C(4)-C(7)-N(9) 104.75(19)  
C(3)-C(4)-C(7)-C(8) -19.4(2)  
C(5)-C(4)-C(7)-C(8) 159.40(17)  
C(7)-C(4)-C(5)-C(6) -177.96(17)  
C(3)-C(4)-C(5)-C(6) 0.9(3)  
C(5)-C(4)-C(7)-N(9) -76.4(2)  
C(4)-C(5)-C(6)-C(1) -0.7(3)  
O(11)-C(10)-C(12)-C(13) 54.0(2)  
O(11)-C(10)-C(12)-C(20) -61.7(2)  
N(9)-C(10)-C(12)-C(20) 120.15(16)  
N(9)-C(10)-C(12)-C(13) -124.19(16)  
C(13)-C(12)-C(20)-N(21) -152.00(14)  
C(10)-C(12)-C(20)-C(19) 92.34(15)  
C(13)-C(12)-C(20)-C(19) -27.42(17)  
C(10)-C(12)-C(20)-N(21) -32.2(2)  
C(10)-C(12)-C(13)-C(14) -110.61(16)  
C(20)-C(12)-C(13)-C(14) 9.89(19)  
C(12)-C(13)-C(14)-O(15) -101.85(16)  
C(12)-C(13)-C(14)-C(19) 11.2(2)  
O(15)-C(14)-C(19)-C(18) -29.15(17)  
O(15)-C(14)-C(19)-C(20) 89.01(15)  
C(13)-C(14)-C(19)-C(18) -146.23(15)  
C(13)-C(14)-C(19)-C(20) -28.07(18)  
O(17)-C(16)-C(18)-C(19) 162.9(2)  
O(15)-C(16)-C(18)-C(19) -17.6(2)  
C(16)-C(18)-C(19)-C(20) -82.98(17)  
C(16)-C(18)-C(19)-C(14) 28.07(18)  
C(14)-C(19)-C(20)-N(21) 161.46(13)  
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C(18)-C(19)-C(20)-C(12) 145.07(14)  
C(14)-C(19)-C(20)-C(12) 34.23(16)  
C(18)-C(19)-C(20)-N(21) -87.70(16)  
 
 
Hydrogen-bonds for 85 [Å and deg.]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
N(9)-H(9)...O(11)#1 0.8800 22.800 3.1540(19) 175.00 
N(21)-H(21)...O(23)#2 0.8800 21.500 2.9926(19) 159.00 
C(7)-H(7)...O(11) 1.0000 24.300 2.849(2) 104.00 
C(14)-H(14)...O(15)#3 1.0000 25.600 3.391(2) 141.00 
C(19)-H(19)...O(23)#2 1.0000 24.400 3.236(2) 136.00 
C(26)-H(26B)...O(17)#4 0.9800 25.100 3.417(3) 153.00 
C(27)-H(27A)...O(23) 0.9800 24.900 2.977(2) 110.00 
C(28)-H(28C)...O(23) 0.9800 24.900 3.065(2) 118.00 
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Tricyclic intermediate during Jones oxidation 142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal data and structure refinement for 142. 
 
Empirical formula  C16H22NO3,Cl 
Formula weight  311.80 
Crystal size  0.220 x 0.120 x 0.060 mm 
Crystal description  prism 
Crystal colour  translucent, colourless 
Crystal system Orthorhombic  
Space group  P 21 21 21  
Unit cell dimensions              a = 9.0050(9) Å   alpha = 90 deg. 
                                        b = 10.7653(12) Å    beta = 90 deg. 
                                        c = 16.745(2) Å   gamma = 90 deg. 
Volume  1623.3(3) Å3  
Z, Calculated density  4,  1.276 Mg/m3  
Absorption coefficient  0.245 mm-1  
F(000)  664 
Measurement device 
type  
STOE-IPDS diffractometer  
Measuremnet method  rotation  
Temperature  297(1) K 
Wavelength  0.71073 Å  
Monochromator   graphite  
Theta range for data 
collection  
2.25 to 25.31 deg. 
Index ranges  -10<=h<=10,  
-12<=k<=12,  
-20<=l<=20 
Reflections collected / 
unique  
12705 / 2926 [R(int) = 0.0891] 
Reflections greater 
I>2\s(I) 
1723 
Absorption correction  None  
Refinement method  Full-matrix least-squares on F2  
Data / restraints / 
parameters  
2926 / 0 / 190 
Goodness-of-fit on F2  0.834 
Final R indices 
[I>2sigma(I)]      
R1 = 0.0444, wR2 = 0.0866 
OMeO
N
Bn
H
142
HO
Cl
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R indices (all data)              R1 = 0.0839, wR2 = 0.0965 
Absolute structure 
parameter  
0.05(10) 
Largest diff. peak and 
hole  
0.389 and -0.165 e. Å -3  
 
 
Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å 2 x 103) for 
142. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 x y z U(eq) 
     
O(1) -2096(3) -5255(2) -7053(2) 72(1)  
O(2) -5798(3) -2649(2) -5337(2) 71(1)  
O(3) -4325(2) -4293(2) -7907(1) 53(1)  
N(1) -3193(3) -3437(2) -7654(1) 42(1)  
C(1) -2719(3) -2663(3) -9067(2) 47(1)  
C(2) -2797(4) -1389(3) -9172(2) 59(1)  
C(3) -3313(5) -900(4) -9873(2) 73(2)  
C(4) -3735(4) -1644(5) -10489(3) 82(2)  
C(5) -3649(5) -2895(5) -10407(3) 81(2)  
C(6) -3137(4) -3399(4) -9695(2) 65(1)  
C(7) -2102(3) -3207(3) -8321(2) 48(1)  
C(8) -2372(3) -4060(3) -6925(2) 48(1)  
C(9) -3403(4) -3790(3) -6253(2) 55(1)  
C(10) -3887(3) -2451(3) -6396(2) 51(1)  
C(11) -5465(4) -2154(3) -6103(2) 59(1)  
C(12) -6453(3) -2712(4) -6733(2) 63(1)  
C(13) -5647(3) -2501(3) -7526(2) 53(1)  
C(14) -3997(3) -2335(3) -7307(2) 46(1)  
C(15) -4900(5) -2150(5) -4722(2) 91(2)  
C(16) -5637(3) -3563(3) -8105(2) 57(1)  
Cl(1) -807(1) -560(1) -7177(1) 84(1)  
O(1) -2096(3) -5255(2) -7053(2) 72(1)  
O(2) -5798(3) -2649(2) -5337(2) 71(1)  
O(3) -4325(2) -4293(2) -7907(1) 53(1)  
N(1) -3193(3) -3437(2) -7654(1) 42(1)  
C(1) -2719(3) -2663(3) -9067(2) 47(1)  
C(2) -2797(4) -1389(3) -9172(2) 59(1)  
C(3) -3313(5) -900(4) -9873(2) 73(2)  
C(4) -3735(4) -1644(5) -10489(3) 82(2)  
 
 
 
 
 
 
 
 
 
 
 
 
E.   Appendix  161 
Bond lengths [Å] and angles [deg] for 142. 
 
O(1)-C(8) 1.327(4)  
O(2)-C(11) 1.420(4)  
O(2)-C(15) 1.416(5)  
O(3)-N(1) 1.438(3)  
O(3)-C(16) 1.457(3)  
O(1)-H(1O) 0.8200  
N(1)-C(8) 1.576(4)  
N(1)-C(14) 1.506(4)  
N(1)-C(7) 1.508(4)  
C(1)-C(6) 1.369(5)  
C(1)-C(7) 1.488(4)  
C(1)-C(2) 1.385(5)  
C(2)-C(3) 1.368(5)  
C(3)-C(4) 1.360(6)  
C(4)-C(5) 1.356(8)  
C(5)-C(6) 1.389(6)  
C(8)-C(9) 1.489(5)  
C(9)-C(10) 1.525(5)  
C(10)-C(14) 1.535(4)  
C(10)-C(11) 1.537(5)  
C(11)-C(12) 1.505(5)  
C(12)-C(13) 1.531(4)  
C(13)-C(14) 1.541(4)  
C(13)-C(16) 1.499(5)  
C(2)-H(2) 0.9300  
C(3)-H(3) 0.9300  
C(4)-H(4) 0.9300  
C(5)-H(5) 0.9300  
C(6)-H(6) 0.9300  
C(7)-H(7A) 0.9700  
C(7)-H(7B) 0.9700  
C(8)-H(8) 0.9800  
C(9)-H(9A) 0.9700  
C(9)-H(9B) 0.9700  
C(10)-H(10) 0.9800  
C(11)-H(11) 0.9800  
C(12)-H(12A) 0.9700  
C(12)-H(12B) 0.9700  
C(13)-H(13) 0.9800  
C(14)-H(14) 0.9800  
C(15)-H(15A) 0.9600  
C(15)-H(15B) 0.9600  
C(15)-H(15C) 0.9600  
C(16)-H(16A) 0.9700  
C(16)-H(16B) 0.9700  
C(11)-O(2)-C(15) 113.2(3)  
N(1)-O(3)-C(16) 107.22(19)  
C(8)-O(1)-H(1O) 109.00  
O(3)-N(1)-C(7) 110.4(2)  
O(3)-N(1)-C(8) 106.72(19)  
C(7)-N(1)-C(8) 109.7(2)  
C(7)-N(1)-C(14) 118.0(2)  
C(8)-N(1)-C(14) 105.2(2)  
O(3)-N(1)-C(14) 106.1(2)  
C(2)-C(1)-C(6) 117.5(3)  
C(2)-C(1)-C(7) 121.0(3)  
C(6)-C(1)-C(7) 121.3(3)  
C(1)-C(2)-C(3) 120.5(3)  
C(2)-C(3)-C(4) 121.3(4)  
C(3)-C(4)-C(5) 119.5(5)  
C(4)-C(5)-C(6) 119.6(5)  
C(1)-C(6)-C(5) 121.6(4)  
N(1)-C(7)-C(1) 116.3(2)  
O(1)-C(8)-C(9) 115.3(3)  
N(1)-C(8)-C(9) 102.1(2)  
O(1)-C(8)-N(1) 112.1(3)  
C(8)-C(9)-C(10) 104.1(3)  
C(9)-C(10)-C(14) 104.6(3)  
C(11)-C(10)-C(14) 103.9(2)  
C(9)-C(10)-C(11) 114.3(3)  
O(2)-C(11)-C(10) 113.9(3)  
C(10)-C(11)-C(12) 103.9(3)  
O(2)-C(11)-C(12) 111.0(3)  
C(11)-C(12)-C(13) 105.6(3)  
C(12)-C(13)-C(16) 116.8(3)  
C(14)-C(13)-C(16) 103.7(2)  
C(12)-C(13)-C(14) 105.5(2)  
N(1)-C(14)-C(10) 106.8(2)  
C(10)-C(14)-C(13) 106.8(2)  
N(1)-C(14)-C(13) 106.3(2)  
O(3)-C(16)-C(13) 105.6(2)  
C(1)-C(2)-H(2) 120.00  
C(3)-C(2)-H(2) 120.00  
C(2)-C(3)-H(3) 119.00  
C(4)-C(3)-H(3) 119.00  
C(3)-C(4)-H(4) 120.00  
C(5)-C(4)-H(4) 120.00  
C(4)-C(5)-H(5) 120.00  
C(6)-C(5)-H(5) 120.00  
C(1)-C(6)-H(6) 119.00  
C(5)-C(6)-H(6) 119.00  
N(1)-C(7)-H(7A) 108.00  
N(1)-C(7)-H(7B) 108.00  
C(1)-C(7)-H(7A) 108.00  
C(1)-C(7)-H(7B) 108.00  
H(7A)-C(7)-H(7B) 107.00  
O(1)-C(8)-H(8) 109.00  
N(1)-C(8)-H(8) 109.00  
C(9)-C(8)-H(8) 109.00  
C(8)-C(9)-H(9A) 111.00  
C(8)-C(9)-H(9B) 111.00  
C(10)-C(9)-H(9A) 111.00  
C(10)-C(9)-H(9B) 111.00  
H(9A)-C(9)-H(9B) 109.00  
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C(9)-C(10)-H(10) 111.00  
C(11)-C(10)-H(10) 111.00  
C(14)-C(10)-H(10) 111.00  
O(2)-C(11)-H(11) 109.00  
C(10)-C(11)-H(11) 109.00  
C(12)-C(11)-H(11) 109.00  
C(11)-C(12)-H(12A) 111.00  
C(11)-C(12)-H(12B) 111.00  
C(13)-C(12)-H(12A) 111.00  
C(13)-C(12)-H(12B) 111.00  
H(12A)-C(12)-H(12B) 109.00  
C(12)-C(13)-H(13) 110.00  
C(14)-C(13)-H(13) 110.00  
C(16)-C(13)-H(13) 110.00  
N(1)-C(14)-H(14) 112.00  
C(10)-C(14)-H(14) 112.00  
C(13)-C(14)-H(14) 112.00  
O(2)-C(15)-H(15A) 109.00  
O(2)-C(15)-H(15B) 109.00  
O(2)-C(15)-H(15C) 109.00  
H(15A)-C(15)-H(15B) 109.00  
H(15A)-C(15)-H(15C) 109.00  
H(15B)-C(15)-H(15C) 110.00  
O(3)-C(16)-H(16A) 111.00  
O(3)-C(16)-H(16B) 111.00  
C(13)-C(16)-H(16A) 111.00  
C(13)-C(16)-H(16B) 111.00  
H(16A)-C(16)-H(16B) 109.00  
O(1)-C(8) 1.327(4)  
O(2)-C(11) 1.420(4)  
O(2)-C(15) 1.416(5)  
O(3)-N(1) 1.438(3)  
O(3)-C(16) 1.457(3)  
O(1)-H(1O) 0.8200  
N(1)-C(8) 1.576(4)  
N(1)-C(14) 1.506(4)  
N(1)-C(7) 1.508(4)  
C(1)-C(6) 1.369(5)  
C(1)-C(7) 1.488(4)  
C(1)-C(2) 1.385(5)  
C(2)-C(3) 1.368(5)  
C(3)-C(4) 1.360(6)  
C(4)-C(5) 1.356(8)  
C(5)-C(6) 1.389(6)  
C(8)-C(9) 1.489(5)  
C(9)-C(10) 1.525(5)  
C(10)-C(14) 1.535(4)  
C(10)-C(11) 1.537(5)  
C(11)-C(12) 1.505(5)  
C(12)-C(13) 1.531(4)  
C(13)-C(14) 1.541(4)  
C(13)-C(16) 1.499(5)  
C(2)-H(2) 0.9300  
C(3)-H(3) 0.9300  
C(4)-H(4) 0.9300  
C(5)-H(5) 0.9300  
C(6)-H(6) 0.9300  
C(7)-H(7A) 0.9700  
C(7)-H(7B) 0.9700  
C(8)-H(8) 0.9800  
C(9)-H(9A) 0.9700  
 
 
Anisotropic displacement parameters (A2 x 103) for 142. The anisotropic displacement factor 
exponent takes the form: -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
 
 
U11 
 
U22 
 
U33 
 
U23 
 
U13 
 
U12 
 
O(1) 64(2) 63(2) 88(2) 14(1) 13(1) 2(1) 
O(2) 57(1) 96(2) 60(2) 11(2) 15(1) 3(2) 
O(3) 45(1) 40(1) 73(2) -2(1) -9(1) -7(1) 
N(1) 39(1) 37(1) 50(1) -1(1) -3(1) -3(1) 
C(1) 45(2) 48(2) 47(2) 0(2) 8(2) 3(2) 
C(2) 64(2) 55(2) 59(2) 2(2) 2(2) 1(2) 
C(3) 79(3) 70(3) 71(3) 21(2) 3(2) 4(2) 
C(4) 58(3) 124(4) 63(3) 29(3) -1(2) 3(3) 
C(5) 83(3) 105(4) 54(2) -13(2) 1(2) -11(3) 
C(6) 79(3) 59(2) 57(2) -8(2) 0(2) 6(2) 
C(7) 42(2) 51(2) 52(2) 3(2) 4(2) 5(2) 
C(8) 41(2) 47(2) 57(2) 6(2) 0(2) 4(1) 
C(9) 48(2) 64(2) 52(2) 14(2) 2(2) 4(2) 
C(10) 47(2) 53(2) 53(2) -2(2) 9(2) -3(2) 
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C(11) 55(2) 59(2) 62(2) 5(2) 7(2) 5(2) 
C(12) 39(2) 74(2) 75(2) 11(2) 9(2) 7(2) 
C(13) 41(2) 54(2) 64(2) 8(2) 4(2) 8(2) 
C(14) 45(2) 37(2) 55(2) 6(2) 8(2) -1(1) 
C(15) 75(3) 139(4) 59(3) -4(3) 13(2) 14(3) 
C(16) 41(2) 68(2) 63(2) 6(2) -9(2) -5(2) 
Cl(1) 65(1) 95(1) 93(1) -28(1) 19(1) -35(1) 
O(1) 64(2) 63(2) 88(2) 14(1) 13(1) 2(1) 
O(2) 57(1) 96(2) 60(2) 11(2) 15(1) 3(2) 
O(3) 45(1) 40(1) 73(2) -2(1) -9(1) -7(1) 
N(1) 39(1) 37(1) 50(1) -1(1) -3(1) -3(1) 
C(1) 45(2) 48(2) 47(2) 0(2) 8(2) 3(2) 
C(2) 64(2) 55(2) 59(2) 2(2) 2(2) 1(2) 
C(3) 79(3) 70(3) 71(3) 21(2) 3(2) 4(2) 
C(4) 58(3) 124(4) 63(3) 29(3) -1(2) 3(3) 
 
 
Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2 x 103) for 142. 
 
 x y z U(eq) 
     
H(1O) -1518 -5327 -7428 86 
H(2) -2496 -862 -8762 71 
H(3) -3376 -42 -9929 88 
H(4) -4080 -1297 -10963 98 
H(5) -3932 -3413 -10825 97 
H(6) -3076 -4258 -9644 78 
H(7A) -1333 -2656 -8123 58 
H(7B) -1631 -3990 -8454 58 
H(8) -1431 -3625 -6832 58 
H(9A) -2901 -3872 -5743 66 
H(9B) -4250 -4347 -6262 66 
H(10) -3163 -1863 -6177 61 
H(11) -5605 -1252 -6094 70 
H(12A) -7415 -2306 -6736 75 
H(12B) -6597 -3592 -6637 75 
H(13) -6024 -1749 -7787 64 
H(14) -3595 -1545 -7502 55 
H(15A) -3874 -2315 -4837 109 
H(15B) -5162 -2527 -4223 109 
H(15C) -5054 -1269 -4690 109 
H(16A) -6530 -4060 -8048 69 
H(16B) -5580 -3261 -8650 69 
H(1O) -1518 -5327 -7428 86 
H(2) -2496 -862 -8762 71 
H(3) -3376 -42 -9929 88 
H(4) -4080 -1297 -10963 98 
H(5) -3932 -3413 -10825 97 
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Torsion angles [deg] for 142. 
 
C(15)-O(2)-C(11)-C(10) 63.4(4) 
C(15)-O(2)-C(11)-C(12) -179.8(3) 
C(16)-O(3)-N(1)-C(14) 28.2(3) 
C(16)-O(3)-N(1)-C(7) -100.8(3) 
C(16)-O(3)-N(1)-C(8) 140.0(2) 
N(1)-O(3)-C(16)-C(13) -34.9(3) 
C(7)-N(1)-C(8)-C(9) 159.9(2) 
C(14)-N(1)-C(8)-C(9) 32.0(3) 
C(14)-N(1)-C(7)-C(1) -61.8(3) 
O(3)-N(1)-C(8)-O(1) 43.5(3) 
C(7)-N(1)-C(8)-O(1) -76.2(3) 
C(14)-N(1)-C(8)-O(1) 156.0(2) 
O(3)-N(1)-C(8)-C(9) -80.5(3) 
O(3)-N(1)-C(7)-C(1) 60.4(3) 
C(8)-N(1)-C(7)-C(1) 177.8(3) 
C(7)-N(1)-C(14)-C(10) -132.6(2) 
C(8)-N(1)-C(14)-C(10) -9.9(3) 
O(3)-N(1)-C(14)-C(10) 103.0(2) 
C(8)-N(1)-C(14)-C(13) -123.7(2) 
C(7)-N(1)-C(14)-C(13) 113.6(3) 
O(3)-N(1)-C(14)-C(13) -10.8(3) 
C(2)-C(1)-C(7)-N(1) 89.6(3) 
C(2)-C(1)-C(6)-C(5) -1.2(5) 
C(7)-C(1)-C(6)-C(5) -177.0(3) 
C(6)-C(1)-C(7)-N(1) -94.8(3) 
C(6)-C(1)-C(2)-C(3) 1.7(5) 
C(7)-C(1)-C(2)-C(3) 177.5(3) 
C(1)-C(2)-C(3)-C(4) -1.3(6) 
C(2)-C(3)-C(4)-C(5) 0.3(6) 
C(3)-C(4)-C(5)-C(6) 0.2(6) 
C(4)-C(5)-C(6)-C(1) 0.3(6) 
N(1)-C(8)-C(9)-C(10) -41.6(3) 
O(1)-C(8)-C(9)-C(10) -163.4(3) 
C(8)-C(9)-C(10)-C(11) 149.1(3) 
C(8)-C(9)-C(10)-C(14) 36.1(3) 
C(9)-C(10)-C(11)-C(12) -77.1(3) 
C(9)-C(10)-C(11)-O(2) 43.7(4) 
C(9)-C(10)-C(14)-N(1) -15.3(3) 
C(11)-C(10)-C(14)-C(13) -22.0(3) 
C(9)-C(10)-C(14)-C(13) 98.1(3) 
C(11)-C(10)-C(14)-N(1) -135.4(2) 
C(14)-C(10)-C(11)-O(2) 157.0(3) 
C(14)-C(10)-C(11)-C(12) 36.2(3) 
C(10)-C(11)-C(12)-C(13) -36.8(3) 
O(2)-C(11)-C(12)-C(13) -159.6(3) 
C(11)-C(12)-C(13)-C(14) 22.9(4) 
C(11)-C(12)-C(13)-C(16) 137.4(3) 
C(12)-C(13)-C(14)-N(1) 113.6(3) 
C(12)-C(13)-C(14)-C(10) -0.1(3) 
C(16)-C(13)-C(14)-N(1) -9.7(3) 
C(16)-C(13)-C(14)-C(10) -123.4(3) 
C(12)-C(13)-C(16)-O(3) -89.0(3) 
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C(14)-C(13)-C(16)-O(3) 26.6(3) 
C(15)-O(2)-C(11)-C(10) 63.4(4) 
C(15)-O(2)-C(11)-C(12) -179.8(3) 
 
 
Hydrogen-bonds for 142 [Å and deg.]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
O(1)-H(1O)...Cl(1)#1 0.8200 22.100 2.933(3) 147.00 
C(7)-H(7A)...Cl(1) 0.9700 28.000 3.626(3) 144.00 
C(13)-H(13)...O(1)#2 0.9800 23.500 3.236(4) 150.00 
C(14)-H(14)...Cl(1) 0.9800 27.800 3.457(3) 127.00 
O(1)-H(1O)...Cl(1)#1 0.8200 22.100 2.933(3) 147.00 
C(7)-H(7A)...Cl(1) 0.9700 28.000 3.626(3) 144.00 
C(13)-H(13)...O(1)#2 0.9800 23.500 3.236(4) 150.00 
C(14)-H(14)...Cl(1) 0.9800 27.800 3.457(3) 127.00 
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